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ABSTRACT OF DISSERTATION 
Modulation of Type-I Interferon Mediated Immune Response: A Novel Innate Immune 
Evasion Strategy of Equine Herpesvirus 1 
Equine herpesvirus-1 (EHV-1) is one of the major viral pathogens causing respiratory disease, 
abortion, perinatal mortality and neurologic disease among horses resulting in significant 
economic losses to the equine industry. The virus can also remain latent in the horses and 
recrudesce at any time. Type-I interferons (IFNs) act as a first line of defense against many viral 
infections.  
         In this study we investigated the type-I IFN response against the neuropathogenic T953 
strain of EHV-1 in equine endothelial cells (EECs). The results showed that after a transient 
induction of IFN-β mRNA as well as protein at an early time (3h) post infection (p.i.), T953 
strain of EHV-1 suppressed further induction of IFN-β at later times (12h onwards). Studies were 
done to confirm that the suppression of type-I IFN induction at later time points was not due to 
the normal IFN-β induction kinetics, it was rather because of the active interference by the virus. 
Investigation of the mechanisms by which T953 interferes with IFN-β production revealed that 
the virus degraded the endogenous level of the transcription factor, interferon regulatory factor 3 
(IRF-3) and also down-regulated the activation of IRF-3 followed by its accumulation in the 
nucleus. However, T953 infection caused degradation of nuclear factor κB (NF-κB) inhibitory 
protein IκBα and also induced p50 subunit to translocate into nucleus from cytoplasm suggesting 
activation of NF-κB signaling. This also indicated that inhibition in the type-I IFN production 
was probably not due to the inhibition of NF-κB.  
         The results of these studies also indicated that T953 virus was resistant to the biological 
effect of the recombinant equine IFN-α in vitro. Investigation of the reason of this resistance 
showed that T953 virus interfered with the cellular JAK-STAT signaling mechanism by which 
type-I IFN exerts its antiviral effect. Moreover, the studies revealed that downstream of the JAK-
STAT signaling, T953 virus also inhibited the expression of cellular antiviral proteins including 
interferon stimulated gene 56 (ISG56) and viperin. Altogether, these data indicate that the T953 
strain of EHV-1 interfered with the host cell innate immune responses by modulating type-I IFN 
mediated immune responses at multiple levels in vitro.   
KEYWORDS: Equine herpesvirus-1, Interferon, Interferon regulatory factor-3, JAK-STAT 
signaling, Interferon stimulated gene 
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CHAPTER I: REVIEW OF LITERATURE 
 
1.1 Introduction and History of Herpes: 
         The word ‘herpes’ was originally derived from the Greek word herpein meaning to creep or 
crawl because of the creeping nature of the lesions on the skin caused by the viruses. The origin 
of the word ‘herpes’ probably dates back more than twenty five centuries although the first 
written documentation of human herpes virus infection is believed to be done by Hippocrates 
(460 BC-377 BC) [1-3].  Similar signs of infections have also been mentioned in many other 
ancient documents, e.g., the Sumerian Tablet (3rd Millenium BC), Egyptian Ebers Papyrus (circa 
1500 BC) or in Avicenna’s documentation (880-1036 AD). Celsus was the first who described 
the actual herpetic lesion as ‘initially round but then diffused like serpent’. These signs were 
caused by the herpesvirus now known as varicella zoster virus (VZV) which was also 
documented by Herodotus and later elaborated by Galen [2]. Over the centuries the term ‘herpes’ 
and its meaning have been changed several times to ‘formica’, furfur and again back to ‘herpes’.  
In early medical history the word ‘herpes’ was attributed to many pathological conditions of the 
skin like skin cancer, noma, erysipelas, and ringworm including lupus vulgaris [2, 3]. The 
Byzantine author, Actuarius (John Zachary) is considered to be the first author to certainly use the 
term ‘herpes’ for cutaneous ringworm (reviwed in [3]). In 1275, Saliceto considered ‘herpes’ to 
be different from ‘erysipelas’ as the latter only involves the skin while ‘herpes’ involves also 
underlying tissues (reviewed in [3]). Gorraeus recognized 3 different types of herpes i.e., ‘H. 
esthiomenos’, ‘H. miliaris’ and ‘H.phlyctenodes’ [4]. In contrast to Saliceto, Daniel Sennert still 
believed that ‘herpes’ and ‘erysipelas’ both were caused by same agents and he also mentioned 3 
different types of herpes in his writings, such as ‘H. simplex’ (‘Herpes vero solam cutem 
exulcerat’), ‘H. esthomenos’ or ‘H. exedens’ and ‘H. miliaris’ [5]. Daniel Turner, who gave more 
modern descriptions compared to these previous authors, considered ‘herpes’ to be ‘a choleric 
pustule’[6]. He is the one who described herpes simplex under its modern name [3]. In the 
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pustule’[6]. He is the one who described herpes simplex under its modern name [3]. In the 
beginning of the nineteenth century Robert Willian and Thoms Bateman contributed significantly 
to the field of herpes virology. Bateman recorded 6 different species of ‘herpes’ which are H. 
phlyctaenodes, H. zoster, H. circinatus, H. labialis, H. praeputialis and H. iris [3]. Unna in 1883 
elaborately described the recurrence of herpes infection [7]. Three years later in 1886 a French 
dermatologist, Jean Baptiste Emile Vidal, first showed that skin conditions caused by herpes 
simplex were infectious and could be transmitted from human to human [2, 8]. The great 
discovery of the first virus, tobacco mosaic virus and the fact that agents different and smaller 
than bacteria can cause disease by Dmitri Ivanovski and Martinus Biejerinck in 1892 and 1898, 
respectively, set the milestone for virology research [9, 10]. Within the same time period the first 
book dedicated to herpes, ‘Les Herpes Genitaux’ was published in 1896 by the French doctors 
Charles-Paul Diday and Adrien Doyon [11].  
While herpesviruses have been considered to be evolving along with their hosts over a 
period of about 400 million years, the subgroup alpha herpesviruses have diverged only 180-210 
million years ago [12, 13]. Although human herpesvirus infections started a long time ago, it was 
not until the past four centuries that clinical findings of equine herpes virus were recorded [14].  
1.2 Importance of EHV-1 Infection to United States Horse Industry 
            Kentucky is considered to be the horse capital of the United States (US). The US equine 
industry is a very diverse industry involving almost all the states in US providing an opportunity 
for at least 460,000 direct full-time employment jobs (FTE). 4.6 million Americans of which 2 
million are horse owners are directly involved, and many others are indirectly involved with this 
industry, making every 1 out of 63 Americans involved with horses [15]. The industry involves 
agriculture, business, and recreation impacting significantly at national, state and local 
economies. The 102 billion US dollar (USD) equine industry consists of racing (26.1 billion), 
showing (28.7 billion), recreation (31.9 billion), other (14.6 billion) USD (Figure 1.1) and pays 
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revenue of 1.9 billion to  the US government which includes Federal (588 million), State (1017) 
million and local (275 million) USD revenues [15].   
 
Figure 1.1: Distribution of economic sectors of the US horse industry. Of the 102 billion USD 
horse industry, the most significant contribution comes from recreation followed by showing, 
racing and others. The figure is made from the information available from American Horse 
Council Foundation [15]. 
 
Out of the 9.2 million horses in the US, Kentucky has about 320,200 horses and 194,300 
Kentuckians are involved in the industry either as horse owners, service providers, employees or 
volunteers [15]. The equine industry in Kentucky creates direct 51,900 FTE with a total impact of 
96,000 job opportunities. The horse industry in Kentucky has an impact of 3.54 billion USD in 
terms of gross domestic product added directly to US economy. 
            EHV-1 infection causes serious damage to the horse industry worldwide including in the 
US. As a direct effect of the infection, horses suffer from respiratory disease, neurologic 
disorders, abortions, and neonatal death. The infection also makes horses susceptible to other 
secondary bacterial infections like Streptococcus equi subsp. zooepidemicus [16]. Even though 
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horses may recover from the disease eventually, their productivity is compromised. Late term 
abortions usually in the last trimester and neonatal death cause significant economic losses to 
horse breeders and also set back the industry as whole. EHV-1 induced neurologic disease, also 
known as equine herpes myeloencephalopathy (EHM) causes significant morbidity as well as 
mortality. The restriction in the movement of horses nationally and internationally caused by 
EHV-1 infection and the rescheduling of horse shows and races also impact the equine industry 
negatively. Large amount of money are also spent on the care and management of horses infected 
with EHV-1.    
1.3 Classification of Herpesviruses: 
            The first organized classification of herpesviruses came in 1971 by the International 
Committee on Taxonomy of Viruses (ICTV) [17] and the most recently updated classification 
was adopted in 2009 by the ICTV [18]. Here the newly formed order Herpesvirales are 
considered to have three distinct families: the Alloherpesviridae, the Malacoherpesviridae and the 
Herpesviridae, the latter of which is also the largest amongst the groups. While the 
Alloherpesviridae includes herpesviruses of fish and frogs and the Malacoherpesviridae includes 
a bivalve virus, the revised family of Herpesviridae includes herpesviruses of mammals, reptiles 
and birds [18]. The classifications of different herpesviruses into different families are largely 
based on virion morphological criteria [19].  
         The members of the herpesviridae family have spherical virion morphology with four major 
components: the core, the capsid, the tegument and the envelope (Figure 1.2). The core contains a 
single copy of a linear, double-stranded deoxyribonucleic acid (DNA) molecule which is 
arranged with unique long and unique short regions with terminal and internal repeats. The core 
DNA molecule is encased within an icosahedral capsid with an external diameter of 125-130 nm 
[18, 19]. The capsid is made of 162 capsomeres of which 12 are pentons and 150 are hexons [19]. 
This is surrounded by unstructured proteinaceous matrix, the tegument which consists of 30 or 
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more viral proteins [18]. The external lipid bilayer membrane, or envelope, surrounds the 
tegument and a number of glycoproteins of both virus and host origin are embedded into the 
envelope [19]. 
           
 
Figure 1.2: Basic Architecture of Herpesvirus Virion. All herpesviruses have four major 
components, the core which consists of a dsDNA genome, capsid, tegument and envelope. 
Several glycoproteins are embedded in the envelope. 
 
         Based on the biological criteria, the members of the herpesviridae family are categorized 
into three subfamilies: Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae [20]. 
These subfamilies are further assigned into different genera based on molecular data; mainly 
DNA sequence homology, genome size and structure and relatedness of viral proteins [14, 21].  
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            The members of the Alphaherpesvirinae subfamily are distinct from the other subfamilies 
by their characteristic variable and wide host range, relatively short replication cycle (few hours), 
rapid spread in cell culture with cytolysis and the capability to establish life-long latency in the 
sensory ganglia of the central nervous system or in the lymphocytes of their hosts [22]. The 
subfamily contains four different genera: Simplexvirus, Varicellovirus, Mardivirus and Iltovirus 
[19]. Memebers of the Simplexvirus include Human herpesvirus-1, Human herpesvirus-2, Bovine 
herpesvirus-2, Ateline herpesvirus-1 and Cercopithecine herpesvirus-1 [19]. Members of the 
Varicellovirus include Bovine herpesvirus-1, Bovine herpesvirus-5, Suid herpesvirus-1, Equid 
herpesvirus type-1, -3, -4, -6, -8 and -9, Caprine herpesvirus-1, Canid herpesvirus-1 and Human 
herpesvirus-3 [19]. Members of the Mardivirus infect only birds and include Gallid herpesvirus-2 
(Marek’s disease virus type-1), Gallid herpesvirus-3 (Marek’s disease virus type-2) and 
Meleagrid herpesvirus-1 (Turkey herpesvirus) [18, 19]. Members of the Iltovirus include Gallid 
herpesvirus-1 (Infectious laryngotracheitis virus) and Psittacid herpesvirus-1 (Pacheco’s disease 
virus) [18]. 
         The characteristic features of the members of the Betaherpesvirinae subfamily include 
restricted host range, long reproductive cycle (lasts several days), slow growth in cell culture and 
a characteristic cytomegalia of the infected cells with intranuclear inclusion bodies [14, 22]. In 
many cases the virus causes no apparent clinical symptoms and can be latent in leucocytes, cells 
of reticuloendothelial systems, salivary glands, kidneys and other tissues [23]. The subfamily 
consists of three genera: Cytomegalovirus, Muromegalovirus and Roseolovirus [24]. 
Cytomegaloviruses have large genome size (>200 kbp) and cause characteristic enlargement of 
the infected host cells [24]. Examples of this genus include Human cytomegalovirus and African 
green monkey cytomegalovirus [24]. Muromegaloviruses which include two members, mouse 
and rat cytomegalovirus, also have large genome size (>200 kbp). Roseoloviruses, on the other 
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hand, have smaller (<200 kbp) genome size and infect primarily T cells and the two members of 
this genus include Human herpesvirus-6 and Human herpesvirus-7 [24]. 
         The members of the subfamily Gammaherpesvirinae infect T or B lymphocytes and have 
variable replication cycle [22]. The gammaherpesviruses are very restricted in their host range 
(restricted to the taxonomic family or order of their natural host) and are often found latent in the 
lymphoid tissues [14]. This subfamily consists of four genera: Lymphocryptovirus, Rhadinovirus, 
Macavirus and Percavirus [18]. The members of Lymphocryptovirus include the Epstein-Barr 
virus and Gorilla herpesvirus and these viruses infect only primates [24]. The members of the 
Rhadinovirus have more varied host range compared to other genera of this subfamily and 
include Bovine herpesvirus-4, Macacine herpesvirus-5 and Human herpesvirus-8 [18]. The 
members of the Macavirus genus are genetically very similar and include Caprine herpesvirus-2, 
Alcelaphine herpesvirus-1 and Suid herpesvirus-3 [18]. Members of Percavirus include Equine 
herpesvirus-2, Equine herpesvirus-5 and Mustelid herpesvirus-1 [18]. 
1.4 Herpesvirus Infections of Equids:  
         The equid herpesviruses are one of the most prevalent viral pathogens found among equids 
causing a number of diseases. Equid herpesviruses belong to the order herpesvirales and family 
herpesviridae but to date all the equid herpesviruses isolated are restricted to either 
alphaherpesvirinae or gammaherpesvirinae subfamily. The members of the subfamily of 
alphaherpesviruses of equids include equid herpesvirus-1 (EHV-1),   equid herpesvirus-3 (EHV-
3), equid herpesvirus-4 (EHV-4), asinine herpesvirus-1 (AHV-1) , asinine herpesvirus-3 (AHV-3) 
and Gazelle herpesvirus-1 (GHV-1)  and all of these viruses belong to Varicellovirus [19]. The 
members of the gammaherpesviruses of equids include equine herpesvirus-2 (EHV-2), equine 
herpesvirus-5 (EHV-5) and asinine herpesvirus-2 (AHV-2). The most common equine 
herpesviruses that infects a majority of world’s domestic horses (Equus caballus) are EHV-1 and 
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EHV-4 that have been found for more than 70 years to be significant impediments to the success 
of breeding, competition and recreational horse industries [25].  
1.4.1 Equine Herpesvirus Infections: 
 
1.4.1.1 EHV-1Infection: 
         EHV-1 infection causes respiratory disease characterized by fever (39.5-41.5 ˚C), malaise, 
inappetence, serous nasal discharge, pharyngitis, coughing and submandibular or retropharyngeal 
lymphadenopathy, neonatal death, ocular disease, epizootic abortion storms mainly in the late 
trimester as well as sporadic abortions, and also a neurological disorder known as EHM [26]. 
Progressive secondary bacterial infection  may lead  to rhinopneumonitis [27]. Although horses of 
any age group or breed or sex are susceptible to the viral infection, young horses are more 
susceptible to the respiratory form of the disease and the older horses are more susceptible to the 
development of EHM. Beside domestic horses, the virus has also been isolated from onagers 
(Equus hemionus onager), zebras and gazelles (Gazella thomsoni) [28]. The virus can be latent in 
lymphocytes (mainly CD8+ T lymphocytes) and also in sensory nerve cell bodies within the 
trigeminal ganglia of the infected horse which then becomes a carrier for its lifetime [25]. 
1.4.1.2 EHV-2 Infection: 
         EHV-2 along with EHV-5 was originally described as ‘slowly cytopathic orphan’ 
herpesvirus of domestic horses and was also classified under cytomegalovirus like 
betaherpesviruses [29-31]. With the availability of advanced biotechnological tools, complete 
genomes of both the viruses have been sequenced and the data led EHV-2 and EHV-5 to be 
incorporated under the subfamily of Gammaherpesvirinae and genus Percavirus [29, 32, 33]. 
Initially, the EHV-2 strain isolated in 1962 was a prototype LK strain from a foal suffering from 
‘catarrh and coughing’ by Plummer and Waterson  [34] and after that the virus has been isolated 
in different parts of the globe [29, 35, 36]. The virus has a linear dsDNA of 184 kbp length and 
57% G+C content genome which encodes 77 distinct proteins [29, 32].  Foals of young ages are 
9 
 
more susceptible to EHV-2 infection [30, 37]. The virus can be shed persistently, intermittently or 
continuously or even be latent with sporadic reactivation and this could be very significant 
epidemiologically. It has been noticed that EHV-2 can be shed intermittently from the mucous 
membranes of the respiratory tract of horses for up to 14 weeks [38, 39]. EHV-2 has been isolated 
from peripheral blood leukocytes of 89% of the horses tested in the US and 90% in England [29, 
40]. Moreover, the same animal can be infected with EHV-2 and EHV-5 at the same time [41]. 
Although endemic in the US, severe outbreaks of EHV-2 infections associated with respiratory 
diseases have also been reported [42]. In the field conditions, horizontal transmission of the virus 
is the most common route of spread to new animals [30]. Nasal mucosa, histiocytes and 
Langerhans cells in conjunctiva, and peripheral blood lymphocytes have been shown to be 
reservoirs and sources of excretion of EHV-2 in the environment [43-45].  Severe EHV-2 
infections can show 100% morbidity with the symptoms of respiratory disease like increase in 
body temperature (38.5-39.5 ˚C), dullness, malaise, enlarged lymph nodes, chronic pharyngitis, 
coughing, serous to mucopurulent nasal discharge for several days and also keratoconjunctivitis 
[42, 46-49]. EHV-2 has also been linked to the poor performance syndrome in young performing 
horses and also to immunosuppression of the affected horses [49, 50]. In some isolated cases, 
EHV-2 has also been associated with naturally occurring abortions of mares as well as 
granulomatous dermatitis [51-53]. 
1.4.1.3 EHV-3 Infection: 
         EHV-3 is the causative agent of an infectious, mucocutaneous, venereal disease of mares 
and stallions known as  equine coital exanthema (ECE) which is characterized by the formation 
of  pock-like eruptions and erosions or ulcers on the external genitalia of mares and stallions [54, 
55].  Although the virus is highly contagious, it does not normally cause any abortion or infertility 
or any systemic illness [54, 56]. The virus is antigenically, genetically and pathogenetically 
different from any other alpha or gamma equine herpesviruses and bearing only 2 to 5 per cent 
homology with EHV-1 at DNA level [57]. Unlike EHV-1, EHV-3 has a restricted host range and 
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grows in vitro only in the cells from equids. The virus grows optimally at 34 ˚C and an increase in 
temperature up to 39 ˚C could reduce the infectious progeny virus 106 fold [56, 58, 59]. Latently 
infected horses act as biological reservoirs and can shed the virus periodically, serving as a 
potential source of infection for other animals within the population [54]. It has been estimated 
that about 18-53% population of horses of breeding age possess EHV-3 specific antibodies [54, 
60, 61]. Young and unbred horses are less susceptible to EHV-3 compared to older and breeding 
horses [60, 61]. EHV-3 is principally transmitted by direct skin-to-skin contact during coitus from 
an actively infected virus shedding horse but non-coital transmission by contact with virus 
contaminated buckets, instruments, gloves, or examination sleeves used for the purpose of 
breeding is also seen [54, 55]. After entry into a new horse, the replication of the virus is limited 
within the stratified epithelium of the epidermis or mucocutaneous junctions of the nares, urethral 
orifice, or female genital vestibule; and systemic dissemination of the virus has not been seen 
[54]. Both virus-neutralizing (VN) antibodies and complement-fixing  (CF) antibodies are 
detected in sera from EHV-3 infected horses where VN antibodies persist longer [61]. No 
commercial vaccines are available which prevent ECE [54].   
1.4.1.4 EHV-4 Infection:  
After EHV-1, the most significant and ubiquitous alphaherpesvirus of equids is EHV-4 [25]. 
Unlike EHV-1, EHV-4 infection causes primarily respiratory disease and normally does not lead 
to EHM. However, sporadic, single cases of abortion have been documented occasionally after 
EHV-4 infection in horses [25, 37]. Although EHV-1 and EHV-4 are two distinct viruses, they 
share a great deal of antigenic and genetic similarities. EHV-4 has a linear double stranded DNA 
genome of 145.6 kbp with 50.5% GC content [25]. EHV-1 and EHV-4 share 55 to 84 per cent 
nucleotide identity within the individual homologue genes and the degree of homology in amino 
acid sequences ranges from 55 to 96 per cent [25, 62]. Because of the high degree of homology 
between two viruses, they were considered to be different subtypes of EHV-1 (subtype-1 or S-1 
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for EHV-1, subtype-2 or S-2 for EHV-4) until 1981 [63]. After that the DNA sequencing of 
EHV-1 and EHV-4 confirmed the individual identity of the two viruses [62, 64].  
1.4.1.5 EHV-5 Infection: 
        Along with EHV-2, EHV-5 is another widely distributed gammaherpesvirus of equines [29]. 
The virus was originally isolated from the nasal cavity of two horses from the UK in quarantine 
in Australia in 1970 [42, 65] and since then EHV-5 had also been  isolated from the peripheral 
blood lymphocytes (PBL) of horses suffering from upper respiratory tract diseases or also from 
apparently healthy horses in the US, Australia and Europe [32, 41, 66, 67]. EHV-5 has a linear 
dsDNA genome of 179 kbp length and a G+C content of 52% [68]. Though the virus shares an 
overall 60% homology with EHV-2 at the amino acid level, the two viruses are distinct entities 
[29, 32]. Like EHV-2, EHV-5 has also been shown to exhibit a broad host range and a longer 
replication cycle in vitro in cell culture [29, 69]. In the majority of the cases, EHV-5 infected 
horses have shown inapparent or minimal signs. But recently, EHV-5 has been associated with 
the development of characteristic equine multinodular pulmonary fibrosis (EMPF) and also to 
secondary bacterial infection caused by Rhodococcus equi [42, 70, 71]. Williams et al have 
described the progressive nodular fibrotic lung disease caused by EHV-5 and showed that the 
lungs of the infected horses contained multiple nodules with marked interstitial fibrosis [70]. 
Histological studies found that the airways of the affected horses contained neutrophils and 
macrophages containing the inclusion bodies which were confirmed to be ‘herpesviral-like 
particles’ by transmission electron microscopy [70]. In another report, Wong et al have also 
described EMPF in five horses with multifocal coalescing nodules of fibrosis in the lung 
parenchyma [72]. In other studies Schwarz et al [73] also reported similar EMPF cases in five 
horses in Hungary and Spelta et al [74] documented EMPF cases in three horses in Australia. In a 
very recent study Williams et al infected horses with EHV-5 isolated from the spontaneous cases 
of EPMF and have reproduced the signs of EMPF in the experimentally infected horses [75]. 
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1.4.2 Asinine Herpesvirus Infections: 
 
1.4.2.1 AHV-1 Infection: 
         AHV-1 is another member of the subfamily alphaherpesvirinae and tentatively under 
varicellovirus. The virus is also known as equine herpesvirus-6 (EHV-6). AHV-1 infection in 
donkeys causes very similar skin lesions caused by EHV-3 infection of horses on keratinized 
skin. Infected donkeys had erosive lesions on the muzzles and external genitalia as well as on the 
udders [76, 77]. In spite of disease similarities caused by EHV-3 and AHV-1, the restriction 
endonuclease and DNA hybridization analysis confirmed the distinct identity of AHV-1 [77]. 
1.4.2.2 AHV-2 Infection: 
         AHV-2 is a member of the subfamily gammaherpesvirinae and also tentatively known as 
equine herpesvirus-7 (EHV-7) [42] . The virus has been isolated from the leucocytes of a 
clinically normal donkey as well as also from nasal secretions of a mule [76, 78]. There is very 
little information available on this virus but it is believed that AHV-2 is distantly similar to EHV-
2 and EHV-5 [76]. The characteristic disease symptoms caused by AHV-2 infections are not clear 
and the virus yet needs to be unequivocally correlated with disease [76]. 
1.4.2.3 AHV-3 Infection: 
         Browning et al. isolated one alphaherpesvirus from the nasal cavity of donkeys after high 
doses of corticosteroid treatment and the virus was named asinine herpesvirus-3 [76]. Although 
the sequence analysis study of glycoprotein G gene of AHV-3 showed considerable similarities 
(92% amino acid sequence similarity) with EHV-1, the restriction endonuclease fragment pattern 
confirmed the virus to be a distinct member of  alphaherpesvirinae subfamily and is also named 
equid herpesvirus-8 (EHV-8) [76, 79, 80].  It is believed that donkeys are the primary hosts of 
this virus, but horses can also be naturally infected with AHV-3 [80]. AHV-3 infection primarily 
can cause afebrile rhinitis in donkeys but can also cause fever and rhinitis in horses [76, 80]. Like 
other alphaherpesviruses, AHV-3 can also be latent and can recrudesce at any time [80].  AHV-3 
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seronegative donkeys, when experimentally infected with the virus , showed afebrile rhinitis for 4 
to 5 days, characterized by profuse serous nasal discharge which became mucopurulent later [76]. 
A complete genome sequence of a new strain of EHV-8, Wh by Liu et al revealed that the horse 
strain of EHV-8 has eight nucleotide and two amino acid substitutions in the gG gene when 
compared to other donkey strains of EHV-8 (AHV-3). Unlike EHV-1, AHV-3 has a restricted 
host range and under laboratory conditions AHV-3 does not grow well in equine fetal kidney 
(FEK) cells whereas EHV-1 grows rapidly producing high titers of infectious progeny virus [76]. 
Like EHV-1, AHV-3 also has 80 open reading frames which encode 76 unique proteins [80]. 
1.4.3 Gazelle Herpesvirus Infection: 
         While investigating the cause of death of eight Thomson’s gazelles from epizootic 
encephalitis in a zoological garden in Japan, Fukushi et al. isolated a herpesvirus which was 
serologically very similar to EHV-1 and EHV-4, and they named it Gazelle herpesvirus-1 (GHV-
1) [81].  Although, based on the nucleotide sequences of the conserved region of gB and gG 
genes, the virus has about 95 per cent similarity with EHV-1 and EHV-8 and about 60 per cent 
similarity with EHV-4, DNA fingerprinting  proved its separate identity and hence, GHV-1 was 
considered to be a new equine herpesvirus, equid herpesvirus-9 (EHV-9) [82]. In experimental 
conditions it has been shown that dogs, cats, goats, cattle, horses, mice, hamsters, pigs and non-
human primate common marmosets (Callithrix jacchus) could successfully be infected with 
EHV-9 showing typical signs of fulminant encephalitis [82-84]. It is believed that equids 
(domestic as well as wild) are the natural primary hosts of EHV-9, and natural infections have 
been documented in equids such as Burchell’s zebras (Equus burchelli), Grevy’s zebras (Equus 
grevyi) , Onagers, and other non-equid animals including cattle, deer, llamas,  alpacas, gazelles, 
giraffes, and polar bears (Ursus maritimus) [81, 84-88]. Although the reservoir of this virus is not 
yet known completely, Burchell’s zebras and Grevy’s zebras have been shown to harbor the virus 
[82, 84]. Compared to EHV-1, EHV-9 has a wide host range and unlike EHV-1, EHV-9 does not 
cause encephalitis by vasculitis and hypoxic degeneration in adjacent neuronal tissues [82]. 
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Rather, cases of EHV-9 infections in wild equids and non-equids have shown that EHV-9 has 
tropism for respiratory as well as neural tissues and the infection primarily causes non-
suppurative encephalitis characterized by neuronal degeneration with necrosis as well as 
intranuclear inclusion bodies in neuronal cells [81, 82, 84, 87]. However, the severity of EHV-9 
infection in domestic horses is mild and only limited to transient fever, interstitial pneumonia and 
inapparent encephalitis [83]. 
1.5 Discovery of EHV-1 
         After the discovery of first virus, Tobacco Mosaic Virus in 1882, fifty years passed before 
William Wallace Dimock and Philip Edwards in 1932 first described that other than bacteria, 
different microorganisms could also cause epizootic abortion of mares [89]. In 1933 they first 
noticed that no bacteria could be isolated from the aborted fetuses. It was further demonstrated 
that bacteria-free tissue or body fluids from aborted fetuses could cause abortion in the pregnant 
mares [90]. From that study Dimock and Edwards at Kentucky Agricultural Experiment Station, 
University of Kentucky, Lexington, KY, concluded that a filterable agent was responsible for the 
epizootic abortion storms of mares in Kentucky [89, 90]. Three years later in 1936 Dimock and 
Edwards first documented few salient features that differentiated viral abortions from other 
abortions caused by Streptococcus, Salmonella abortus-equi and they named this abortions as 
‘equine viral abortions’ [91]. In 1940 findings of inclusion bodies in liver cells and lung epithelial 
cells were considered to differentially diagnose ‘equine viral abortions’ from other abortions of 
infectious and non-infectious origins [92].  In 1941 Manninger and Csontos in Hungary also 
documented the same symptoms of viral abortions found in Kentucky along with additional 
syndromes of respiratory diseases including mild fever [93]. Due to the respiratory symptoms 
they first considered that ‘equine viral abortions’ were caused by ‘influenza’ virus [93]. Later, in 
1942 Salyi described both macroscopic as well as microscopic lesions in aborted fetuses in 
Hungary [94]. In the same year (1942), Dimock and Edwards also described the detailed clinical 
features of the viral abortion and the gross  pathological changes of aborted fetuses [95]. Since 
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then, a number of animals including mice, guinea pigs, hamsters as well as different types cells 
have been infected with EHV-1 under laboratory conditions to define the host range of this virus 
[96-100]. In an experimental study by Doll et al it was shown that equine abortion virus from the 
aborted fetuses can cause both respiratory disease and abortion in experimental mares [101]. Doll 
et al named the ‘equine abortion virus’ as ‘equine rhinopneumonitis virus’ to differentiate it from 
another virus, equine arteritis virus causing abortion [102, 103]. However, only in 1963 was the 
virus visualized under electron microscope and determined to be a member of herpesvirus group 
[34]. The rhinopneumonitis virus was then known as ‘equine herpesvirus type-1 (EHV-1)’. 
1.6 Genome Organization Pattern of EHV-1: 
         After the complete genome sequencing of EHV-1 in 1992 by Telford et al  information 
regarding the genome organization has been available [64]. Like other herpesviruses, EHV-1 has 
a linear dsDNA genome encapsidated in a thick-walled, spherical to pleomorphic, ~120 nm 
diameter, icosahedral capsid with 162 capsomeres [104]. The genome is  about 150.224 kbp in 
length with an overall G+C content of 56.7 per cent and encodes 80 open reading frames (ORFs) 
[64, 105]. The viral DNA consists of a long unique region (UL) of 112,870 bp length which is 
flanked by two small inverted repeat sequences of 32 bp long, known as terminal repeats (TRL) 
and internal repeats (IRL) (Figure 1.3) [64]. The UL region is covalently linked to a short unique 
region (US) of 11,861 bp length which is also flanked by two large inverted repeat sequences of 
12,714 bp lengths terminally and internally, known as terminal repeats (TRS) and internal repeats 




Figure 1.3: Genome Organization of EHV-1. The linear dsDNA genome of EHV-1 consists of 
a unique long (UL) and a unique short (US) region of 112.87 kbp and 11.861 kbp respectively. UL 
is flanked by a 32 bp long terminal repeats (TRL) and internal repeats (IRL) and US is also flanked 
by terminal repeats (TRS) and internal repeats (IRS) of 12.714 kbp each. ORFs 64, 65, 66, 67 are 
repeated inversely within the IRS and TRS and the two origin of replications (Oris) are located in 
between ORF 64 and ORF 65. Another origin of replication (OriL) is located within UL regions 
which encode ORFs 1 to 63. The US regions encode ORFs 68 to 76. 
 
The US region of the genome can be oriented in two directions relative to the orientation of fixed 
UL region and this makes the presence of two equimolar mixtures of different isomeric forms of 
EHV-1 DNA [25]. 
         The UL region encodes ORFs 1 to 63 and US region is predicted to encode ORFs 68 to 76 
[64]. Four out of the eighty ORFs, ORF 64, ORF 65, ORF 66, and ORF 67 are duplicated 
inversely in IRS and TRS regions and hence, EHV-1 is predicted to have at least 76 unique genes 
[29, 64]. The ORFs are arranged compactly with little intervening sequences, without any 
extensive ORF overlap and few occurrences of exon splicing [25]. Like other alphaherpesviruses, 
the EHV-1 genome has 20 sets of short, tandemly reiterated DNA sequences, (8 in UL, 2 in US, 5 
in each TRS and IRS) which are mostly present in the noncoding regions [29]. Beside the 
significant homology in the genome organization patterns with other alphaherpesviruses like 
HSV-1, VZV, pseudorabies virus (PrV) and BHV-1, EHV-1 is also assumed to have five unique 
genes encoded by ORF 1, ORF 2, ORF 67, ORF 71 and ORF 75 which have not been found in 
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any other herpesviruses to date [29]. Although the functions of these unique genes are unknown, 
ORF-1 encoded protein, membrane protein UL56 with the help of other unidentified viral 
protein(s) has been shown to down-regulate Major Histocompatibility Complex (MHC-I) 
molecules [106]. These unique genes are believed to be the responsible factor(s) that make EHV-
1 distinct from other viruses of the same family [25]. 
1.7 EHV-1 Proteins: 
         EHV-1 has the capacity to encode 77 different types of proteins from 76 unique genes 
because of the splicing of ORF64 [64]. The architecture of a purified EHV-1 virion is very 
complex and comprises of at least thirty distinct polypeptides of which 6 polypeptides, encoded 
by genes 22, 25, 35, 42, 43 and 56, form the nucleocapsid core. The tegument of the EHV-1 
consists of a number of proteins encoded by genes 8, 11, 12, 13, 14, 15, 19, 23, 24, 40, 45, 46, 48, 
49, 51 and 76 (table 1.1, 1.2, and 1.3).  Most of these tegument proteins also take part in virion 
morphogenesis, gene regulation and membrane fusion. The tegument proteins encoded by ORFs 
19, 24 and 45 are also believed to degrade the host mRNA, help in capsid transport and in DNA 
encapsidation, respectively [105, 108]. At least seven proteins encoded by the ORFs 22, 25, 35, 
35.5, 37, 42, 43 and 56 are involved in the formation of the architecture of the core and the 
nucleocapsid of the virion, of which the ORF 42 encoded major capsid protein is among the most 

















Table 1.1: EHV-1 genes and their functionsϮ 








counterpart Gene Product Functions 
1 1298 1906 NA Membrane protein UL56 
 Downregulate MHC-I expression, 
vesicular trafficking 
2 2562 1945 NA Membrane protein VI Unknown 
3 2841 3614 NA ? Unknown 
4 4249 3647 UL55 Nuclear protein UL55 Unknown 
5 5874 4462 UL54 (ICP27) 
Multifunctional expression 
regulator 
Gene regulation, inhibits premRNA 
splicing, post transcription 
regulation of genes, exports viral 
mRNA from nucleus 
6 7042 6011 UL53 Glycoprotein K (gK) 
Membrane fusion and virion 
morphogenesis 
7 10301 7056 UL52 DNA helicase-primase DNA replication 
8 10300 11037 UL51 Tegument protein UL51 Virion morphogenesis 
9 12115 11135 UL50 Deoxyuridine triphosphatase Nucleotide metabolism 
10 12084 12386 UL49A Glycoprotein N (gN) 
Membrane fusion and virion 
morphogenesis 
11 12549 13463 UL49 Tegument protein VP22 
Virion morphogenesis, possible 
RNA transport in uninfected cells 
12 13595 14944 UL48 
Transactivating tegument 
protein VP16 
Virion morphogenesis, gene 
regulation by transactivating 
immediate early genes 
13 15317 17932 UL47 Tegument protein VP13/14 
 Gene regulation by modulating  
VP16 
14 18083 20326 UL46 Tegument protein VP11/12 
Gene regulation by modulating 
VP16 
15 21170 20487 UL45  Membrane protein UL45 Membrane fusion 
16 22851 21445 UL44 Glycoprotein C (gC) 
Binds to heperan sulphate for cell 
attachment and also block 
neutralization by binding to 
complement factor c3b 
17 24234 23029 UL43  Envelope protein UL43 Membrane fusion 
18 25696 24479 UL42 
DNA polymerase processivity 
subunit  DNA replication 
19 26262 27755 UL41 Tegument host shut-off protein Cellular mRNA degradation 
20 28859 27894 UL40 
Ribonucleotide reductase 
subunit 2  Nucleotide metabolism 
21 31276 28904 UL39 
Ribonucleotide reductase 
subunit 1 Nucleotide metabolism 
22 32916 31519 UL38 Capsid triplex subunit 1 Capsid morphogenesis 
23 33292   UL37 36354 Tegument protein UL37 Virion morphogenesis 
24 36588 46853 UL36 Tegument protein  Capsid transport 
25 47311 46952 UL35 Capsid protein 
Capsid morphogenesis and capsid 
transport 
26 48230 47403 UL34 
Nuclear egress membrane 
protein 





Table 1.2: EHV-1 genes and their functionsϮ (continued) 
27 48791 48369 UL33 DNA packaging protein UL33 DNA encapsidation 
28 48763 50625 UL32  DNA packaging protein UL32 
DNA encapsidation and capsid 
transport 
29 50618 51598 UL31  Nuclear egress lamina protein 
Interacts with nuclear egress 
membrane protein 
30 55184 51522 UL30 
DNA polymerase catalytic 
subunit  DNA replication 
31 55453 59082 UL29 
 Single stranded DNA-binding 
protein DNA replication, gene regulation 
32 59243 61570 UL28 
DNA packaging terminase 
subunit 2  DNA encapsidation 
33 61432 64374 UL27 Glycoprotein B (gB) 
Membrane fusion, cell entry, cell-
to-cell spread 
34 64578 65060 NA ProteinV32   
35 67093 65153 UL26 Capsid maturation protease Capsid morphogenesis 
35.5 66142 65153 UL26.5 Capsid scaffold protein Capsid morphogenesis 
36 68975 67212 UL25 DNA packaging protein UL25  
Possibly stabilizes the capsid and 
retains the genome inside capsid 
37 69897 69079 UL24 Nuclear protein UL24 Possible neuropathogenecity factor 
38 69910 70968 UL23 Thymidine kinase  Nucleotide metabolism 
39 71192 73738 UL22 Glycoprotein H (gH) 
Cell entry and cell-to-cell spread of 
virion 
40 76224 74632 UL21 Tegument protein UL21 
Virion morphogenesis, interacts 
with microtubule 
41 76793 77512 UL20  Envelope proteinUL20 
Membrane fusion and virion 
morphogenesis 
42 77703 81832 UL19 Major capsid protein;  Capsid morphogenesis 
43 82083 83027 UL18 Capsid triplex subunit 2 Capsid morphogenesis 
44 84320 83148 UL15 
DNA packaging terminase 
subunit 1 DNA encapsidation 
45 84480 86600 UL17 
DNA packaging tegument 
protein UL17 DNA encapsidation 
46 86620 87732 UL16 Tegument protein UL16; Possibly virion morphogenesis 
47 88917 87886 NA ?   
48 88947 89900 UL14 Tegument protein UL14 Virion morphogenesis 
49 89369 91153 UL13 
Tegument serine/threonine 
protein kinase Protein phosphorylation 
50 91135 92832 UL12 Deoxyribonuclease DNA processing 
51 92784 93008 UL11 Myristylated tegument protein Virion morphogenesis 
52 94472 93120 UL10 Glycoprotein M (gM)  
Virion morphogenesis and 
membrane fusion 
53 94390 97053 UL9 
DNA replication origin-binding 
protein DNA replication 





Table 1.3: EHV-1 genes and their functionsϮ (continued) 
55 100332 99421 UL7 Tegument protein UL7 virion morphogenesis 
56 102391 100130 UL6 Capsid portal protein  DNA encapsidation 
57 102375 105020 UL5 DNA helicase-primase subunit  DNA replication 
58 105070 105747 UL4 Nuclear protein UL4   
59 106416 105877 NA Protein V57  Possibly virion morphogenesis 
60 107116 106478 UL3 Nuclear protein UL3 Unknown 
61 108144 107206 UL2 Uracil-DNA glycosylase DNA repair 
62 108843 108147 UL1 Glycoprotein L (gL)  Cell entry, cell-to-cell spread 
63 111985 110387 ICP0  Ubiquitin E3 ligase ICP0;  
Proteasome mediated degradation 
of cellular proteins like ND10, gene 
regulation 
64ᵮ 118591 144569 ICP4 
Transcriptional regulator ICP4 or 
immediate early gene  gene regulation 
  114128 149032       
65ᵮ 121368 141792 US1 Regulatory protein ICP22 
Gene regulation, expression of late 
genes 
  122249 140911       
66ᵮ 122862 140298 US10 Virion protein US10 Unknown 
  123572 139588       
67ᵮ 125194 137966 NA Virion protein V67 Colocalizes with nuclear lamin 
  124376 138784       
68 126275 125019 US2 Virion protein US2 Interacts with cytokeratin 18 
69 126411 127559 US3 
 Serine/threonine protein kinase 
US3 
Nuclear egress, apoptosis and 
protein ohosphorylation 
70 127681 128916 US4 Glycoprotein G (gG) cell-to-cell spread of virion 
71 129097 131490 US5  Glycoprotein J (gJ) Unknown 
72 131583 132791 US6 Glycoprotein D (gD) Cell attachment 
73 132899 134173 US7 Glycoprotein I (gI) Cell-to-cell spread of virion 
74 134406 136058 US8 Glycoprotein E (gE) Cell-to-cell spread of virion 
75 136055 136447 NA Membrane protein US8A Unknown 
76 136783 137442 US9 Membrane protein US9  Axonal transport 
Ϯ= Tables 1-3 are prepared on the basis of the data published in Allen et. al [25], Ma et. Al  [106], Telford et. al   [64], 
Davison et. al  [105] Kasem et. Al [107]. ᵮ= ORFs are duplicated in the US regions of the genome; NA= Not available. 
 
          
         The ORFs 6, 10, 16, 33, 39, 52, 62, 70, 71, 72, 73 and 74 encode envelope glycoprotein K 
(gK), gN, gC, gB, gH, gM, gL, gG, gJ, gD, gI and gE respectively, homologues of which have 
been identified in other alphaherpesviruss like HSV-1 [109-115]. These glycoproteins are 
involved in different critical functions like attachment and entry of the virus into a cell, viral 
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determinants of cell tropism, cell-to-cell spread, pathogenesis and immune responses [25, 109, 
112]. However, EHV-1 also has three unique glycoproteins, gp2, gp10, and gp21/22a [110]. The 
five glycoproteins, gB, gD, gH, gL and gK have been shown to be essential for viral replication 
while some other glycoproteins including gC, gE, gG, gI, gM and gp300 have been found non-
essential for viral replication but involved in virulence of the virus [25, 116]. Neubauer et al using 
an EHV-1 mutant devoid of gB gene, have shown that gB is essential for the virus growth and 
cell-to-cell spread [117] in viro. It has been suggested that gB plays a major role in the entry of 
the virus by cell-to-cell fusion [118]. Monoclonal antibodies against gB protein have been shown 
to prevent the typical alphaherpesviral syncytium or cell-to-cell fusion in vitro [119]. A number 
of studies involving gB protein have documented its role as the most important immunogenic 
protein of EHV-1 [120, 121]. gC, another transmembrane glycoprotein, is the major determinant 
of virus attachment. gC of EHV-1 binds with the abundantly found glycosaminoglycans (GAG), 
and heparan sulfate (HS) present on the host cell surface and this binding helps concentrate the 
EHV-1 particles on the cell membrane which in turn potentiates the interaction with another 
glycoprotein, gD [122, 123]. This interaction of gC with gD is followed by another interaction 
with a specific cellular entry receptor that causes the stable attachment of the virus particle to the 
host cell membrane [124]. gC of EHV-1 is a very immunogenic protein that has been shown to 
induce high titers of neutralizing antibody and also cell mediated immune responses [125]. EHV-
1 gC can also bind to the complement factor, C3b and inactivate it eventually allowing the virus 
to evade complement mediated lysis [126]. gD protein is absolutely necessary for the virus entry 
as well as virus-induced cell-to-cell fusion [124]. Other glycoproteins, gH and gL, form a 
heterodimer and gH is shown to be essential for direct fusion of the viral envelope with the host 
cell membrane, virus entry and virus-induced cell-to-cell fusion [127, 128]. On the other hand, 
the glycoprotein gE/gI complex is involved in the transmission of EHV-1 by cell-to-cell spread 
within the same host [116].  
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        Like other herpesviruses, the gene expression pattern of EHV-1 is also temporally regulated 
resulting in the sequential expression of immediate early (IE or α) gene first, followed by early 
genes (E or β) and then the late genes (L or γ). Unlike HSV, EHV-1 has only one IE gene (ORF 
64), the protein product of which is involved in the regulation of the expression of other genes of 
EHV-1 [25, 129]. 
         The gene products of ORFs 7, 9, 18, 20, 21, 27, 28, 30, 31, 32, 36, 44, 45, 50, 53, 54, 57 and 
61 are either origin-binding proteins, DNA polymerase or DNA packaging proteins which are 
involved in the replication and packaging of viral DNA [64, 105]. 
1.8 The Life Cycle of EHV-1: 
         EHV-1, during its life cycle, can undergo two different pathways- one for the lytic life cycle 
and the other for latency. During the lytic stage of the life cycle, EHV-1 actively replicates within 
the epithelial cells of the upper respiratory tract, endothelial cells of the blood vessels, and 
leucocytes and as a result, the animal harboring the virus sheds EHV-1 through the nasal route 
which can infect new horses [25]. New naive cells can be infected either by direct binding of 
virus or by cell-to cell contact with infected cells [130]. The lytic replication cycle of EHV-1 is 
depicted in the figure 1.4. After the attachment and entry into the cells, EHV-1 uncoats its 
nucleocapsid which will be transported to nuclear pore complex. In the nucleus, the viral genes 
are sequentially transcribed and eventually translated into different viral proteins, some of which 
form new capsids. Once the genome replication is complete, new genomes are then encapsidated 
within the nucleus and then transported into cytoplasm where the progeny virus is enveloped 
from host cell membrane and buds out as progeny virion. The newly formed progeny virus can 





















Figure 1.4: Lytic Life Cycle of EHV-1. EHV-1 enters into host cell by either direct membrane 
fusion or endocytosis. After entry virus uncoats its nucleic acid in the cytoplasm which is then 
transported to nucleus where viral gene expression starts. At the beginning IE gene (ORF64) will 
be expressed, then IE (α) protein will help to express E (β) genes. IE (α) and E (β) proteins both 
help in the expression of L (γ) genes. Viral genome replication starts within the nucleus 
immediately after the translation of E (β) genes. Next, some of the L (γ) proteins will form the 
capsid and the capsid assembly occurs within nucleus with the help of some chaperone proteins 
like pre-VP22a. After the assembly of capsids, the viral DNA concatamers are cleaved into unit 
length genomes by terminase enzyme with the additional help of pac1 and pac2 packaging 
signals.The assembled virions will acquire an outer membrane from nucleus which is lost during 
budding into cytoplasm where nucleocapsids acquire tegument proteins. Then it will get its 
secondary envelope from cytoplasm or endosomic vesicle and will be transported into cell surface 
and the nascent virus will be released by the fusion of vesicles with the plasma membrane.  
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1.8.1 The Lytic Life Cycle of EHV-1: 
1.8.1.1 Virus Attachment and Entry: 
         EHV-1 can enter into the host cells by two major pathways: either through the direct fusion 
of the virus to the host cell membrane or through the cellular endocytosis or phagocytosis 
pathways depending upon the cell types [131-133]. The first step in the entry process of EHV-1 is 
the attachment to the host cell through receptor mediated binding. Multiple mechanisms and 
proteins of EHV-1 are involved in the attachment with host cell membranes since deletion of one 
particular protein cannot prevent virus attachment or replication completely [132, 134]. The 
initial EHV-1 particle attachment occurs through the interaction of gB and gC and host cell GAG 
proteoglycans. Glycoprotein C and also gB bind reversibly with heparan sulfate (HS), 
ubiquitously present on the mammalian cell surface [123, 134]. Osterrieder et al using a gC 
deletion mutant EHV-1 has shown that the virus can attach, enter and replicate both in non-equine 
cells (RK-13) and primary equine cells in the absence of gC although the titer of the virus is 
reduced to 5-10 fold for non-equine and 48-210 fold for primary equine cells [134]. A Study by 
Sugahara et al [123] has shown that mutation in gC gives the protein increased affinity towards 
HS and helps EHV-1 to adapt to different non-equine cells also. After the labile initial 
attachment, gD binds to specific cell-surface receptors which causes a conformational change 
allowing gD to interact with gH/gL and also gB, and this complex interaction makes the virus 
attachment stable and triggers the viral fusion with the host cell membrane [124]. gD of 
alphaherpesviruses has been shown to be indispensable for virus entry for HSV-1, PrV, and BHV 
but not for Marek’s disease virus or VZV which do not encode a gD homologue [135-139]. By 
studies involving CHO cells expressing EHV-1 gD or studies using monoclonal antibody against 
EHV-1 gD, or using a gD deletion mutant of EHV-1 it has been shown that gD is essential both 
for virus attachment and entry as well as for cell-to-cell fusion [124, 140, 141].  Unlike HSV-1, 
no specific receptor for gD of EHV-1 has been identified to date; although it is postulated that 
there is a novel entry receptor for EHV-1 gD other than HveA, HveB and HveC [142]. The 
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protein gH or gH/gL heterodimer also plays a major role in the entry and spread of EHV-1 from 
one infected to uninfected cells by cell-to-cell fusion and seems to be conserved among 
alphaherpesviruses [127].  
         Beside the classical pathway of entry by membrane fusion, EHV-1 also enters into certain 
cell types by endocytosis [132]. After the initial findings by Frampton Jr. et al studies by van de 
Walle et al  have documented that EHV-1 can utilize cellular integrins such as αVβ5 with the 
ability to recognize the RSD motif [131, 132]. The interaction between the RSD motif present in 
gD of EHV-1 and cellular integrins like αVβ5 triggers the endocytosis of EHV-1 [131]. It has 
also been shown that EHV-1 enters into cells like PBMCs mainly by endocytic/phagocytic 
pathways while the virus enters into the endothelial cells by direct membrane fusion [131]. 
1.8.1.2 Transport of EHV-1 Capsid to the Nucleus: 
         Following membrane fusion the de-enveloped virion particles are deposited in the cytosol. 
In the case of endocytosis, the membrane of virion envelope fuses with the endosomal membrane 
inside the cell  and eventually the naked capsids are released into the cytoplasm [143]. During 
this time some tegument proteins are dissociated from the capsid [14] and then the nucleocapsids 
are transported into the nucleus of the cell through the nuclear pore complex (NPC) [143]. This 
intracellular trafficking of viral nucleocapsids is achieved by the help of microtubules which are α 
and β dimers of tubulins with a structural orientation of positive end towards the periphery of the 
cell and the negative end towards the microtubule organizing center (MTOC) close to the nucleus 
[143-145]. EHV-1 nucleocapsid and some tegument proteins will be transported into the nucleus 
by the minus-end directed motor protein, dynein, along the microtubule. As has been shown by 
Frampton Jr. et al that in the presence of dynein inhibitor but not kinesin inhibitor, the EHV-1 
replication is severely compromised [143]. EHV-1 triggers the acetylation of microtubules which 
causes its stabilization which is a primary requisite for dynein to transport the virion particles 
[143].   
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         Whether by membrane fusion or endocytosis, in both cases, the cellular kinase Rho 
associated coiled-coil kinase 1 (ROCK-1) must be activated for the effective intracellular 
trafficking of nucleocapsid [132, 143] as inhibitors of ROCK-1 were shown to prevent the 
nuclear transport of capsid [143]. It is assumed that ROCK-1 will either mediate the interaction 
between virus and microtubules and/or other cytoskeletal components, or it can aid in the fusion 
of viral envelope with cellular membrane [143]. Once the nucleocapsids reach the NPC, a 
conformational change in NPC will allow the translocation of the viral genome as a densely 
packaged, rod shaped structure into the nucleoplasm through the dilated NPC [14, 130] and the 
empty capsids are then dissociated from NPCs and the genome transcription starts [146]. 
1.8.1.3 Expression of Viral Genes and Biosynthesis of Proteins: 
         Once the viral genome is in the nucleus of the host cell, the expression of EHV-1 genes, 
DNA replication, capsid assembly and DNA packaging will occur. As discussed earlier, 
expression of EHV-1 genes is temporally regulated and tightly coordinated. At the beginning, the 
IE (α) gene is expressed which triggers the expression of the E (β) genes, followed by L (γ) genes 
[129]. Six different regulatory proteins that control this cascade of gene expression are EHV-1 IE 
protein, EHV-1 infected cell protein 0 (EICP0), EICP22 or also known as IR4, EICP27, IR2 
protein (splice variants of IE gene) and EHV-1 α-gene transinducing factor (ETIF or VP16) [147-
152]. ETIF, the protein product of ORF12, is the only EHV-1 tegument associated late protein 
(γ2) that can transactivate the sole IE gene (ORF64) transcription without the help of any other 
proteins and this incident will trigger the EHV-1 gene transcription cascade. In HSV-1 the ETIF 
homologue α-TIF (VP16) with the help of a protein, host cell factor, interacts with the cellular 
transcription factor Oct-1 bound to the consensus sequence TAATGARAT (R= purine motif) 
present in the promoter regions of all the IE genes. A similar consensus sequence is also located 
within the EHV-1 IE promoter [147]. ETIF interacts with transcription factors TFIIB and 
dTAF40 and the interaction may form a preinitiation complex that starts the transcription of  
EHV-1 IE gene [147]. Structural analysis has shown that the IE protein has several domains 
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essential for the transactivation of viral genes such as acidic transcriptional activation domain, a 
serine rich tract that binds to the cellular EAP, nuclear localization signal and a DNA binding 
domain [152]. Once the IE (α) gene is expressed, it transactivates the promoters of the early genes 
EICP22 and EICP27 and enhances their transcription. EICP22 and EICP27 then synergistically 
transactivate the expression of IE promoter and the gene products of all these 3 proteins together 
synergistically transactivate the promoters of other early genes resulting in their enhanced 
transcription [150, 151]. The IE protein together with either EICP22 or EICP27 can transactivate 
the promoters of E (β) as well as L (γ) genes of EHV-1 [151]. The IE protein cannot transactivate 
the promoter of any of the late genes (γ1 or γ2) independently including the ETIF gene [147]. In 
contrast, EICP0 is a potent transactivator of all classes (α, β, and γ) of EHV-1 promoter and can 
strongly transactivate the promoter of ETIF gene too [149]. Surprisingly, the IE protein will 
repress the transactivation property of EICP0 genes [149, 153].  EICP0 and EICP27 
synergistically can also transactivate the promoters of early and γ1 late genes while EICP0 and 
EICP22 transactivate γ2 gene promoters [149].  
         The IE (α) gene, however, trans-represses its own expression through the consensus IE 
protein binding site (5’-ATCGT-3’) near to the TATA box and transcription initiation site [154]. 
On the other hand, the IR2 protein which is a truncated form of IE protein (amino acid 323 to 
1487) binds with the promoter regions of IE, EICP0, EICP22, EICP27, thymidine kinase and late 
IR5 genes through the interaction with the transcription factor TATA box-binding protein (TBP) 
and represses the transcription of those viral genes [152].  
1.8.1.4 Replication of Viral Nucleic Acid: 
         From the work done with other alphaherpesviruses like HSV-1, it is known that once the 
early proteins are synthesized, viral DNA replication will be started with the help of at least seven 
early proteins including the gene products of UL5, UL8, UL9, UL29, UL30, UL42 and UL52 
[105, 155, 156]. In fact, the late genes are only produced in appreciable amount after a few 
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rounds of viral DNA replication [14]. After the viral DNA is deposited into the nucleus, it 
becomes circularized by DNA ligase IV/XRCC4 [104]. Simultaneously, some of the newly 
translated E (β) proteins which are essential for  
 
Figure 1.5: Model for HSV-1 DNA Replication: In the nucleus, the linear genome is 
circularized by DNA ligase IV/XRCC4 and the circular DNA serves as template for the viral 
replication machinery. At the beginning theta-type replication is initiated at three redundant 
origins of replication oriS and oriL and later proceeds towards the rolling circle replication 
generating concatameric head-to-tail DNA. Lower figure shows the HSV-1 replication fork. The 
figure is adapted from Muylaert et al [156] with permission.  
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viral DNA replication, will bind to the template DNA to form the replication machinery and 
initiate the DNA replication which continues on a rolling circle mechanism (Figure 1.5) resulting 
in head-to-tail concatamers of viral DNA [157]. Although the mechanism of EHV-1 DNA 
replication is not well studied, the analogous process of HSV-1 DNA replication has been 
deciphered in much detail.       
         The viral DNA has 3 origins of replication, one in UL and two in US regions (Figure 1.3). It 
is generally believed that at the beginning there will be bidirectional theta type of replication 
which makes circular daughter DNA that eventually undergoes rolling circle type of DNA 
replication, creating concatameric viral DNA [158]. The origin binding protein (product of UL9) 
will recognize, bind and activate the origins of replication, OriS and OriL, and unwind the viral 
DNA and this triggers other proteins to form a replisome consisting of DNA polymerase (protein 
product of UL30 and UL42), trimeric helicase-primase (protein product of UL5, UL8 and UL52) 
and ssDNA binding protein (protein product of UL29) [155, 159]. Besides the viral proteins, 
many host proteins and enzymes including DNA polymerase α-primase, DNA ligase, and 
topoisomerase II also play important roles in this process. The newly formed head-to-tail 
concatamers will later be cleaved to be packaged into individual capsids [159].  
1.8.1.5 Assembly of Capsid and Encapsidation of Viral DNA: 
         The capsid assembly process in HSV-1, EHV-1 and even in cytomegalovirus is very similar 
[104] and takes place in the nucleus of the host cell [155]. The process starts only after the 
replication of viral DNA and synthesis of new capsid proteins and it is initiated by the 
oligomerization of the major capsid protein VP5.  
Most of the proteins involved in the process are translocated into the nucleus themselves but VP5, 
VP23, VP26 require the additional help of other proteins such as VP19C or scaffolding protein 
pre-VP22a [155].  The capsid assembly continues as the oligomers of VP5 and pre-VP22a 
interact each other and to the edges of the growing capsid which is secured by VP23 [159]. Once 
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the viral DNA is packaged, the VP5-pre-VP22a complex is lost and then VP19C and VP23 
proteins interact with each other to form partial capsids [155]. The triplex structures consisting of 
one molecule of VP19C and two molecules of VP23 link the individual capsomeres [155, 160]. 
Twelve copies of UL6 proteins forming the portal complex are added to the nascent capsid chain 
which becomes closed to form the procapsid [158, 160]. A series of structural transformations 
will lead to the maturation of procapsid into capsid [161]. After the assembly of capsids, the viral 
DNA concatamers are cleaved into unit length genomes by terminase enzyme with the additional 
help of pac1 and pac2 packaging signals [162, 163]. The viral protease cleaves and removes the 
scaffolding proteins VP21 and VP22a from  inside the capsid and replaces them with newly 
replicated DNA genome [161]. Several other proteins such as UL6, UL15, UL17, UL28, UL32, 
UL33, UL36 and UL37 have also been implicated in the process of encapsidation of viral DNA 
[164-166]. 
1.8.1.6 Egress: 
         After the encapsidation of the viral DNA, the nucleocapsids then undergo the process of 
egress by the ‘envelopment-deenvelopment-reenvelopment pathways’ [167]. The newly formed 
nucleocapsids will acquire primary envelope from the inner leaflet of the nuclear membrane and 
bud out (Figure 1.6). The protein products of two conserved herpesvirus genes, UL31 and UL34, 
genes have been shown to be involved in primary envelopment [168]. Eventually the primary 
envelope will be lost (deenvelopment) and the nucleocapsids then move to the cytoplasm where 
they acquire the tegument [169]. Herpesviruses like HSV-1 have at least 15 different types of 
tegument proteins while VZV or CMV has been reported to have more than 15 tegument proteins 
[169]. Tegument proteins UL36 and UL37 play a major role in the maturation of the virion as the 
absence of those proteins abolishes the formation of the mature virion and its subsequent egress 
[169]. UL36 protein interacts with the major capsid protein, UL19 and forms the first layer of 
tegument around the icosahedral capsids [167, 169]. UL36 protein also interacts physically with 
UL37 protein which forms the second layer of tegument [169, 170]. The tegument protein UL48 
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(α-TIF) interacts with other proteins like UL41 and UL49 directly and also interacts with gB, gD, 
gH directly or indirectly [169]. The absence of UL48 severely impairs the tegumentation and 
affects virion morphogenesis downstream from envelopment and probably in the 
 
Figure 1.6: Summary of the Herpesvirus Egress Pathway. In the nucleus, the newly 
synthesized herpesviral nucleocapsids will acquire primary envelopment by budding through the 
inner nuclear membrane and then capsids will undergo de-envelopment during its translocation 
towards cytoplasm where tegumentation occurs. Following to this, final envelopment occurs both 
in the cytoplasm or vesices derived from trans-Golgi network (TGN) and at the endosome and 
eventually be transported to cell surface and the mature virions will bud out of the plasma 





virus assembly in cytoplasm [169, 171]. Von Einem et al have shown that ETIF, the HSV-1 
UL48 homologue in EHV-1 has an indispensable role in the replication cycle of EHV-1 and 
besides its IE-gene transactivating property, it is also involved in secondary envelopment of the 
virion [171]. Although some tegument proteins are indispensable for the virus maturation, it has 
been noted that virion morphogenesis continues even in the absence of tegument proteins such as 
UL13, US3, UL41, UL46, UL47, and UL49 [169]. 
After the final tegumentation in the cytoplasm, the nucleocapsids will acquire the secondary 
envelope through protein-protein interactions occurring both in the cytoplasm or cytoplasmic 
vesicles derived from the trans-Golgi network (TGN) as well as at the endosomal network (Figure 
1.6) [167, 172]. The nascent virions are transported to the cell surface by utilizing the cellular 
transport machinery and released by the fusion of vesicles with the plasma membrane (Fig 1.6) 
[172].  
1.8.2 The Latent Life Cycle of EHV-1: 
         The initial lytic replication of EHV-1 in the respiratory epithelium of horses after the 
primary infection is followed by the onset of the latent stage of infection in which infected horses 
show no clinical signs of disease, virus shedding or cell associated viremia [25, 130]. Although 
the specific site of EHV-1 latency is not clear, it has been observed that the virus can remain 
latent in the sensory nerve-cell bodies of the trigeminal ganglia and also in lymphocytes, both in 
peripherally circulating lymphocytes as well as in lymphocytes found in draining lymph nodes 
[173-177]. The principal sub-population of the lymphocytes that can harbor latent EHV-1 are 
CD5+/CD8+ T lymphocytes (>80%) though a smaller sub-population of CD5+/CD8-/CD4- T 
lymphocytes (20%) can also support latency of EHV-1 [178].    
         It is not clear what factors drive EHV-1 to enter into the latent cycle from the lytic one or 
what mechanisms actually control latency. It is, however, known that absence or interference in 
the activation of α-genes by VP16 protein can be related to the latency of HSV-1 [179]. Like 
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other alphaherpesviruses, the transcription of the EHV-1 genome during the latent infection is 
restricted, and only latency associated transcript (LAT) mRNA which is antisense to either the 
regulatory β-gene ORF 63 or the α-gene ORF 64 is transcribed. Because none of the viral proteins 
are expressed, the latently infected host cells escape immune surveillance and clearance [25, 130]. 
         However, the latent horses become carriers for their lifetimes. These are potential reservoirs 
of infection in which the viral lytic cycle can be reactivated at any time when given favorable 
conditions like stress [16, 25]. It has been reported that in the field, stress induced by weaning, 
transportation, re-housing, infection by other viruses like EHV-2, or corticosteroid treatments 
have caused the reactivation of the EHV-1 from latency [25, 173, 176, 180]. Smith et al. have 
shown that treatment with interleukin-2 (IL-2) or gonadotropin causes the reactivation of latent 
EHV-1 from CD5+/CD8+ T lymphocytes through an indirect stimulation [178].  Viral factors also 
may play a major role in the reactivation process. A mutant EHV-1 devoid of thymidine kinase 
gene (TK-) was shown to possess impaired reactivation capacity although the same mutant virus 
can achieve latency under experimental conditions [176]. During the reactivation process, the 
latent EHV-1 genome in a small subset of lymphocytes starts active transcription resulting in the 
expression of fusogenic viral glycoproteins on the cell surface, then cells undergo the transition 
from latency towards the active lytic replication cycle [181]. However, for the assembly and 
egress of infectious progeny virus following reactivation, lymphocytes carrying latent EHV-1 
require fusion with permissive cells like endothelial cells [25]. Reactivation of latent EHV-1 from 
lymphocytes or trigeminal ganglia may cause infectious virus to reach the nasopharyngeal 
epithelium and result in viremia,  abortion, or neurologic disease [25]. It is noteworthy that horses 
with  reactivated virus may become silent virus shedders as reactivation often fails to cause 
apparent clinical signs of respiratory disease [25]. The cycle of latency and reactivation contribute 
importantly to the epidemiology of EHV-1 abortions since a majority of natural EHV-1 abortion 
have been documented even weeks or months after the cell-associated viremia ceases [25].  
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 1.9 Epidemiology and Transmission: 
         EHV-1 infection is ubiquitous in nature among equids around the world and about 80-90% 
of horses have been estimated to get infected in the first two years of their life by either EHV-1 or 
its close relative EHV-4 [16]. Young horses and horses with compromised immune systems are 
more susceptible to EHV-1 infection [63]. Because of the capacity of EHV-1 to become latent, 
horses recover from the primary infection but become carriers for their lifetime and frequently 
shed infectious virus which helps to maintain the uninterrupted transmission cycle of EHV-1 to 
other susceptible animals [25, 63]. More than 80 million horses around the world have latent 
EHV-1 infection, which are the principal reservoir of infection and maintain the epidemiology of 
EHV-1 infection [25]. Studies reveal that about 54% of central Kentucky broodmares carry latent 
EHV-1 infection [182]. Although environmental contamination can cause indirect transmission, 
the environment may not be the principal reservoir since the virus is unable to survive even 35 
days in the environment outside horse body [130]. 
         EHV-1 is a highly contagious virus and it can be transmitted from one infected animal to 
others either by direct contact or indirectly [63]. Contact with virus-shedding horses with either 
acute infection or reactivated EHV-1 infection from latency, or virus-laden aborted fetuses or 
placenta are probably the major routes of EHV-1 transmission [63]. After contact of the horses 
with virus containing respiratory secretions, fomites or aerosols, the virus enters into the host 
initially through the upper respiratory tract epithelial cells [16, 25]. Naïve horses when exposed to 
EHV-1 infection shed virus from the respiratory mucosa for longer durations (as long as 15 days) 
compared to horses with experience of prior exposure or horses with reactivated EHV-1 from 
latency (2 to 3 days) [183, 184]. It is also documented that semen could be a source of EHV-1 
infection and the virus may be transmitted via the semen during mating or through artificial 
insemination [185]. Most foals may get the infection for the first time during their first year of 
life, either before or after weaning [25]. EHV-1 infection has even been documented from foals 
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as young as 22 days old [186]. Unweaned foals probably get the infection from the reactivation of 
latent EHV-1 in their dams [25].  
1.10 Pathogenesis and Clinical Signs: 
1.10.1 Respiratory Disease: 
          The incubation period of the respiratory form of EHV-1 disease is very short, usually 1 to 3 
days. It can be up to 10 days depending on the strain of virus, infecting dosage and immune 
condition of the host [25, 183, 187]. In the absence of mucosal antibody EHV-1 first infects and 
replicates in the nasal and nasopharyngeal epithelial cells although the conjunctival epithelium 
can also be infected after the direct contact with aerosol [25, 188]. In the case of intranasal 
experimental infection, virus can be detected in the infected epithelial cells of the nasopharynx, 
trachea and bronchi as early as 12 hours post infection [25, 189]. Subsequently, rounds of lytic 
replication of the virus cause the necrosis of the epithelial cells resulting in the formation of 
multiple erosions in the nasopharyngeal mucosa. These will cause the shedding of infectious virus 
in the first week of infection [25, 130].  Shortly the virus infection reaches to the underlying layer 
of lamina propria and infects the mononuclear leucocytes, which are drained into the draining 
lymph nodes where the virus is amplified by more rounds of lytic replication [189]. These 
infected leucocytes are transported to the circulatory system resulting in a cell-associated viremia 
that spreads the virus to the endothelial lining of the pregnant uterus as well as the central nervous 
system (CNS) causing abortion and neurologic disease, respectively [63, 190]. The identity of the 
sub-populations of the leucocytes that support the replication of EHV-1 during the cell-associated 
viremia is controversial [130]. Although primarily CD5+/CD8+ T lymphocytes are involved with 
viremia, EHV-1 DNA has been identified in CD4+ T lymphocytes, monocytes, and B cells during 
the acute phase of viremia [25, 130]. The cell-associated viremia, which is a prerequisite for 




Figure 1.7: EHV-1 Pathogenesis. EHV-1 enters through the respiratory tract. It replicates in the 
respiratory epithelium and spreads to lamina propria where it infects lymphocytes and other 
immune cells. Infected cells are drained into lymph nodes where the virus is amplified by more 
rounds of replication. Infected cells then enter into the circulation causing viremia through which 
virus reaches to the blood vessels of uterus, brain and spinal cord where the virus replicates and 
causes inflammatory pathology resulting in abortion and EHM. 
 
The magnitude of EHV-1 viremia ranges from 1 in 104 to 1 in 107 infected leucocytes in horse 
blood [63, 191].  However, in the case of the nasal and conjunctival routes of infection, the virus 
will disseminate to the trigeminal ganglion within 48 hours of primary infection [176]. Within 2-
13 days post infection the virus can be detected in pulmonary leucocytes, epithelial and 
endothelial cells [189]. 
         EHV-1 and EHV-4 infections principally cause disease of the upper respiratory tract which 
include rhinopharyngitis and tracheobronchitis, although infection with EHV-1 can also result in 
severe sequelae such as abortion, neonatal death, pulmonary vasculitis, ocular disease or 
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neurologic disease [25]. Often the respiratory form of disease may be asymptomatic especially in 
older horses with previous exposure to the virus or in the case of reactivation from latency [63]. 
In foals, EHV-1 infection involves bronchi and lungs making them vulnerable to secondary 
bacterial pneumonia [16]. In young horses, the clinical signs include depression, anorexia, fever, 
coughing, and initial bilateral nasal discharge. This is serous for first 2-3 days of infection and 
then becomes mucopurulent with desquamated respiratory cells along with inflammatory cells, as 
the condition progresses towards secondary bacterial infection [25, 63, 183]. In experimental 
infections with the AB4 strain of EHV-1, foals showed a biphasic fever (39-42 ºC) with one peak 
at 1-2 days post infection and another at 6-7 days post infection [183]. Other clinical signs 
include neutropenia, lymphopenia, and progressive lymphadenopathy of submandibular lymph 
nodes as well as of retropharyngeal lymph nodes [192]. When the virus reaches the lower 
respiratory tract, the infected foals show the signs of bronchopneumonia [130]. The horse’s 
immune system eliminates the virus from the respiratory tract within three weeks of the primary 
infection and one to two weeks of the subsequent infection or after reactivation from latency 
[183]. Even after clearing the infection from the respiratory tract, horses may develop some non-
specific symptoms like bronchial hypersensitivity, chronic obstructive pulmonary disease 
syndrome or compromised athletic performance which is known as the ‘poor performance 
syndrome’ [16, 183, 193]. 
1.10.2 Abortion, Neonatal Diseases and Diseases of Stallions: 
         Abortion caused by EHV-1 is the most common type of infectious abortion in horses and it 
is estimated to be about 10% of all diagnosed abortions in thoroughbreds [194]. When viremia is 
established and the virus reaches to the gravid uterus, it infects the endothelial cells of the small 
arteriolar branches in the glandular layer of the endometrium at the base of microcotyledons, 
resulting in multifocal vasculitis [195]. The inflammation in the affected blood-vessels leads to 
thrombosis which further causes ischemic necrosis of the overlying microcotyledons and 
intercotyledonary stroma followed by the anoxic death of the fetuses leading to its expulsion 
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[195, 196]. The necrosis of the microcotyledons of the placenta sometimes causes the premature 
separation of the placenta which thereafter is expelled.  In some cases, fetuses may be born alive 
even after the expulsion of placenta but shortly become affected with interstitial pneumonia 
[197].  In most cases of EHV-1 induced abortions, virus can be isolated from the aborted fetuses, 
yet, in some experimental abortions induced by EHV-1, the virus could not be isolated from the 
fetuses [198-200]. Virus is consistently isolated from the endothelial cells of the aborted fetuses, 
for which reason endothelial cells are thought to be the primary cells spreading EHV-1 to the 
adjacent parenchymal cells [25]. The pathogenesis and the severity of the disease (abortion) 
depends on a number of factors like the level of viremia, the strain of virus, immune status of the  
animal and some host factors such as hormones. It has been shown by Mumford et al and others 
that virulent strains of EHV-1, such as AB4 or Army 183 strains cause higher abortion rates 
compared to less-virulent strains like V592 [201]. Even one neurovirulent strain, OH-03 or 
Findley strain of EHV-1 produced a lower abortion rate when compared with AB4 (another 
neurovirulent strain) in an intranasal experimental infection [202]. On the other hand, host factors 
like prostaglandin hormone which is secreted at the uteroplacental interface are assumed to play 
roles to initiate the abortion [25]. 
         EHV-1 infected mares may abort without any previous symptoms within 9 days to 4 months 
of infection although most abort within 21 days after infection [203]. EHV-1 induced abortions 
could be sporadic as well as epidemic. The majority of the EHV-1 induced abortions occur in late 
gestation usually during the last 4 months [204]. Normally the abortions do not compromise the 
mare’s future reproductive capability and the mares can become pregnant very soon after the 
abortion [63, 205]. Foals can be infected either within the uterus of the mare or can get the 
infections from their mothers just after they are born but both the cases lead to pneumonia, 
respiratory failure and death [206, 207]. Foals also suffer from gastrointestinal disease and 
neurological signs [207]. Treatment is usually not effective against the foetal EHV-1 infections 
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and most of the foals succumb to respiratory infection followed by secondary bacterial infection 
[208]. 
         Although not well-studied, the reproductive ability of stallions could also be compromised 
by EHV-1 infections. Stallions have been reported to suffer from scrotal edema and loss of libido 
[209, 210]. Tearle et al have documented that stallions experimentally infected with EHV-1 
showed a significant number of morphologically abnormal sperm cells and there was also 
evidence of shedding of infectious virus into the semen [211]. 
1.10.3 Neurologic Disease:  
         Although sporadic in nature the neurologic form of EHV-1 disease or equine herpesvirus 
myeloencephalopathy (EHM) is the most severe form of the infection. However, there has been 
an increase in the number of cases of EHM in recent years as has been documented in recent 
outbreaks in riding schools, racetracks as well as veterinary hospitals all over North America and 
Europe. This has caused the USDA-APHIS to list this disease as an emerging infectious disease 
[212, 213]. Unlike pathologies caused by other alphaherpesviruses like HSV-1, EHV-1 induced 
neurologic disease is developed as a result of the vasculitis of the blood vessels of the CNS. After 
the entry of the virus, and subsequent development of viremia, EHV-1 reaches to the different 
systems including the CNS where the virus establishes infection of endothelial cells of the 
arterioles of the brain and spinal cord. This causes an acute inflammatory response resulting in 
swelling, infiltration of inflammatory cells including lymphocytes releasing different types of 
cytokines such as tumor necrosis factor (TNF) with resulting tissue damage, deposition of 
immune complexes and formation of thrombi within the blood vessels. The vasculitis and thrombi 
lead to hypoxic degeneration and malacia of the surrounding nervous tissues of both the white 
and the grey matter with multifocal hemorrhages. The damage to the neural tissues also impairs 
blood flow and nutrient supply to the surrounding nervous tissues of the spinal cord and brain, 
aggravating the hypoxic degeneration leading to the death of neural cells. Although EHV-1 is an 
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endotheliotropic virus, it has also been occasionally isolated from the neural tissues of EHV-1 
infected horses.  
         Outbreaks of EHM can occur as a squeal to respiratory disease or abortion or it can occur 
without the horse showing the signs of respiratory disease or abortion [214, 215]. There are 
probably multiple factors contributing to the development of EHM. Host factors like immune 
status of the animal, or vaccination frequency, virus factors like the strain of virus, and also 
environmental factors have been reported to influence the development of EHM.  Although 
previously it appeared to be primarily a disease of pregnant and lactating mares, recent reports 
suggested that the disease can affect horses of any age or sex as has been evidenced by reports of 
outbreaks of EHM in foals, yearlings, geldings, mares and stallions [63].Younger foals can 
develop the disease but older horses are more prone to develop EHM [216]. Allen (2008) reported 
that in an experimental study older horses (>20 years of age) with reduced frequency of cytotoxic 
T-lymphocyte (CTL) precursors were more susceptible to the development of EHM [217]. Some 
researchers also suggested that the season may also influence horses to develop EHM as most 
EHM outbreaks were reported to occur during late autumn, winter and spring [216]. A recent 
study by Nugent et al has linked a single point mutation from the nucleotide adenine (A) to 
guanine (G) in the DNA-polymerase gene of EHV-1 encoded by ORF30 at position 2254 
(ORF30; A2254→G2254) to EHM [218]. This mutation changes the amino acid asparagine (N) 
to aspartic acid (D) at position 752 (N752→D752) of EHV-1 DNA-polymerase protein and this 
mutation enables the virus to cause high titer-viremia and develop EHM in horses [218]. It is 
interesting to note that EHV-1 with A2254 also has been reported to cause EHM in several cases 
while in other cases EHV-1 with G2254 has not produced any neurologic sign [219-221]. 
Moreover, a study by Kasem et al has suggested that the UL24 gene encoded by ORF37 is a 
determining factor for development of neurologic disease in a mouse encephalitis model [107]. 
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These contradictory findings suggest that a single viral factor may not be responsible for 
development of EHM; rather, the disease is a multifactorial one.  
         The onset of neurologic signs of EHM starts within 6-10 days after the beginning of the 
respiratory tract infection; however, signs of EHM may appear as early as 24 hours following the 
onset of fever. Clinical signs may vary and are dependent on the location and severity of the 
lesions in the CNS [222]. The signs reach at peak within 48-72 hours after the onset of the 
symptoms of EHM [25]. Usually there is high fever (41.1 ºC) before appearance of the signs of 
the neurologic disorder such as temporary ataxia, proprioceptive deficiency, stiffness and 
weakness of the limbs, swaying, stumbling and falling or complete paralysis [14, 25]. Although 
paralysis of the hind limbs is usually seen, quadriplegia has also been frequently reported. 
Normally the recumbency as a result of paralysis occurs within the first 24 hours of the onset of 
the symptoms of hind limb paralysis. Horses tilt their heads, and lose the sensation and sensory 
reflexes in the perineal area, inguinal areas and hind limbs although the appetite may remain 
normal [214].Due to bladder dysfunction there may be urinary incontinence or retention of urine 
and signs of vulvar or penile flaccidity with cystitis are also reported. Horses will be severely 
depressed and the recovery time varies from several days to 18 months depending on the severity 
of the neurologic symptoms [215]. In the United States, the morbidity rate related to EHV-1 
infection causing EHM ranges from 1% to 90% whereas the case-fatality rate ranges from 0.5% 
to as high as 40% [222]. 
         Prognosis for the non-recumbent horses may be good but horses recumbent for more than 
48 hours usually develop  fatal complications like pneumonia, colic or bladder rupture, and 
eventually die in coma or convulsion [25, 222].  In some cases, however, severely recumbent 
horses also recover and the recurrence of the signs of neurologic disease from the recovered 
horses has not been reported [222]. 
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1.10.4 Ocular Disease: 
         Hypervirulent strains of EHV-1 infection in foals may sometimes cause serious ocular 
disease, primarily chorioretinitis resulting in the visual impairment [223]. Within 3-5 weeks after 
respiratory tract infection by EHV-1, foals show the chorioretinal lesions which may be focal, 
multifocal, or diffuse [25]. Uveitis may also be seen in some foals after the outbreak of EHM 
[210]. Some reports also suggest that severe ocular infection can cause extensive retinal 
destruction leading to blindness [223]. Evidences suggest that diffuse retinal lesions can cause 
blindness while focal and multifocal lesions do not compromise the vision greatly [25]. 
1.11 Laboratory Diagnosis: 
For the proper control of the disease, diagnosis at an early stage is of paramount importance. A 
physical examination of the infected horses for the clinical signs along with proper history is very 
important in the diagnosis of EHV-1 infection [16]. The respiratory form of the infection can be 
diagnosed at a laboratory by virus isolation on a number of EHV-1 sensitive cell lines such as 
rabbit kidney 13 (RK-13) cells, or baby hamster kidney cells (BHK) [214]. The level of EHV-1 
specific serum antibody can be evaluated by enzyme linked immunosorbent assay (ELISA), or by 
the serum neutralization test. Development of an EHV-1 specific ELISA which can distinguish 
EHV-4 from EHV-1 has been very useful in the diagnosis of EHV-1 infection [224]. The most 
sensitive diagnostic tool for the diagnosis of EHV-1 is probably the real-time RT-PCR. Recently 
multiple real-time PCR assays have been developed not only to diagnose specifically EHV-1 but 
also to differentiate between neuropathogenic and non-neuropathogenic strains of EHV-1 on the 
basis of the presence of ‘G’ or ‘A’ nucleotide at 2254 position in DNA polymerase gene [225, 
226]. Another important tool to diagnose EHV-1 is by immunofluorescence assay by using EHV-
1 specific monoclonal antibodies [16]. After necropsy, immunohistochemical staining of paraffin 
embedded tissues is done to confirm the diagnosis of EHV-1 abortion as well as EHM cases 
[214]. Although the diagnosis of EHM is more difficult, a proper physical examination for the 
presence of neurological signs along with the history often helps tremendously. Clinical 
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specimens that are collected to diagnose EHM are nasal swabs, whole blood, cerebrospinal fluid, 
acute and convalescent serum [222]. Macroscopically, on Post-mortem examination brain and 
spinal cord may show a brownish patchy discoloration [214]. Microscopically, signs of vasculitis 
with ischemic and hemorrhagic infarction, perivascular edema and necrosis of parenchyma are 
seen [214]. 
         However, differential diagnosis is often required from other similar infections like EHV-4 
infection, equine influenza virus infection, or equine arteritis virus (EAV) infection for the 
respiratory form of disease; EAV infection for abortion; West Nile virus infection, Sarcocystis 
neurona infection for EHM in order to confirm EHV-1 infection. 
1.12 Treatment and Supportive Care:  
         No specific treatment is available for EHV-1 induced diseases. However, supportive care 
such as good management practices to limit the spread of the infection, symptomatic treatment of 
infected horses, and use of antibiotics to control secondary bacterial infection can be very helpful 
to deal with EHV-1 infections. During EHV-1 induced rhinopneumonitis, phenylbutazone at 3 
mg/kg body wt (bwt), PO, q 12h to 24h or, flunixin meglumine at 1.1 mg/kg bwt, IM, q 12h to 
24h are the drugs of choice [16]. Trimethoprim-sulfadiazine preparation at 30 mg/kg bwt, PO, q 
24 h for 7-10 days is used to prevent secondary bacterial infection [16]. In severe bacterial 
infections in young horses, broad-spectrum antimicrobials like amikacin, procaine Penicillin G, 
Cetiofur, or Ceftazidine can be used [16]. Horses with anorexia may need fluid electrolyte 
therapy. In case of paralytic EHV-1 infections, parenteral administration of corticosteroids (0.1 
mg/kg bwt, IV, q, 24h) and nasogastric intubation of dimethyl sulfoxide (3 ml/kg bwt, q, 24h) 
may be used to reduce the inflammation [16]. In some cases of EHM or neonatal foal infection, 
nucleoside analogues such as acyclovir may also be used. Although use of acyclovir in vitro 
showed an inhibition in EHV-1 replication [227] but in vivo use of acyclovir in neurologic 
disease was not beneficial [228]. Beside acyclovir, valacyclovir also has been tried in 
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experimentally infected horses with EHV-1. Valacyclovir treatment, however, has not shown any 
significant reduction in clinical signs, virus shedding, and viremia of EHV-1 infected horses 
[229]. In case of EHM affected horses, cystitis is a common symptom which could be dealt with 
careful catheterization with antibiotics [14].  Laterally recumbent horses may be considered for 
euthanasia [16].  
1.13 Prevention: 
         Complete elimination of EHV-1 infection from the herd is impractical because of the latent 
reservoirs of carrier horses that remain a continuous threat. However, the prevention of EHV-1 
infection can be done by prophylactic immunization and good management practices in the herd. 
1.13.1 Vaccination: 
         For all horses at risk of EHV-1 infection, vaccination is advised as a preventive measure. 
Maternally derived antibody through colostrum decreases with age and foals at the age of 5-6 
months become maximally susceptible to infection [16]. Young foals at weaning should be 
provided two intramuscular injections of vaccines at an interval of 3 months, with the subsequent 
booster dose at every 3-6 months to prevent the respiratory form of disease [16]. Pregnant mares 
should be vaccinated to reduce the risk of EHV-1 induced abortions [16]. No vaccine is available 
to prevent either EHM or development of carrier state [230]. 
         Both inactivated vaccines as well as modified live virus (MLV) vaccines are available and 
the immune response elicited against EHV-1 vaccination depends on the type of vaccines [230, 
231]. The MLV vaccine induces both CTL mediated immunity and humoral immunity and have 
been found to reduce cell associated viremia [230]. On the other hand, inactivated vaccines have 
been shown to induce virus neutralizing antibody and also reduce viremia and nasal shedding of 
virus [231]. A DNA vaccine and also a recombinant vaccine using canarypox virus as vector 
expressing EHV-1 glycoprotein gB, gC, and gD were shown to suppress initial virus replication 
in the upper respiratory tract and the vaccines also induced neutralizing antibodies [232]. 
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However, the vaccines provided a partial protection and did not protect EHV-1 challenged horses 
from cell-associated viremia [232]. In another study Soboll et al have observed that DNA 
vaccines comprising of EHV-1 glycoproteins gB, gC, and gD provided partial protection [233]. In 
spite of the promising results, none of the DNA vaccines targeting the glycoproteins provided 
horses with complete protection from EHV-1 abortions or EHM. Very interestingly, a 
recombinant vaccine consisting of IE gene of EHV-1 in modified live vaccinia virus vector 
provided significant protection from clinical disease as well as cell-associated viremia to EHV-1 
challenged horses [234]. The vaccine induced both humoral and CTL mediated immunity but a 
compete protection from abortion and neurologic disease are yet to be achieved [234]. 
1.13.2 Management: 
It has been reported that good managemental practices and sound vaccination strategy can reduce 
75% of the EHV-1 induced abortions in the United States [235]. Management of herds should be 
primarily done to reduce the spread of epidemics [63]. Horses should be divided into small 
groups and segregated on the basis of distinct categories like weanlings, yearlings, new arrivals 
and transients [16, 63]. Any new horse to be included in the small groups should first be kept in 
quarantine or isolation for a period of 21 days [16]. Reduction of stress due to crowding, poor 
nutritional state, heavy parasite infestation, disruption of established social groups or inclement 
weather should be minimized [16]. Horses on prolonged transportation should also be kept for 21 
days in isolation [16, 25]. Proper disinfection and hygienic practices must be followed to prevent 
the spread of EHV-1 infection during an already present outbreak [63].  
1.14 Host Immune Responses to EHV-1: 
         After the discovery of EHV-1 in the early 1930s there have been numerous efforts over the 
decades by many scientists to characterize the protective immune responses against EHV-1 in 
order to find a suitable vaccine [230, 236]. EHV-1 infection will induce a short-lived protective 
immune response [237]. Both virus neutralizing (VN) as well as complement fixing (CF) 
antibodies have been found in the sera of EHV-1 infected horses as early as 2 weeks after 
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infection both in experimental as well as field conditions [27, 238]. VN antibody is EHV-1 type 
specific and gives protection for longer (maximum 1yr) than CF antibody (maximum 3 months) 
which cross reacts with EHV-4. Antibodies are directed principally against envelope 
glycoproteins, gB, gC, gD, gH and gp2 of the virus [110, 124, 239, 240]. gC and gD proteins of 
EHV-1 have been reported to have neutralizing epitopes [241, 242]. There is a controversy 
whether the humoral immunity of horses can protect them from clinical disease by EHV-1. It is 
however, true that the mucosal antibody, predominantly IgA, takes an important role in the 
protective response to EHV-1 infection by neutralizing the cytolytically replicating EHV-1 to 
reduce the nasopharyngeal virus shedding [243]. Re-infection with EHV-1 is very common in 
horses and, interestingly, even the presence of virus-specific high antibody titers cannot prevent 
horses from viremia during re-infection [243, 244]. Although VN antibody can reduce the signs 
of EHV-1 induced respiratory disease, it cannot protect the horses from abortion as well as 
neurologic disease, EHM [237]. 
         As with other intracellular viruses, clearance of EHV-1 infection also depends on T 
lymphocytes, primarily on the CD8+ cytotoxic T lymphocytes (CTLs) which are the major 
effector arm of the cellular branch of the immune system [230, 233]. It has been demonstrated 
that there is a direct correlation between the frequency of CTL precursors (CTLp) and the level of 
protection in experimental EHV-1 infections [245]. Older ponies with high CTLp frequencies 
showed reduced signs of clinical disease after experimental EHV-1 infection [246]. Kydd et al. 
have reported that there is enhanced CTL activity and increased frequency of CTLp after 
experimental EHV-1 infection [245]. Since the identification of the importance of CTL-mediated 
immunity in the clearance of EHV-1, many attempts have been made to find the CTL target 
epitopes.  Studies have shown that the immediate early (IE) protein encoded by ORF64 of EHV-1 
serves as the CTL epitope which induces the virus-specific CTL-mediated killing of infected cells 
[233, 234, 247]. This CTL response to EHV-1 has been reported to be MHC class I serological 
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haplotype A3/B2 restricted [230, 233, 234, 237]. In another study, beside the IE protein, some 
glycoproteins such as gC, gD, gI, and gL were also shown to have CTL epitopes, although the 
findings were only seen in individual horses [248]. However, studies by Soboll et al did not find 
any significant EHV-1 specific lymphoproliferative or CTL responses when they challenged 
ponies with EHV-1 after DNA vaccination expressing gB, gC or gD [233].  
1.15 Immune Evasion Strategies of EHV-1 and Other herpesviruses: 
         Despite these protective immune responses, complete clearance of this pathogen from the 
infected host is yet to be accomplished because of many impressive immune evasion strategies 
that EHV-1 possesses. The virus can interfere with all 3 principal immune effector mechanisms, 
namely antibody dependent lysis, CTL-mediated killing and NK cell mediated killing of infected 
cells [237].  
1.15.1 Evasion from Antibody Mediated Immunity: 
         Herpesviruses are known to have co-evolved with their hosts for a long time. During this 
period of evolution the virus evolved a number of immunomodulatory mechanisms to escape 
from host immune surveillance to assure its existence throughout the host’s lifetime. Antibody 
(Ab) dependent humoral immunity gives protection against viruses either by neutralization of the 
cell-free viruses, opsonization or antibody dependent cell cytotoxicity (ADCC). After the 
infection of the host cells by EHV-1, viral glycoproteins are synthesized and transported to the 
surface of the cell membrane. In general, the virus specific antibody recognizes these 
glycoproteins or viral antigens and triggers the host effector arms such as complement, 
phagocytic cells and NK cells which then clear the virus from the host. After the recognition of 
viral antigens, the complement component C1q binds to the Fc region of the virus-specific 
antibody and initiates the subsequent cascade of reactions resulting in the destruction of the virus 
infected cells. Similarly, NK cells as well as phagocytic cells like macrophages also express Fc 
receptors that recognize the Fc domain of the virus-specific antibody bound to virus infected cells 
and subsequently causes the lysis of the infected cells.  
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         Although EHV-1 vaccination or infection induces a short-lived antibody responses, the 
recognition of EHV-1 infected cells is however, not optimal. EHV-1 can hide its antigenic 
proteins from being expressed on the surface of infected PBMCs as has been demonstrated by 
van der Meulen et al [249, 250]. More than 98% of EHV-1 infected PBMCs did not express any 
viral envelope proteins in their study even in the presence of cell-associated viremia. This 
prevents the virus infected cells from antibody mediated clearance and is a potent immune 
evasion mechanism adopted by EHV-1 [250]. Although late viral envelope glycoproteins were 
undetectable inside the infected PBMCs, the IE protein and early proteins such as ICP22 were 
detectable suggesting that viral replication in the PBMCs was restricted to the early phase [250]. 
It has, however, also been suggested that viral replication may not be restricted in PBMCs, but 
instead infected PBMCs expressing viral envelope proteins may be selectively removed from the 
circulation [250]. In both ways, interference in the expression of the envelope proteins on the 
surface of PBMCs makes the infected PBMCs resistant to the neutralizing effect of the circulating 
virus-specific antibodies. This helps the virus to escape from Ab-mediated killing of the infected 
cells and the viremic PBMCs can spread to different organs and systems. Interestingly, these 
infected PBMCs with restricted viral replication still have the capacity to transmit infectious 
viruses to susceptible cells like endothelial cells by direct contact [250]. It is possible that direct 
contact with susceptible cells may trigger yet unknown cell-signaling which initiates the onset of 
transition of the viral replication cycle from early to late phase [250]. 
         On the other hand, a few PBMCs still express the viral envelope proteins but more than 
two-third of these cells cannot be cleared in the presence of complement and virus-specific Ab in 
vitro [249]. This escape from complement mediated lysis of infected cells could be attributed to 
the low efficiency of equine complement [251]. But this escape phenomenon may also be 
attributed to viral proteins which actively interfere with complement mediated cell lysis. Indeed, 
it has been shown that the envelope protein gC of EHV-1 binds to the C3 component of 
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complement interfering with downstream cascade events and this causes the virus to be resistant 
to complement mediated killing resulting in evasion of another major branch of the immune 
system [126].  
1.15.2 Evasion from CTL mediated Immunity: 
         Because herpesviruses are intracellular parasites and are able to thwart Ab-mediated 
immunity, CD8+ cytotoxic T lymphocytes play a crucial role in clearing them from the host’s 
system. The CD8+ CTL-mediated immune system exerts its effect via the recognition of viral 
peptides presented by Major Histocompatibility Complex-I (MHC-I) molecules on the infected 
cell surface.  In general, after the infection of the host cells by virus, viral proteins will be 
expressed and nascent proteins will be folded within the host cells. However, within the 
cytoplasm some of the nascent viral proteins, mainly misfolded proteins, will be cleaved by the 
host multi-subunit proteasome complex into smaller peptide fragments of 8-10 amino acids (aa) 
in length in an ubiquitin-dependent manner [252, 253]. These cleaved peptides are then 
transported into the endoplasmic reticulum (ER) via the Transporters associated with Antigen 
Processing -1 and -2 (TAP1 and TAP-2) [254]. Meanwhile, the newly synthesized MHC class I α 
chains will be transported into the ER for folding with the help of the chaperone protein, calnexin, 
and then will associate with β2-microglobulin (β2m) to form a heterodimeric complex (α:β2m) 
[253]. The short antigenic peptide fragments will then associate with the α:β2m heterodimer via 
TAP with the help of tapasin, another chaperone protein, to form a stable peptide-MHC-I 
complex which will finally be transported to the cell surface via the Golgi apparatus [254, 255]. It 
is also important to note that if MHC-I molecules do not associate with antigenic peptides they 
will be transported back to cytosol and be degraded by proteasome complexes in an ubiquitin 
dependent manner [256]. The peptide antigens  (Ag) presented by MHC-I molecules on the 
infected cell surface will be recognized by the Ag-specific CD8+ T cells which will be 
subsequently activated and converted to effector cells known as CTLs [253, 256]. These CTLs 
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will then induce apoptosis in the infected cells, resulting in the clearance of the virus infected 
cells from the host’s system [253]. 
         Even in the presence of these intricate host mechanisms, herpesviruses are still able to 
escape the host immune surveillance and co-exist with their hosts by adopting multiple immune 
evasion strategies.  Using different continuous cell lines, such as equine embryonic lung cells, 
NBL-6 cells, or equine kidney primary fibroblasts, it has been shown that EHV-1 directly 
downregulates the surface expression of the MHC-I molecules on the infected cells in vitro [257, 
258].  Rappocciolo et al reported that EHV-1 interferes with the cellular antigen presentation 
pathways by downregulating the cell surface expression of MHC-I molecules via the induction of 
enhanced endocytosis by early viral proteins [257]. Many herpesviruses inhibit the transport of 
peptides by interfering with the function of TAP, in order to interfere with the Ag presentation 
pathways. EHV-1 proteins were found to interfere with the peptide transport activity of TAP, 
causing the reduced availability of antigenic peptides in the ER for association with MHC-I 
molecules, which in turn results in reduced maturation and thereby downregulation of the cell 
surface expression of MHC-I molecules [237, 258]. Koppers-Lalic et al found that the EHV-1 
protein pUL49.5 inhibits TAP and thus inhibits the expression of MHC-I molecules on the 
surface of infected cells [259].  Kurtz et al however, argued about two possible mechanisms for 
the downregulation of the surface expression of MHC-I molecules by early EHV-1 proteins 
[260]. Because EHV-1 utilizes MHC-I as an entry receptor, they suggested that it is possible that 
after EHV-1 binds to its receptor, that molecule will quickly be internalized along with the virus 
[260]. Another possible mechanism is that EHV-1 utilizes its receptor to enter into the cells and 
the MHC-I molecules are not internalized; rather, EHV-1 protein pUL49.5 suppresses further 
expression of the molecules on the cell surface [260]. Like EHV-1, other members of the genus 
Varicellovirus such as EHV-4, BHV-1 and PrV have been found to encode the novel TAP 
inhibitor, pUL49.5 protein, but the mechanism of inhibition is different for different viruses of the 
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same genus [261]. While pUL49.5 proteins of EHV-1 and EHV-4 interfere with the binding of 
ATP to TAP, the same protein of BHV-1 is found to trigger TAP for proteasomal degradation 
[261]. In a very recent study, it has been revealed that another novel EHV-1 phosphoprotein, 
pUL56 encoded by the ORF1, directly inhibits the surface expression of MHC-I molecules in 
vitro and this inhibition was independent of pUL49.5 mediated inhibition of TAP [106]. It has 
been assumed that at the early stage of infection pUL56 will remove most of the MHC-I 
molecules from the surface of the infected cells even before the loading of most viral peptides on 
to the binding groove of MHC-I molecules [106]. However, in the later stage of the infection, 
pUL56 will synergistically suppress MHC-I expression with pUL49.5 and interfere with the 
presentation of viral antigenic peptides to the CTLs [106]. The mechanism of this pUL56 
mediated suppression of the surface expression of MHC-I molecules is yet to be determined but 
phosphorylation of pUL56 protein is not necessary for this action [106].  
         In vitro EHV-1 infection was found to decrease the expression of MHC-I significantly on 
the surface of infected PBMCs [237, 250]. But in vivo, infected and non-infected PBMCs from 
the same ponies experimentally infected with EHV-1 did not show a considerable difference in 
the expression of MHC-I molecules [237]. It is possible that this apparent difference was because 
of restricted EHV-1 replication in vivo compared to in vitro and also because only the absolute 
percentage of MHC-I positive PBMCs was considered, and the amount of MHC-I expression per 
infected PBMC was not considered in that particular study [237, 250].  
         Another strategy that herpesviruses could use to subvert the cell-mediated immunity is to 
destroy lymphocytes directly, and indeed experimental EHV-1 infection by Kydd et al showed an 
acute and transient reduction in the number of T lymphocytes, both CD4+ and CD8+ T 
lymphocytes, but increased neutrophils in the lungs of infected horses at 2 days post infection 
(d.p.i.) [237, 262]. This reduction of the lymphocyte numbers could be either due to direct 
destruction of the lymphocytes, or selective migration of the immune cells causing overwhelming 
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infiltration of the neutrophils into the lung resulting in the decline in the number of lymphocytes 
[262]. Kydd et al also reported an increase in the number of CD8+ T lymphocytes at 21 d.p.i. 
[262]. Another study by McCulloch et al argued that the lymphopenia after EHV-1 infection may 
be either due to direct destruction of these lymphocytes by virus or partly may be due to the 
selective migration of different inflammatory cells in different times after infection [192]. In fact, 
there are multiple reports suggesting a decrease in the number of CD4+ as well as CD8+ T 
lymphocytes in the blood of infected horses [192, 263]. Beside these, EHV-1 may possess many 
other immune evasion strategies that are yet to be discovered to escape from CTL mediated 
eradication from the host’s system. 
1.15.3 Evasion from NK cell-mediated immunity: 
         NK cells are a type of cytotoxic lymphocyte and are considered to be cells of the innate 
immune system. The cells have two types of receptors, activating and inhibitory receptors [264]. 
The activation of the NK cells depends on the intricate balance between these two types of 
receptors [264, 265]. The inhibitory receptors can sense the self MHC-I molecules on the surface 
of the antigen presenting cells and pass inhibitory signals to the cells [265]. But in general, during 
viral infections expression of MHC-I molecules on the infected cell surface is reduced or altered 
and that missing MHC-I molecules (known as ‘missing self’ hypothesis) triggers the activating 
receptors which in turn activate the NK cells to kill the infected cells [265]. The NK cells are 
considered to be evolved to supplement the function of CTLs which is inhibited by the reduced 
surface expression of different types of MHC-I molecules [265].  
         Many viruses including herpesviruses have been shown to develop specific strategies to 
evade NK cell-mediated immune surveillance [266]. Like other alphaherpesviruses, EHV-1 also 
has been shown to selectively downregulate the surface expression of certain types of MHC-I 
molecules while not affecting other types which indicates that the downregulation of MHC-I 
molecules is allele specific [257]. If that selective downregulation of MHC-I alleles does not 
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involve those molecules responsible for recognizing the inhibitory receptors, it is possible that the 
virus may easily evade NK cell-mediated detection and removal from the host’s system [257, 
265]. Thus by selectively reducing the surface expression of MHC-I molecules on the infected 
cells, EHV-1 may escape both CTL as well as NK cell-mediated immunity.  
1.15.4 Evasion from Cytokine Network: 
         Cytokines are small, hormone-like regulatory proteins (~25KDa) that are secreted from 
various cells in the body in response to different stimuli and act in autocrine, paracrine as well as 
endocrine manners via specific receptors present on various immune and non-immune cells. 
Cytokines play a critical role in control of the innate and the adaptive immune systems by 
controlling the development and expression of a broad array of immune responses [267]. 
Chemokines are pro-inflammatory cytokines that are chemoattractant in nature and are secreted in 
the early phase of the infection inducing direct recruitment of inflammatory cells and 
lymphocytes in adjacent cells [268]. Viruses have developed different strategies to evade the 
cytokines responses such as mimicking host cytokines or cytokine receptors, induction of 
inhibitory cytokines, or secretion of cytokine binding proteins [269]. Viral homologues of 
cytokines (virokines) or viral homologues of cytokine receptors (viroceptors) compete with their 
corresponding host cytokines or cytokine receptors respectively and modulate the host immune 
response by cytokines [270]. 
         Experimental EHV-1 infections of ponies were shown to induce an inhibitory circulating 
cytokine, transforming growth factor β (TGF-β) that is reported to cause suppression of 
lymphocyte proliferation in vitro [271]. The subsets of immune cells that secrete active TGF-β 
after EHV-1 infection are alveolar macrophages, lymphocytes, and platelets [272]. Scientists also 
documented similar reports of EHV-1 mediated suppression of lymphocytes but unlike other 
studies, their reports did not find any circulating factor to be responsible for that 
immunosuppression [273-275]. EHV-1 also alters cytokine functions of the host with its envelope 
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protein, gG which is a viral homologue of chemokine binding receptors. The glycoprotein gG 
exists in two different forms, either in secreted soluble form or integrated into the cell membrane. 
The secreted gG binds to a broad range of chemokines and blocks the interaction of cellular 
cytokines with cellular receptors resulting in the suppression of chemokine mediated recruitment 
of inflammatory cells [276]. It has also been suggested that gG protein inhibits equine IL-8 
mediated migration of neutrophils in the lungs of EHV-1 infected horses [277]. Furthermore, gG 
protein was also shown to suppress migration of murine macrophages by macrophage 
inflammatory protein 1α (MIP-1α) [131]. Thus, EHV-1 has been found to interfere with all major 
types of immunity of horses: cytokine-mediated immunity, Ab-mediated humoral immunity, 
CTL-mediated cellular immunity, and NK cell-mediated immunity. 
1.16 Type-I Interferon and Host Immune Response: 
         Interferons are a group of biological regulatory proteins also known as cytokines which act 
as a first line of defense against many viral infections [278-280]. These cytokines are synthesized 
and secreted by the virus infected host cells and inhibit virus replication in the infected cells as 
well as nearby uninfected cells to induce a global antiviral state. While studying interference of 
influenza virus replication, Isaacs and Lindenmann first reported that a secreted antiviral factor 
induced by inactivated influenza virus could interfere with the replication of live influenza virus 
and they named the factor ‘interferon’ [281]. To date three classes of interferons (IFN), namely 
type-I, II and III, have been characterized on the basis of the amino acid sequences [279]. Type-I 
IFN includes IFN-α (multiple subtypes), β, κ, ε, τ, and ω; type-II includes IFN-γ and type-III 
includes λ1, λ2 and λ3 [278, 279]. Type-I and III IFNs are induced principally in viral infections 
by different types of cells including epithelial, fibroblast and dendritic cells. On the other hand, 
type-II IFN, which is also known as ‘immune IFN’, is expressed by the cells of the immune 
system, principally by activated T cells, NK cells and macrophages [282]. Type-III IFN functions 
by recruiting immune cells such as leucocytes, and macrophages to the site of inflammation and 
also contributes to induction of an antiviral state inside the host cell [282]. However, type-II IFN 
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is best known for its immune modulatory function rather than antiviral effect [278]. While type-I 
IFNs signal through IFN receptor 1 and 2 (IFNAR1 and IFNAR2), and type-II through IFN 
gamma receptor 1 and 2 (IFNGR1 and IFNGR2), type-III IFNs signal through IFN-λ receptor 
1(IFN-λR1) and IL-10R2 [283]. 
 
Figure 1.8: IFN-β  Induction Pathways: Viral PAMPs are recognized by different PRRs present 
either in the cytoplasm or endosome or on the outer cell surface. This recognition triggers the 
activation of different adapter proteins and kinases resulting in the activation of transcription 
factors IRF-3, and NF-κB, which then are translocated into the nucleus and associate with the 
promoter region of IFN-β gene. This causes an increased transcription of IFN-β gene which is 
then translated in the cytoplasm. IFN-β then signals through JAK-STAT signaling pathways 
resulting in the expression of IFN-α genes. 
Type-I IFN induction by virus infected cells occurs in 3 phases- sensitization, induction and 
amplification [284].  In the sensitization or first phase, the viral motifs known as pathogen 
associated molecular patterns (PAMPs) are detected by the pattern recognition receptors (PRRs) 
present in the cells resulting in the signal transduction. These signals will converge to coordinate 
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activation of transcription factors like interferon regulatory factor 3 (IRF-3), and NF-κβ which 
induce IFN-β at a very low level [280, 285] (Figure 1.8). Two families of PRRs that play the 
major role in sensing the viral motifs are toll-like receptors (TLRs) and retinoic acid inducible 
gene-I (RIG-I) like receptors (RLRs). Among these PRRs, TLR-3, 7, 8 and 9, which are localized 
in endosomes and RLRs like melanoma differentiation-associated gene-5 (MDA-5), and 
Laboratory of Genetics and Physiology 2 (LGP2), which are localized into cytoplasm, are mostly 
engaged in viral PAMP detection. Most of the known PRRs signal through activation of IRF-3 by 
phosphorylation which forms dimers and translocates into nucleus, binds to the promoter of IFN-
β and induces the transcription of IFN-β [284]. 
         In the induction or second phase, the secreted IFN-β binds to its cognate receptors (IFNAR1 
and IFNAR2) present ubiquitously on the cell surface (Figure 1.9). On binding of IFNs to their 
receptor subunits, there is heterodimerization and subsequent phosphorylation of tyrosine 
residues in the receptors [286]. This in turn triggers the activation of proteins in the receptor 
associated Janus kinase (JAK) family, such as JAK-1 and Tyk-2, by phosphorylation [286]. 
Activated JAKs phosphorylate signal transducer and activator of transcription-1 (STAT-1) and 
STAT-2 at tyrosine residues. These phosphorylated STATs associate with interferon regulatory 
factor 9 (IRF-9) forming a heterocomplex known as ISGF3 [287] (Figure 1.9). ISGF3 
translocates into the nucleus where it binds to the interferon stimulated response elements (ISRE) 
of different IFN inducible genes including IRF-7 causing their enhanced transcription [287]. 
Activated IRF-3 forms a heterodimer with IRF-7, translocates into the nucleus and binds to the 
promoter of IFN-α genes causing their increased transcription [285]. 
         In the amplification or third phase, the synergistic effect of IFN-α and IFN-β induces 
enhanced transcription of a diverse set of genes known as interferon stimulated genes (ISGs) 




Figure 1.9: Type-I IFN signaling pathways. Type-I IFNs bind to their cognate receptors 
IFNAR1 and IFNAR2 causing the receptor dimerization which triggers activation of the JAK-1 
and Tyk-2 protein kinases. The kinases then phosphorylate STAT-1 and STAT-2 molecules 
which then form a dimer and then translocate into the nucleus from the cytoplasm. Subsequently, 
the dimers associate with another protein, IRF-9 forming a trimeric complex, ISGF3, that binds to 
the interferon sensitive response elements (ISRE) to enhance the transcription of a number of 
ISGs. 
 
1.17 Antiviral Immunity by Interferon Stimulated Genes: 
         IFNs exert their antiviral effects through direct functioning of ISGs (Figure 1.9) which 
interfere with transcription and translation of viral genes, or promote apoptosis of the infected 
cells [284, 288]. Among more than 300 known ISGs, the most characterized type-I IFN induced 
genes are dsRNA dependent protein kinase R (PKR), 2’-5’-oligoadenylate synthetase (OAS), 
ISG-15, ISG54 and ISG-56 [280]. PKR activation requires binding to dsRNA, which is a 
byproduct derived during the replication of both DNA and RNA viruses. Activated PKR 
autophosphorylates, homodimerizes and then phosphorylates the eukaryotic translation initiation 
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factor, eIF-2α, inhibiting further translation of host cell proteins. In addition to this, PKR can 
induce NF-κB activation by phosphorylating IκB [289]. OAS activation also requires binding to 
dsRNA. This in turn converts ATP to 2’-5’-oligoadenylate which then activates a cytoplasmic 
enzyme, RNase L, leading to degradation of viral as well as cellular mRNAs and thus OAS 
inhibits virus replication [290].  
        ISG15 is, on the other hand, an antiviral protein that is upregulated dramatically in response 
to type-I IFN. ISG15 is an ubiquitin-like protein which covalently associates with many cellular 
proteins and ubiquitinylate those proteins for proteasome mediated degradation [291].  
         Another very important ISG of antiviral importance is ISG56 which happens to be the first 
IFN inducible gene to be discovered and cloned subsequently [292]. The ISG56 family of 
proteins includes ISG54 (p54), ISG56 (p56), ISG58 (p58) and ISG60 (p60) [293]. Human ISG54 
and ISG56 have been reported to interact with translation initiation factor, eIF3 complex, and 
subsequently inhibit its ability to stabilize the ternary complex, eIF2-GTP-Met-tRNAi formed 
during the initial step of translation [293, 294]. Furthermore, recently it became known that 
ISG56 can also directly bind to viral proteins and inhibit replication of that virus. For example, 
ISG56 protein interacts with a key human papillomavirus (HPV) protein, E1 helicase and 
inactivates it [295].  
          Very recently one IFN inducible gene was identified while studying the genes induced by 
human cytomegalovirus (HCMV) infection and was named viperin (‘virus inhibitory protein, 
endoplasmic reticulum-associated, interferon-inducible’) [296, 297]. Viperin is a multidomain, 
multifunctional protein with 3 distinct domains: an N-terminal domain containing an amphipathic 
α helix, a central domain containing three cysteine residues organized in a CXXXCXXC motif 
and a C-terminal conserved domain. Viperin is also known as radical S-adenosylmethionine 
domain containing 2 or RSAD2. The protein is induced in a variety of cell types by a number of 
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stimuli such as different DNA or RNA viruses, type-I, -II, -III IFNs, polyinosinic-poly cytidylic 
acid (poly I:C), or lipopolysaccharide (LPS) [297]. Viperin has been reported to interfere with the 
replication of a broad spectrum of DNA and RNA viruses such as HCMV, West Nile Virus, 
Dengue virus, and Influenza A virus through diverse mechanisms. It has been found that 
overexpression of viperin in fibroblasts interferes with the expression of HCMV structural 
proteins like gB, pp65, and pp28 that are required for viral maturation and assembly and thus 
inhibits replication of HCMV [296]. Viperin has also been found to bind and inactivate an 
enzyme, farnesyl diphosphate synthase  required for the synthesis of cholesterol and other 
isoprenoid derived lipids [297]. As a result it can disrupt the lipid rafts present in the cell 
membrane and it can play a major role in the replication of viruses that use lipid rafts. It has 
indeed been found that overexpression of viperin inhibits the replication of influenza A virus by 
disrupting the membrane lipid rafts [298]. In addition to its antiviral property, viperin has also 
been suggested to be involved as a mediator in the intracellular signaling pathways that control 
immune responses. In plasmacytoid dendritic cells (pDC), viperin has been shown to mediate 
TLR7 and TLR9 mediated production of type-I IFN by recruiting signaling mediators IRAK1 and 
TRAF6 to lipid droplets [299].  
     Beside the ISG mediated innate immune response, type-I IFN also regulate adaptive immune 
responses [285]. IFN-α/β has been shown to upregulate monocyte derived dendritic cell (MoDC) 
maturation markers like MHC-I, MHC-II, CD80, CD86, CD40 and CD83 in vitro [300]. It has 
even been reported that monocytes cultured in GM-CSF + IFN-α/β rather than GM-CSF + IL-4 





1.18 Evasion of Type-I Interferon Response by Alphaherpesviruses: 
         As successful pathogens, viruses will always try to modulate the antiviral responses 
provided by type-I IFN. Multiple viruses have been reported to possess diverse mechanisms to 
evade the IFN-response. Some viruses interfere with global protein synthesis of the host cell; 
some viruses limit IFN induction by interfering with the production of viral PAMPs or their 
availability to PRRs; others inhibit IFN signaling pathways at multiple levels or interfere with the 
function of ISGs; or some viruses even develop replication strategies that are insensitive to IFN 
[279]. Herpesviruses are the master regulators of modulating host immune responses to their 
benefit. Because of their large coding capacity, herpesviruses have evolved multiple proteins to 
interfere with the type-I IFN response. Alphaherpesviruses like bovine herpesvirus-1 (BHV-1) 
and herpes simplex virus-1 (HSV-1) encode an IE protein in the infected cells known as ICP0 
which has been shown to interfere at multiple steps of the type-I IFN response. ICP0 has a zinc 
RING finger domain at its amino-terminus which has E3-ubiquitin ligase activity [302, 303]. An 
intact zinc RING finger domain is necessary for the activity of ICP0 protein in most cases [285, 
303]. Bovine ICP0 (bICP0) degrades IRF3 through its RING finger domain and it also interferes 
with IRF7 resulting in inhibition of IFN-β promoter activity as well as ISG promoters [302-304]. 
In contrary to BHV-1, HSV-1 ICP0 does not degrade IRF3 but sequesters IRF3 from binding to 
promoters of type-I IFN and ISGs [305, 306]. A variety of other mechanisms adopted by HSV-1 
ICP0 have been reported by different researchers including inhibition of IRF7 mediated ISG 
induction as reported by Lin et al [307] and interference with STAT-1 activation as reported by 
Halford et al [308].  
         HSV-1 ICP27 is another multifunctional IE protein that has been shown to be involved at 
multiple steps in the viral lifecycle including viral gene expression and export of viral mRNAs 
[309-311]. The protein is also involved in repressing host transcription as well as mRNA stability 
leading to host shut off of protein synthesis [310]. Studies by Melchjorsen et al have revealed that 
ICP27 inhibits IRF3 activation leading to inhibition of IFN-β induction [306, 312]. ICP27 has 
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also been reported to inhibit STAT-1 activation and its nuclear translocation during wild type 
(WT) HSV-1 lytic infection, further establishing its role in interfering with type-I IFN response 
[313, 314]. HSV-1 infection to Vero cells causes secretion of a heat stable, IFN-antigonizing 
protein that inhibits nuclear translocation of STAT-1 in the infected as well as uninfected 
bystander cells [314]. Very interestingly mere expression of ICP27 protein of HSV-1 induces the 
cell to secrete the same antiviral protein with the ability to inhibit STAT1 activation as well as 
nuclear translocation [314]. 
         A late protein of HSV-1, known as virion host shut off protein (Vhs), has been shown to be 
involved in inhibiting protein synthesis by degrading both host as well as viral mRNA[315]. Vhs 
is thought to interfere with the induction phase of the IFN response where IFN mRNA may be 
degraded by Vhs [316]. A Vhs-deleted HSV-1 has been reported to induce greater amounts of 
type-I IFN and ISGs in murine embryonic fibroblasts (MEF) compared to WT HSV-1 [317]. Vhs 
is also involved in the inhibition of the phosphorylation of STAT-1 [318, 319] and in the 
degradation of ISG transcripts [307, 320]. 
         Another late protein, US3 (a serine threonine kinase) of HSV-1, is also involved in the 
evasion of the type-I IFN response by interfering with the TLR3 mediated immune response 
[321].  Peri et al found an increased induction of IFN-β mRNA and ISGs due to  infection to 
monocytic cells with US3-deleted HSV-1, compared to decreased TLR3 mRNA and decreased 
dimerization of IRF3  in WT HSV-1 infection [322].  
         UL13 protein, which is also a serine threonine kinase of HSV-1, has also been reported to 
be involved in evading the type-I IFN response although the mechanism is not well characterized 
[323]. Besides, ICP34.5 and US11 have also been shown to be involved in interfering with the 
type-I IFN response [324, 325]. 
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         Some of the homologue proteins of HSV-1 and BHV-1 involving the type-I IFN-response 
have also been found in EHV-1 but their functions in the equine host in regard to the type-I IFN 
response are yet to be identified.  
1.19 Statement of Problem and Hypothesis 
         EHV-1 continues to be a very important viral pathogen causing significant economic loss to 
the equine industry all over the world including the United States. As stated earlier, no existing 
vaccine can completely protect horses from abortion, EHM or reinfection. Moreover, within the 
past decade, the number of cases of EHM in EHV-1 outbreaks has been unusually high [212] 
which made this pathogen a great concern for the equine industry. 
        Most of the research characterizing the immune response to EHV-1 infection is focused on 
the adaptive immune system. Unfortunately, the interaction of EHV-1 with the innate immune 
system has not been well characterized. As that there is a strong correlation between neurologic 
symptoms and level of viremia [182, 226, 234, 326], the effective control of EHV-1-induced 
abortion and neurologic disease requires control of viremia [234]. Antibodies are inefficient in 
controlling the cell-associated viremia and even the CTL-mediated immune responses cannot 
clear the virus completely from the host [327]. To cause an abortion or EHM, infection of 
endothelial cells of the blood vessels of the uterus and nervous system by EHV-1 followed by 
lytic replication of EHV-1 in those cells is required. Characterization of the interaction of EHV-1 
with the innate immune system may provide information about the mechanisms that EHV-1 
employs in order to establish infection in endothelial cells, bypassing host innate immunity. This 
knowledge could be useful for designing of novel antiviral therapies against EHV-1 abortion or 
EHM. The innate immune responses to EHV-1 infection in endothelial cells are not well 
characterized and our current knowledge is rudimentary in this regard. 
         The most important mediator of the innate immune system that plays a major role in 
mediating potent antiviral responses to restrict viral replication irrespective of virus specificity is 
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IFN, especially type-I IFN. Type-I IFN are even capable of limiting some viral infections in the 
absence of adaptive immunity [328]. Although, most viruses like herpesviruses (alpha, beta and 
gamma), influenza viruses, and paramyxoviruses stimulate the induction of type-I IFN [285, 303, 
305, 328, 329], viruses like porcine arterivirus and dengue inhibit its induction as a potential 
immune evasion mechanism [330, 331]. The type-I IFN response to EHV-1 infection has not 
been well-studied. Very few published reports are available [332] describing the type-I IFN 
response to EHV-1 infection. Edington et al reported the increased presence of type-I IFN [332] 
in the serum as well as increased production by cultured PBMC from the EHV-1 infected horses 
[332]. EHV-1 infection shows many distinct patterns of type-I IFN response compared to other 
herpesviruses. For example, pretreatment of fibroblasts with type-I IFNs cause reduction in the 
replication of alphaherpesviruses like HSV-1 in vitro [333]. Additionally,  a combination of type-
I and II IFN causes a greater reduction in HSV-1 replication in infected cells in vitro [329]. 
Again, in the cases of HSV infection in mice and humans and herpes zoster in man [332, 334, 
335], low levels of type-I IFN correlate with higher spread of disease. On the other hand, 
Edington et al have observed that during EHV-1 infection in vivo, serum IFN levels are at their 
peak when viral pathogenicity is highest suggesting that high levels of serum IFN correlate with 
the severity of clinical disease [332]. Edington’s group also has demonstrated that EHV-1 is not 
susceptible to the action of type-I IFN [336]. Contrary to that report, Steinbach et al showed a 
marked reduction in the replication of EHV-1 due to the treatment of IFN-α [337]. This typical 
IFN response pattern raises some questions: does EHV-1 stimulate or inhibit type-I IFN 
production in vitro in cell culture and does this correlate with the in vivo findings of Edington et 
al [332]? If it stimulates the production of IFN, then how does the virus multiply in the presence 
of IFNs and why does the virus titer remains highest when serum level of IFN is highest? There 
are no detailed reports of the nature of the type-I IFN response against EHV-1 infection in vitro. 
Given the importance of the innate immune system in viral infection, it is important to 
characterize the EHV-1 interaction with the innate immune system, and especially the role of the 
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type-I IFN response in detail in equine endothelial cells (EECs). Finding the role of host innate 
factors in the pathogenesis of EHV-1 could also provide new and effective ways to control this 
pathogen. 
The central premise of this work is that EHV-1 has mechanisms to evade the antiviral effects of 
type-I IFN response of the horse. It is apparent from the work of Edington et al that EHV-1 
induces a type-I IFN induction in horses but the virus resists the antiviral effects of type-I IFN. A 
neuropathognic strain of EHV-1, T953 will be used as a model virus for this study. The type-I 
response will be studied in EECs. Because,EECs will be considered to provide in vitro analogue 
of cellular responses responsible for EHV-1 abortion and EHM. As reviewed above that for the 
pathogenesis of EHV-1-induced abortion and EHM, replication of the virus in endothelial cells in 
horse is a key step [338]. To elucidate the mechanisms the sub-hypotheses of this study are 
H1. EHV-1 infection will cause suppression of type-I IFN induction compared to uninfected 
cells, when treated with known type-I IFN inducer. 
H2. EHV-1 will show reduced sensitivity to the antiviral effects of exogenous equine type-I IFN 
(rEqIFN-α) compared to VSV.  
To test these hypotheses, the specific aims are 
A1. To measure the induction of type-I IFNs in EECs infected with either T953 virus in the 
presence of known IFN-stimuli such as polyinosinic-polycytidylic acid (poly I:C) or absence of 
stimuli. 
A2. To determine the effect of rEqIFN-α on the replication of EHV-1 in vitro in EECs compared 
to IFN-sensitive virus VSV. 
The preliminary results from this study suggested an evasion of type-I IFN response by EHV-1 in 
vitro. Based upon those results, additional aims were also included to elucidate the mechanism of 
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suppression of type-I IFN response along with the viral genes responsible for that suppression in 
T953 infected EECs. The additional specific aims are 
A3. To identify EHV-1 genes involved in the evasion of type-I IFN mediated immune response 
A4. To identify the mechanism(s) used by EHV-1 to modulate the type-I IFN mediated immune 
response 
         The experimental approaches that will be taken to evaluate the specific aims are as follows: 
In specific aim A1, EECs will be infected with T953 or Sendai virus (SeV) at a multiplicity of 
infection (MOI) of 5 or co-infected with T953+SeV or T953+poly I:C and at different time points 
type-I IFN production will be evaluated by real-time RT-PCR as well as type-I IFN bioassay. The 
viral infection and replication will also be evaluated by indirect immunofluorescence assay (IFA) 
and plaque assay respectively. In the specific aim A2, equine cells will be pre-treated with 
rEqIFN-α to induce antiviral ISGs in those cells and then cells will be challenged with T953 virus 
at low MOI to see if the virus can evade the ISG mediated response. Virus replication in the IFN-
treated cells will be the criterion to determine if the virus can evade type-I IFN response. In the 
specific aim A3, viral DNA polymerase will be inactivated using phosphonoacetic acid which in 
turn will block viral late gene expression and then the effect of late gene blocking on type-I IFN 
production will be evaluated in EECs. In the specific aim A4, EECs will be infected with T953 
and different signaling pathways for IFN production such as IRF-3 and NF-κB signaling 
pathways will be studied to know if the virus is interfering with the activation process of those 
signaling pathways to suppress type-I IFN response. The signaling pathways by which type-I IFN 
functions (JAK-STAT signaling pathways) will also be investigated. In addition to this, role of 
T953 on the expression of different antiviral molecules induced by type-I interferon signaling will 
be elucidated in this study. 
Copyright © Sanjay Sarkar 2014 
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CHAPTER II: MATERIALS AND METHODS 
2.1 Antibodies, Cytokines and Other Reagents 
         All the antibodies that were used in this study for immunofluorescence assay (IFA) and 
Western blot (WB) have been listed Table 2.1.  
Table 2.1: Antibodies used in this study 
 
Name of Ab Source 
Working 
Dilution/Concentration 
Anti-rabbit IRF-3 (D6I4C 
XP) 
Cell Signaling Technology, Danver, 
MA 
1:200 (IFA), 1:1000 
(WB) 
Anti-rabbit IRF-3  Santa Cruz Biotechnology, Dallas, TX 1:500 (WB) 
Anti-rabbit phospho-IRF-3  
Cell Signaling Technology, Danver, 
MA 1:1000 (WB) 
Anti-rabbit STAT-1 Ab Santa Cruz Biotechnology, Dallas, TX 1:500 (WB) 
Anti-rabbit STAT-1 Ab Origene, Rockville, MD 1:100 (IFA) 
Anti-rabbit phospho-STAT-1  
Cell Signaling Technology, Danver, 
MA 1:1000 (WB) 
Anti-rabbit β-actin 
Cell Signaling Technology, Danver, 
MA 1:1000 (WB) 
Anti-rabbit lamin A/C GenScript USA Inc., Picataway, NJ 0.5 μg/ml 
Anti-rabbbit viperin Abcam, Cambridge, MA 3 μg/ml 
Anti-rabbit ISG56 
Pierce through Thermo Fisher 
Scientific, Rockford, IL 1:2000 (WB) 
Anti-rabbit IκBα Santa Cruz Biotechnology, Dallas, TX 1:500 (WB) 
Anti-rabbit IE1  Dr. Dennis O'Callaghan [339] 
1:1500 (IFA), 1:3000 
(WB) 
Anti-mouse gC Dr. George P. Allen [110, 241] 
1:100 (IFA), 1:1000 
(WB) 
Goat anti-rabbit IgG 
conjugated to HRP 
Cell Signaling Technology, Danver, 
MA 1:3000 (WB) 
Goat anti-mouse IgG 
conjugated to HRP 
Cell Signaling Technology, Danver, 
MA 1:3000 (WB) 
Goat anti-rabbit IgG (H+L) 
conjugated to FITC Santa Cruz Biotechnology, Dallas, TX 1:300 (IFA) 
Texas Red goat anti-mouse 
IgG (H+L)  Life Technologies, Grand Island, NY,  1:400 (IFA) 
 
         For the detection of EHV-1 infection, anti-rabbit IE1 mAb (1:1500 for IFA, 1:3000 for WB) 
was received as a kind gift from Dr. Dennis O’Callaghan, Louisiana State University.Anti-mouse 
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         For the detection of EHV-1 infection, anti-rabbit IE1 mAb (1:1500 for IFA, 1:3000 for WB) 
was received as a kind gift from Dr. Dennis O’Callaghan, Louisiana State University.Anti-mouse 
EHV-1 gC mAb was developed by the late Dr. George P. Allen at Maxwell H. Gluck Equine 
Research Center, University of Kentucky, Lexington, KY 40503 and was kindly provided by Dr. 
Udeni B.R. Balasuriya, Maxwell H. Gluck Equine Research Center, University of Kentucky, 
Lexington, KY 40503. Polyinosinic-polycytidylic acid (poly I:C), was purchased from InvivoGen 
(CA, USA) and phosphonoacetic acid (PAA) was purchased from Thermo Fisher Scientific, 
Rockford, IL, USA. Recombinant equine IFN-α (rEqIFN-α) was purchased from Kingfisher 
Biotech, Saint Paul, MN, USA. 
2.2 Culture of Cells  
         All the cell culture medium and reagents used in this study are enlisted in the table 2.2. 
Table 2.2: List of cell culture reagents used in this study 
Cell culture reagents Source 
Eagle’s Minimum Essential Medium (EMEM) Mediatech Inc.,Manassas, VA 
Minimum Essential Media (MEM) Invitrogen, Carlsbad, CA 
Dulbecco’s Modified Eagle’s Medium (DMEM) Mediatech Inc.,Manassas, VA 
Dulbecco’s Phosphate-Buffered Salaine (D-PBS), 
pH 7.4 
Mediatech Inc.,Manassas, VA 
Fetal Calf Serum (FCS) Hyclone Laboratories Inc., Logan, UT 
Fetal Bovine Serum (FBS) Hyclone Laboratories Inc., Logan UT 
Penicillin-Streptomycin Gibco, Carlsbad, CA 
Sodium Pyruvate Gibco, Carlsbad, CA 
Sodium Bicarbonate Gibco, Carlsbad, CA 
L-glutamine Gibco, Carlsbad, CA 
Non-essential Amino Acids Gibco, Carlsbad, CA 
Trypsin-EDTA Mediatech Inc., Manassas, VA 
Rabbit Kidney-13 (RK-13) Cells ATCC, CCL37, Manassas, VA 
Madin-Darby Bovine Kidney (MDBK) Cells ATCC, CCL22, Manassas, VA 
African Green Monkey Kidney Cells (Vero Cells) ATCC, CCL81, Manassas, VA 
 
Equine endothelial cells (EECs) from pulmonary artery [340] were kindly provided by Dr. Udeni 
B.R. Balasuriya at Maxwell H. Gluck Equine Research Center, University of Kentucky, 
Lexington, KY, USA. EECs were maintained as confluent monolayers in 150-cm2 cell culture 
flasks in Eagle’s Minimal Essential Medium (EMEM) with 10% fetal calf serum, 100 U/ml 
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penicillin-streptomycin, 1 mM sodium pyruvate, 200 mM L-glutamine and sodium bicarbonate 
(0.6 g/L) at 37°C in the absence of CO2. When confluent, the cell monolayer was washed 2x with 
30 ml D-PBS and then trypsinized with 2 ml Trypsin-EDTA at 37 oC for 2-3 min. Cells from one 
150-cm2 cell culture flasks were then resuspended in 100 ml enriched DMEM containing 10% 
fetal calf serum, 100 U/ml penicillin-streptomycin, 0.1 mM non-essential amino acid and 200 
mM L-glutamine and were propagated into four 6-well plates. When needed (such as for 
immunofluorescence study) EECs were also grown onto cover slips in 24-well cell culture plates 
in DMEM containing 10% fetal calf serum, 100 U/ml penicillin-streptomycin, 0.1 mM non-
essential amino acid, and 200 mM L-glutamine.  
         Rabbit kidney-13 cells (RK-13 cells), African Green Monkey Kidney cells (Vero cells) and 
Madin-Darby bovine kidney cells (MDBK cells) were maintained in 75-cm2 cell culture flasks in 
EMEM supplemented with 10% fetal bovine serum, 100 U/ml Penicillin-streptomycin, 1 mM 
sodium pyruvate and 200 mM L-glutamine.  
 
2.3 Virus Strains 
         The equine herpesvirus used in this study was the neurovirulent T953 strain of EHV-1 
(also known as Findlay strain or OH’03 strain of EHV-1). The virus was originally isolated from 
the nasopharyngeal swab of a horse suffering from EHV-1 induced quadriplegia during the 
extensive neurologic disease outbreaks that occurred at the Veterinary Medical Teaching 
Hospital, at The University of Findlay, Ohio, USA in January, 2003. [213]. The virus was 
isolated and archived by the late Dr. George P. Allen and it was kindly provided by Dr. Udeni 
B.R. Balasuriya at the Maxwell H. Gluck Equine Research Center, University of Kentucky, 
Lexington, KY. The neurovirulence phenotype of EHV-1 T953 strain was further confirmed by 
experimental inoculation of horses with low passaged EHV-1 T953 strain by the late Dr. George 
P. Allen [217]. The virus was originally isolated and propagated on the equine fibroblast cell line 
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at a low MOI. For this study, the virus was amplified in EECs and passage 3 (P3) of this virus 
was used. 
         Another neuropathogenic strain of EHV-1, Ab4 was isolated from a mare suffering from 
paresis in England in 1980 [341]. The recombinant Ab4 mutant virus which was generated by 
deleting ORF1 and ORF2 genes (Ab4ΔORF1/2) and WT Ab4 [342] were kindly provided by Dr. 
Nikolaus Osterrieder, Institut für Virologie, Freie Universität Berlin, Berlin, Germany.  Sendai 
virus (ATCC VR907, Cantell Strain) was purchased from Charles River Laboratories 
International Inc., Wilmington, MA, USA. The recombinant vesicular stomatitis virus expressing 
green fluorescent protein (VSV-GFP) was kindly provided by Dr. Adolfo García-Sastre (Mount 
Sinai School of Medicine, NY, USA). 
2.4 Preparation of Viruses 
         To prepare a stock of EHV-1 virus, EECs in 175 cm2 cell culture flasks were infected with 
EHV-1 T953 at an MOI of 0.1. When nearly 100% cytopathic effect (CPE) was shown, viruses 
were harvested by three cycles of freeze-thaw of the infected flasks.  The viruses were clarified at 
2000 g for 30 min at 4̊C, filtered through 0.45 μm cellulose acetate membrane filter (Thermo 
Fisher Scientific, Pittsburgh, PA) and the tissue culture fluids (TCFs) containing the virus was 
aliquoted and preserved at -80 °C as stock virus. From this stock, the virus was again amplified in 
EECs and clarified as stated and TCFs were further purified by ultracentrifugation at 100,000 x g 
for 4 h at 4oC through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine 
(Beckman Coulter, CA, USA). To maximize the titer of the virus, each pellet was then 
resuspended in minimum volume (100-200 μl) of sterile DMEM with 2% FBS, sonicated briefly 
(30 sec x 3 cycles, with 1 min rest in between a cycle) and aliquoted at 100 μl each in 1.5 ml 
eppendorf tubes to save at -80 ̊C. The viruses were titrated on RK-13 cells by plaque assay. Ab4 
wild type (WT) and Ab4ΔORF1/2 viruses were propagated and amplified on EECs and purified 
in the same manner as T953 was done. 
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         UV inactivation of EHV-1 T953 strain was achieved by using UV Stratalinker 1800 
(Stratagene). 
Briefly, 1 ml of TCF containing the T953 virus was placed in a 35 mm petridish and was exposed 
to the ultra-violet rays with a wavelength of 254 nm for 30 min on ice from a distance of 10 cm 
from the UV bulb. After the UV treatment, the virus was propagated on a monolayer of RK-13 
cells to confirm the inactivation. 
         Sendai virus was inoculated into the allantoic cavities of ten day old specific pathogen free 
embryonated hen eggs, which were incubated at 37°C for 72 h. Allantoic fluids were harvested 
and clarified at 2000 x g for 30 min at 4̊C and then purified by ultracentrifugation at 100,000 x g 
for 4 h at 4 °C through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine 
(Beckman Coulter, CA, USA). The pellet was resuspended in calcium-magnesium free D-PBS, 
and aliquoted at 100 μl each in 1.5 ml eppendorf tubes and saved at -80 °C for future use. The 
virus was titrated by plaque assay on Vero cells. 
         VSV-GFP was amplified in MDBK cells by infecting confluent layers of MDBK cells in 
800 cm2 Corning roller bottles (Sigma Aldrich, St. Louis, MO, USA) at an MOI of 0.5. When 
approximately 100% CPE was shown, viruses were harvested by three cycles of freeze-thaw of 
the infected roller bottles. The viruses were then clarified at 2000 g for 30 min at 4 °C, filtered 
through a 0.45 μm cellulose acetate membrane filter, and TCFs containing the virus were 
aliquoted and saved at -80 °C as stock virus. This stock virus was again amplified in MDBK cells 
and clarified as stated and TCFs were further purified by ultracentrifugation at 100,000 x g for 4 h 
at 4 °C through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine (Beckman 
Coulter, CA, USA). The pellets were then resuspended in minimum volume (100-200 μl) of 
sterile MEM, sonicated briefly (30 sec x 3 cycles with 1 min rest between each cycle) and 
aliquoted at 100 μl each in 1.5 ml eppendorf tubes to save at -80 °C. The virus was titrated on 
MDBK cells by plaque assay. 
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2.5 Virus Infection of EECs 
         EECs were cultured in 175 cm2 tissue culture flasks and were propagated in either 6-well or 
24-well plates before infection. At confluency, EECs were washed twice with sterile D-PBS and 
then infected with either T953, SeV or combination of both of the virus at an MOI of 5. During 
infection in a 6-well plate, virus was added in a total volume of 200 μl and in case of 24-well 
plate virus was added in a total volume of 100 μl. The virus was adsorbed onto the EECs for 1 h 
at 37 ˚C, 5% CO2 with an intermittent gentle mixing of the plates at every 10 min interval. Cells 
were mock infected with virus diluent (DMEM+2% FBS).  After the incubation, the plates were 
washed again with D-PBS and the growth medium was added. The infected plates were then 
incubated at 37 ˚C with 5% CO2 in a humidified chamber for the indicated time points and 
different assays were performed as will be described below. 
2.6 Plaque Assay  
         The virus was titrated by plaque assay as described by McCollum et al with little 
modification [343]. Briefly, RK-13 cells or MDBK cells or Vero cells were propagated in 6-well 
plates. Then the confluent monolayers were washed twice with D-PBS and infected with 10 fold 
serial dilutions (10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, 10-8, 10-9, and 10-10) of cell culture 
supernatants containing virus. 10 fold serial dilutions of virus were made by adding 100 μl of 
virus to 900 μl of sterile MEM. For each dilution of the virus, duplicate wells were infected. The 
virus was let to adsorb for 1 h with intermittent shaking at 10 min interval at 37°C inside an 
incubator in presence of 5% CO2. Next, the plates were washed twice with PBS (pH 7.4) to 
remove the unadsorbed viruses and the growth medium (enriched EMEM with 10% FBS) with 
0.75% carboxy-methyl cellulose (CMC)  (Sigma Aldrich, St. Louis, MO) were added and the 
plates were further incubated for 96 h at 37oC, 5% CO2. Then the growth medium was removed 
and the plates were stained with 1% crystal violet solution in buffered formalin (10%) for 
visualization of plaques.  
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The titers were calculated by counting the number of plaques and multiplying by the dilution 
factors. Finally, the titers of the viruses were expressed in plaque forming units/ml (PFU/ml). 
2.7 Infectious Center Assay  
         The infectious center assay (ICA) is normally used to calculate the proportion of cells 
within a culture of sensitive cells which are infected with virus. This assay was performed in this 
study to know if rEqIFN-α treatment of EECs makes the cells resistant to virus entry following 
infection with T953 virus. During the early phase of the infection or eclipse phase, there is no free 
virus and as a result no CPE is found within the indicator cells.  
         EECs were propagated into 6-well plates and at about 90% confluency, the cells were 
treated with rEqIFN-α at 1000 IU/ml for 24. One group of EECs was also left untreated. After 
IFN-treatment the cells were washed 2X with D-PBS and challenged with T953 at an MOI of 0.5 
and incubated at 37 °C for 1 h in presence of 5% CO2. After virus adsorption, the cells were 
washed 2X with D-PBS, trypsinized and resuspended as single cell suspensions in growth media. 
Cells were then counted and equal numbers of cells (2x105 cells in total volume of 200 ul) were 
plated in duplicate wells for each dilution onto confluent monolayers of RK-13 cells (indicator 
cells). The cells were then overlaid with 0.75% CMC in EMEM complete growth media and 
incubated at 37 °C with 5% CO2 for 96 h. After that the growth medium was removed and the 
plates were stained with 1% crystal violet in buffered formalin for 2 h at RT. The plates were 
washed under running tap water and the plaque numbers were counted. The number of plaques 
which were formed on the indicator cells indicated the number of EECs that were originally 
infected with T953. Then the infected cell numbers per 2 million EECs  that were originally 






2.8 RNA Extraction and Real-Time RT-PCR Assay 
         Total cellular RNA was extracted from mock or T953 infected or otherwise coninfected 
(T953+SeV or T953+poly I:C or T953+EqIFN-α) EEC samples from 3 h, 6 h, 12 h and 18 h post 
infection (p.i.) using the RNeasy Mini Kit (Qiagen, Valencia,CA) following the manufacturer’s 
protocol. The possible genomic DNA contamination was removed by in-column treatment of 
RNA with DNase-I (RNase free DNase set, Qiagen, Valencia, CA). The quality and the quantity 
of the RNA were assessed by measuring the absorbance ratio of RNA at optical density (OD) 
values at 260 nm and 280 nm (OD260/OD280) and OD260 value  respectively by NanoDrop (Thermo 
Scientific, Wilmington, DE). One microgram of total cellular RNA was brought to a volume of 
41.5 μl using nuclease free water (Qiagen, Valencia, CA) and  reverse transcribed in a 80 μl total 
volume reaction using 38.5 ul reverse transcription master mix containing 0.5 μl [20 U/μl] avian 
myeloblastosis virus [AMV] reverse transcriptase [Promega, Madison, WI], 1 μl oligo dT primer 
[0.5 μg/μl, Promega], 1 μl RNasin plus RNase inhibitor [40 U/μl, Promega], 4 μl dNTP [10 mM, 
Promega], 16 μl AMV buffer [Promega], and 16 μl MgCl2 [25 mM, Promega]) as described by 
Coombs et al. [344]. The reaction mixture was incubated at 42 °C for 15 min followed by 95 °C 
for 5 min in a thermocycler. The cDNA was then diluted 1:1 with sterile nuclease-free water 
(Qiagen, Valencia, CA). Equal amounts of cDNA were used for the gene expression analysis of 
different cytokines by TaqMan real-time PCR using an Applied Biosystems 7500 Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA). The sequences of specific primers and 
probes used in this study targeting specific genes are provided in Table 2.3. In each PCR reaction 
in 384-well plates, 5 μl master mix (SensiMixTM II Probe Kit, Bioline), 0.5 μl  20X primer-probe 
mix (Applied Biosystems) and 4.5 μl template cDNA were added and incubated at 95 °C for 10 






Table 2.3: Primers and probes for real-time RT-PCR used in this study 
 
 
All reactions were performed in duplicate. The quantitative real-time PCR (qPCR) data were 
normalized to mRNA levels of equine ribosomal protein large P0 (RPLP0) as endogenous 
controls. Initially, several house-keeping genes [RPLPO, β glucuronidase (β-GUS), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β2-microglobulin, β-actin and eukaryotic 
18s rRNA] were tested and the expression level of RPLPO was found to be the most stable during 
EHV-1 infection. As a result, RPLPO was used to normalize the qPCR data. PCR efficiency for 
all reactions was assessed by LinReg software [347]. Fold changes in the gene expression were 
calculated by the relative quantitation method described by Livak et al [348] which assumes that 
the relative concentration of target mRNA is equal to 2 –ΔΔCt where ΔΔCt = [(Avg. Ct of gene of 
interest – Avg. Ct of RPLP0) sample – (Avg. Ct of gene of interest – Avg. Ct of RPLP0) calibrator]. 




Sequences (5’ to 3’)/ Information References 
EqRPLP0 Fwd: CTGATTACACCTTCCCACTTGCT 
Rev: AGCCACAAATGCAGATGGATCA 
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ 




Horohov et al [346] 
EqISG56 Fwd: AGCCCATTCAGCTAAACAAAAC 
Rev: CAGTGTCTTCAATTAGCAAATCCC 
Probe: 5'- /56-FAM/TCC AGC CTG /ZEN/TCC TTG 
ATG TGA TCTTC/3IABkFQ/ -3' 
 
Sarkar et al from this 
study 
EqViperin Fwd: CGCCAGTGCAATTACAAGTG 
Rev: TCTCCGCCCGAAAAGTTTATC 
Probe: 5'- /56-FAM/CTT CCA CAC /ZEN/GGC CAA 
GAC TTCCT/3IABkFQ/ -3' 
 




2.9 Type-I Interferon Bioassay  
         For interferon bioassays, EECs were either mock infected or EHV-1 infected or treated as 
specified and the supernatants were harvested at different times post infection. The supernatants 
were filtered through Vivaspin 2 (Sartorius Stedim North America Inc., Bohemia, NY) to remove 
virus particles. Filtered supernatants were added on to a monolayer of MDBK cells at 100 μl/well 
in duplicate wells and incubated for 24 h at 37oC, 5% CO2. The efficiency of the Vivaspin 2 filter 
to remove virus particles from TCF was confirmed by the absence of CPE when looked under an 
inverted light microscope. MDBK cells were then grown in 96-well plates and at 80 % 
confluency the cells were treated with 100 μl/well of serially two fold diluted filtered 
supernatants. After 24 h of incubation, the cells were washed twice with warm D-PBS and 
challenged with VSV-GFP at an MOI of 0.1. At 18 h post challenge, the growth medium was 
discarded and cells were then stained with 1 % crystal violet with buffered formalin. The results 
were expressed as laboratory unit (LU)/ml. The dilution in which 50% of a well was protected 
after VSV-GFP challenge was considered to have one LU of type-I interferons. 
2.10 Immunofluorescence Assay 
         EECs were grown on poly L-lysine-coated coverslips (Fisher Scientific, Waltham, MA) in 
24-well plates and treated as specified. At indicated time points, the cells were washed with ice 
cold PBS (pH 7.4) and fixed with 4 % PFA at room temperature (RT) for 30 min. After washing 
3X with PBS-glycine (10mM glycine in PBS), cells were permeabilized with 0.1 % Triton X-100 
in D-PBS (pH 7.4) for 10 min at RT, washed again 3X times with PBS-glycine (10 mM) and then 
blocked with 5 % goat serum in PBS for 30 min at RT. The coverslips were then washed again 
3X with PBS-glycine and incubated with primary antibodies at RT for 50 min. The name of the 
antibodies and their dilutions used in this study are enlisted in table 2.1. Next, the unbound 
primary antibodies were washed off with PBS-glycine and then the coverslips were incubated 
with corresponding secondary antibodies conjugated with either fluorescein isothiocyanate 
(FITC) or tetramethyl rhodamine isothiocyanate (TRITC) for 50 min at RT. Finally, the 
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coverslips were washed and mounted in VECTASHIELD Mounting Medium containing 4’, 6’-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and observed under an 
inverted fluorescence microscope (Nikon ECLIPSE Ti, Melville, NY, USA). 
2.11 Western Blot Analysis  
         EECs were grown on 6-well plates and treated with T953 or as described. At indicated time 
points the cells were washed in cold PBS (pH 7.4) and harvested in cell lysis buffer containing 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM ethylene glycol tetraacetic acid 
(EGTA; Sigma), 1% Triton X-100 (Sigma), 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 1mM phenylmethylsulfonyl fluoride 
(PMSF; Fisher Scientific) enriched with protease and phosphatase inhibitors (Halt Protease and 
Phosphatase Inhibitor Cocktails, Thermo Scientific, Rockford, IL) on ice. The lysates were 
briefly sonicated and centrifuged at 14,000 g for 10 min at 4 °C. These protein samples were 
mixed with 5X reducing sample buffer (Lane Marker Reducing Sample Buffer, Thermo 
Scientific,) containing  proprietary pink tracking dye in 0.3M Tris-HCl, 5% sodium dodecyl 
sulfate (SDS), 50% glycerol, 100mM dithiothreitol (DTT), boiled at 95 °C for 5 min and cooled 
immediately. Denatured proteins were separated onto 10 % SDS polyacrylamide resolving gels 
and 5 % stacking gels at 200 V for 40 min. After that, proteins were transferred onto a 
polyvinylidene difluoride (PVDF, Bio-Rad Laboratories, CA) membranes at 100 V for 50 min to 
75 min (depending upon the molecular weight of the protein of interest) and blocked with 5 % 
non-fat dry milk (Bio-Rad) in Tris-buffered saline (TBST) for 1 h at RT. Following blocking, the 
membranes were incubated overnight with primary antibodies either in blocking buffer or 5 % 
bovine serum albumin (BSA) in TBST at 4 °C. The unbound primary antibodies were removed 
by washing the membranes 3X with TBST, with 10 min each washing. The membranes were then 
incubated with corresponding secondary antibodies for 1 h at RT followed by 3X washing with 
TBST (10 min each wash) and then developed by using the enhanced chemiluminescence 
(SuperSignal West Pico Chemiluminescent Substrate Kit, Thermo Scientific) detection method. 
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The protein bands in the membrane were visualized by Fluorche E System (Cell Biosciences, San 
Jose, CA). 
 
2.12 Separation of Cytoplasmic and Nuclear Proteins   
         EECs were maintained in T150 flasks in complete growth media and infected with T953 at 
an MOI of 5 or left uninfected. At indicated time points the cells were lysed and cytoplasmic as 
well as nuclear proteins were separated by cell fractionation by NE-PER® Nuclear and 
Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Rockford, IL, USA) as per 
manufacturer’s protocol. Briefly the cells were washed two times with D-PBS (pH 7.4) and 
harvested with trypsin-EDTA and centrifuged at 500 x g for 5 min. The pellet was washed again 
by suspending it in D-PBS and pelleted again by centrifugation at 500 x g for 3 min. The 
supernatants were removed very carefully leaving the pellet as dry as possible. Next, an 
appropriate volume of cytoplasmic extraction reagent I (CER I) solution was added to resuspend 
the pellet with vigorous vortexing. The volume of CER I was dependent on the volume of cell 
pellet following the chart supplied with the kit. The tube was incubated on ice for 10 min and 
then ice cold CER II was added followed by vortexing. It was then incubated on ice for 1 min and 
vortexed again and centrifuged at 16000 x g for 5 min at 4 °C. Immediately after that the 
supernatant containing the cytoplasmic proteins were transferred into pre-chilled tubes and stored 
at -80 °C until further use. The insoluble pellet containing nuclei was resuspended again using ice 
cold nuclear extraction reagent (NER) by vortexing briefly and was incubated on ice for 40 min 
with 15 seconds vortexing at 10 min intervals. The tubes were then centrifuged at 16000 x g for 
10 min at 4 °C and the supernatant containing the nuclear proteins was separated and stored at -80 
°C. The cytoplasmic and nuclear protein lysates were mixed with 5X sample buffer for separation 
by SDS-PAGE in a 10% bis-crosslinked polyacrylamide gel as described earlier. After separation, 
proteins were transferred onto a PVDF membrane and blotted with corresponding primary and 
secondary antibodies and developed as described earlier. 
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2.13 Quantification of Band Intensity  
         The relative intensity of the expression level of different protein bands in the western blot 
images was quantified by densitometric analysis using ImageJ software, National Institute of 
Health (NIH), USA following the manufacturer’s instructions. The  
2.14 Statistical Analysis 
         All the experiments were repeated 3 times if not otherwise stated. The data were analyzed 
either by Student’s t test or analysis of variance (ANOVA) and Pairwise Multiple Comparison 
Procedures by Holm-Sidak Method using statistical analysis software Sigmaplot 12.3 (Systat 
Software Inc. San Jose, CA). In the case when only two groups were compared (as in the case of 
real-time PCR data in ISG mRNA induction experiment), Student’s t test was performed. In all 


















CHAPTER III: RESULTS 
 
3.1 Standardization of EHV-1 Infection in EECs 
         To determine the MOI to be used for the study, EECs were grown on 6-well plates and were 
infected with a neuropathogenic strain of EHV-1, T953 at an MOI of either 0.5, 5 or 10. At 12 h 
post infection, cells were fixed with 4% PFA and the virus infection was evaluated by IFA using 
EHV-1 IE1 specific antibody. It was found that >95% cells were IE1 positive at an MOI of 5 
(Figure 3.1) and hence, this MOI was selected, unless otherwise stated. 
 
Figure 3.1: Immunofluorescence images showing the infection of EECs with T953: EECs 
were infected with T953 at an MOI of 5 and at 12 h.p.i. the cells were fixed and stained with anti-
rabbit IE1 antibody. Mock treated EECs stained with DAPI for nucleus (A), anti-rabbit IE1 Ab 
conjugated with FITC (B), and merged images of A and B (C). T953 infected EECs stained with 






3.2 Replication of T953 in EEC: 
         To evaluate whether T953 can replicate and produce infectious progeny virus in EECs, 
monolayers of EECs were infected at an MOI of 5 and virus titers in the supernatants of infected 
cells collected at various time post-infection (3, 6, 12 and 18 h.p.i.) were determined by plaque 
assay. Results showed that T953 can successfully replicate in the EECs producing progeny virus. 
 
Figure 3.2: Replication of T953 in EECs: EECs were infected with T953 at an MOI of 5 and at 
3, 6, 12 and 18 h.p.i. supernatants from the infected cells were collected and titrated for virus. At 











3.3 Effect of T953 Virus Infection on IFN-β Gene Transcription in EECs                                                                                                                                                                                                       
T953, a neuropathogenic strain of EHV-1, is an endotheliotropic virus which replicates in the 
endothelial cells of blood vessels, causing ischemic damage which results in the neurologic 
disease, EHM. One of the sub-hypotheses was that T953 virus suppresses type-I IFN induction in 
the infected endothelial cells making the microenvironment more conducive for enhanced viral 
replication which adds to the severity of the disease. Previously, it has been shown that EHV-1 
infections of PBMCs induce significant amounts of type-I IFN both in vivo and in vitro [332, 
349], but there is no report whether EHV-1 has the ability to interfere with type-I IFN immune 
responses of horse. Here, EECs were infected with T953 at an MOI of 5. SeV and poly I:C served 
as positive controls for the type-I IFN induction. Virus diluent (DMEM + 2% FBS) treated EECs 
were used as negative controls. At 3, 6, 12 and 18 h.p.i. IFN-β gene expression was evaluated by 
real-time RT-PCR assay. T953 infection of EECs induced a significant amount of IFN-β mRNA 
transcription (p<0.001) at early times post infection (3 and 6 h.p.i.) [Fig 3.3A] but at later time 
points (12 and 18 h.p.i.) there was no significant amount of IFN-β mRNA induction (Fig 3.3A). 
There was also a gradual decrease in the transcription of the IFN-β gene from 3 to 6 h.p.i. On the 
other hand, UV inactivated T953 virus did not induce any IFN-β mRNA either at early or late 












Figure 3.3: T953 suppresses IFN-β mRNA induction. EECs were either mock infected or 
infected with different viruses separately or together or treated with chemicals as indicated. At 
indicated time points equine IFN-β mRNA was quantified by real-time RT-PCR and data were 
normalized to endogenous control equine RPLP0. T953 infection inhibited IFN-β mRNA at later 
time points (12 h onwards) after an initial induction at early time points (3 h) [Fig 3.3A]. T953 
virus also suppressed IFN-β mRNA induced by SeV [Fig 3.3B] and poly I:C [Fig 3.3C]. Data 
represents mean with standard deviation from 3 independent experiments. *** = p<0.001, ** = 
p<0.01 and * = p<0.05 were considered significant. 
 
         To identify if T953 virus can inhibit the IFN-β mRNA induction by other known stimuli, 
EECs were coinfected with SeV at an MOI of 5 or co-treated with poly I:C and T953 virus for 
indicated time periods. It was observed that from 6 h.p.i. onwards, T953 and SeV coinfected 
EECs had significant decreases (p<0.01, p<0.001, p<0.001 at 6, 12 and 18 h.p.i respectively) in 
the IFN-β mRNA induction compared to only SeV infected EECs (Fig 3.3B). T953 virus 
infection also significantly suppressed the poly I:C induced IFN-β mRNA transcription at 12 h.p.i 






3.4 Effect of T953 Virus Infection on Type-I IFN Production in EECs 
         To evaluate the effect of T953 virus on type-I IFN induction at the translational level, a 
type-I IFN bioassay using a recombinant VSV-GFP virus was performed on the saved 
supernatants from the previously infected EECs for real-time RT-PCR assay. It was seen that 
T953 infection of EECs induced a significant amount of type-I IFN activity at 3 and 6 h.p.i. when 
compared to mock infected EECs (p<0.05) [Fig 3.4 𝐴].  The virus infection also induced type-I 
IFN activity in the later time points (12 and 18 h.p.i.) [Fig 3.4 A], although there was a gradual 
decrease in the type-I IFN activity. As with IFN-β mRNA transcription, UV-inactivated T953 
virus did not induce any significant amount of type-I IFN activity. 






Figure 3.4: T953 suppresses type-I IFN activity. EECs were either mock infected or infected 
with different viruses separately or together or treated with chemicals as indicated. At indicated 
time points cell supernatants were collected and type-I IFN activity was quantitated by interferon 
bioassay using VSV-GFP. Type-I IFN bioassay is performed by incubating IFN-sensitive cells 
with serially diluted samples containing IFN and then challenging those cells with IFN-sensitive 
virus VSV-GFP. The well of a 96 well plate at which 50% of the cells were protected from VSV-
GFP CPE was considered as 1 laboratory unit (LU). Data represents mean with standard error 
from 3 independent experiments. ** = p<0.01 and * = p<0.05 were considered significant. T953 
infection to EECs induced type-I IFN activity at all time points (Fig 3.4A). But, T953 inhibited 
type-I IFN activity induced by SeV at 6 h, 12 h and 18 h (Fig 3.4B). The virus also suppressed 




To determine whether T953 virus could inhibit production of type-I IFN induced by other known 
stimuli at translational level, EECs were coinfected with T953 and SeV or T953 and poly I:C for 
different periods of time. It was observed that T953 coinfected with SeV induced significantly 
decreased type-I IFN activity at 6 h.p.i (p<0.05), 12 h.p.i. (p<0.01) and 18 h.p.i (p<0.01) 
compared to only SeV induced type-I IFN activity (Fig 3.4B). Data also suggested that T953 
virus could suppress the type-I IFN activity induced by poly I:C significantly (p<0.05) at later 
times post infection (12 and 18 h.p.i.) [Fig 3.4C]. The results of these studies involving IFN-β 
gene expression kinetics also suggested that the longer the virus was incubated the more was the 
IFN-inhibitory effect. This suggested that expression of late viral genes might be responsible for 
the suppression of type-I IFN production.   
 
3.5 The T953 Strain of EHV-1 Actively Suppresses IFN-β Gene Expression Induced 
by Sendai Virus 
         In the coinfection model of the previous experiment, EECs were infected with SeV and 
T953 together and were incubated for same period of time. It was possible that decreased IFN-β 
induction at later time points were due to the normal IFN kinetics or due to the absence of stimuli 
at late stage of the infection. To assure that T953 virus but no other reasons can actively suppress 
the type-I IFN production, a coinfection study was done where first T953 or SeV was allowed to 
express its genes for some time (3 h), then the same cells were infected with the other virus and 
were incubated for another 6 h. At 9th hour after first infection, IFN-β mRNA production was 




Figure 3.5: T953 actively suppresses SeV induced INF-β mRNA transcription. EECs were 
either infected with SeV  or T953 and at 3 h.p.i. cells were re-infected with T953 or SeV 
respectively for another 6 h. At 9 h.p.i. cells were lysed for total cellular RNA and IFN-β mRNA 
were quantitated from the reverse transcribed cDNA by real-time qPCR assay. Data were 
normalized to endogenous control equine RPLP0. Data represents mean with standard deviation 
from 3 independent experiments. T953 infection to EECs actively suppressed the transcription of 
IFN-β mRNA induced by SeV. Data were significant at p<0.001 (***).  
 
When EECs were first infected with T953 virus and allowed to express its genes for 3 h, then 
infected the same cells with SeV for another 6 h, it was found that coinfected EECs produced a 
significantly  lower amount of IFN-β mRNA (p<0.001) compared to only SeV infected cells for 6 
h (Fig 3.5).  Even when EECs were first stimulated with SeV for 3 h and then same cells were 
infected with T953 for another 6 h, there was a significant (p<0.001) decrease of IFN-β mRNA 
compared to only SeV infected cells for 9 h (Fig 3.5). These data suggested that T953 virus 




actively suppressed the type-I IFN induction capability induced by another known virus stimulus 
(SeV).  
3.6 T953 Virus Actively Suppresses IFN-β Gene Expression Chemically Induced by 
Poly I:C 
       In the above coinfection experiment, it was considered possible that one virus infection to a 
cell could restrict the entry of another virus into the same cell. If so, it was possible that decreased 
IFN-β mRNA production by Sev and T953 coninfected EECs was due to the interference of SeV 
entry into the coinfected EECs by T953. To rule out that explanation for the suppression of IFN-β 
mRNA induction, EECs were first infected with T953 virus and allowed to express viral genes for 
different time periods (0, 3, 6 and 12 h) and then same infected cells were stimulated with the 
chemical inducer, poly I:C at 80 μg/ml for 12 h. IFN-β mRNA transcription was evaluated by 
real-time RT-PCR assay. The results showed that T953 infected EECs produced significantly 
lower amount of IFN-β mRNA when co-stimulated with poly I:C compared to only poly I:C 




Figure 3.6: T953 actively inhibits poly I:C induced IFN-β mRNA transcription. EECs were 
infected with T953 virus and at 0, 3, 6 and 12 h.p.i. infected cells were stimulated with poly I:C at 
80 μg/ml for an additional 12 h. Cells were then lysed for total cellular RNA which was reverse 
transcribed and IFN-β mRNA transcripts were quantitated by real-time qPCR assays. Equine 
RPLP0 was used as endogenous control to normalize the data. Data represents mean with 
standard deviation from 3 independent experiments. IFN-β mRNA transcription of T953 + poly 
I:C coinfected  EECs was compared with only poly I:C treated cells. T953 actively inhibited 
transcription of chemically induced IFN-β mRNA by poly I:C. a, b, c are significantly different 
from each other at p<0.001. 
 
From these data it was also evident that the longer the virus was allowed to express its genes, the 
greater the suppressive effect. By 12 h.p.i., T953 infected EECs stimulated with poly I:C were no 
longer able to make significant amounts of IFN-β mRNA. This supports the hypothesis that T953 




can actively suppress type-I IFN induction by known exogenous stimuli including poly I:C and 
SeV.  
3.7 Effect of Late Gene Blocking of EHV-1 on Type-I IFN Production 
         The preceding results show that T953 infection suppresses IFN-β responses and indicated a 
possible link of EHV-1 late genes with the reduced IFN-β mRNA at later time points. The next 
goal of this study was to block the late gene expression of T953 virus. EECs were infected with 
T953 virus in presence of a chemical inhibitor, phosphonoacetic acid (PAA) which is known to 
inactivate the herpes viral DNA polymerase [350]. The late gene expression of T953 virus at 
protein level was evaluated at 18 h.p.i. by an immunofluorescence study using a monoclonal 
antibody against the late gene, gC. A titration on PAA concentration was done to find the right 
concentration to be used without host cell toxicity. PAA at a concentration of 300 μg/ml of 
growth media during T953 infection to EECs, prevented the majority of viral late gene, gC 
expression (Fig.3.7). In addition to blocking of L (γ) genes, it was also evaluated whether PAA 
had any effect on IE gene expression by using another antibody (α-IE1 Ab) specific to IR1 
protein (IE gene product). The results showed that IE gene expression was unaffected by PAA 
treatment (Fig 3.7). This confirms that PAA blocks the late gene expression of herpesvirus 
including EHV-1 but it does not interfere with the expression of IE gene and thus allowed for the 
evaluation of the effect of IE (α) and E (β) genes on the suppression of the type-I IFN both at 
mRNA and protein levels. EECs were infected with T953 in the presence or absence of PAA for 
3, 6, 12 and 18 h. EECs treated only with PAA in virus diluent medium were used as negative 
controls. At indicated time points type-I IFN production was evaluated by measuring the 
transcription of IFN-β mRNA by real-time RT-PCR assay as well as type-I IFN activity by 
interferon bioassay. 







Figure 3.7: PAA blocks late gene expression but not IE gene expression. EECs were infected 
with T953 in the presence or absence of PAA at 300 μg/ml. At 18 h.p.i. viral gene expression was 
evaluated by IFA using EHV-1 late gene gC specific Ab (anti-gC Ab) and IE gene specific Ab 
(anti-IE1 Ab).Upper panel shows the staining of mock infected EECs treated with PAA. Middle 
panel shows that in the presence of PAA, T953 infected EECs showed no gC expression but 
showed IE gene expression. The lower panel shows that in the absence of PAA, T953 infected 





Figure 3.8 A: Late gene blocking induces robust IFN-β mRNA transcription at later time 
points. EECs were infected with T953 in the presence or absence of PAA and at indicated time 
points cells were harvested to extract total cellular RNA. Transcription of IFN-β mRNA was 
quantitated by real-time RT-PCR assay. Data were normalized to the endogenous control equine 
RPLP0. Data represents mean with standard deviation from 3 independent experiments. Late gene 
blocking of T953 by use of PAA induced more IFN-β mRNA in EECs compared to only T953 
infected EECs without PAA at 12 and 18 h.p.i. Data are significantly different from each other at 
p value of <0.01 (**). 
 
Significant differences (p<0.01) were observed in the IFN-β mRNA transcription starting at 12 
h.p.i. and at 18 h.p.i. T953 infected EECs in the presence of PAA caused a robust IFN-β mRNA 
production compared to T953 infected EECs in the absence of PAA (Fig. 3.8 A). It was further 
investigated whether blocking of viral late genes had the same type-I IFN inducing effect at the 
level of translation. Results of the type-I IFN bioassay performed on the infected cell supernatants 
showed that T953 virus infected EECs produced significantly higher levels of type-I IFN activity 
at 12 and 18 h.p.i. when expression of viral late genes was blocked by PAA treatment compared 
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to T953 infected EECs in the absence of PAA treatment (p<0.05 and p<0.001, Fig 3.8 B). It is 
interesting to note that the same effect was even more evident at 24 h.p.i.(data not shown).  
 
Figure 3.8 B: Late gene blocking induces robust type-I IFN activity at later time points. 
EECs were infected with T953 in the presence or absence of PAA and at indicated time points 
cell supernatants were collected and titrated for type-I IFNs by interferon bioassay. Data 
represents mean with standard deviation from 3 independent experiments. Late gene blocking of 
T953 by use of PAA induced significantly more type-I IFN activity in EECs compared to only 
T953 infected EECs at 12 and 18 h.p.i. Data were considered significant at p value of <0.01 (**) 




These data suggest that EHV-1 has mechanisms which actively inhibit type-I IFN immune 
responses and viral late genes but not IE or E genes play a major role in this suppression. 





3.8 Effect of T953 Virus Infection on the Stability of IRF-3   
         It is well established that for the production of type-I IFN, triggering of either IRF-3/7, AP-
1 or NF-κB transcription factors is necessary. As reviewed above, different viruses may target 
different transcription factors to interfere with production of this important host antiviral 
cytokine. Like BHV-1 IE protein bICP0 or HSV-1 it seemed plausible that EHV-1 protein(s) 
directly degrade the most important transcription factor, IRF-3 in the type-I IFN production 
pathways. To elucidate the mechanisms, EECs were either infected with T953 or mock infected. 
At 3, 6, and 12 h.p.i. cells were lysed to prepare total cell lysates and were analyzed by Western 
blot using anti-IRF-3 antibody. 
         The Western blot analyses on T953 infected cell lysates showed that virus infection of 
EECs indeed caused down-regulation of the endogenous level of IRF-3 proteins (Fig 3.9 A) as 
early as at 6 h.p.i. At 12 h.p.i. the majority of the endogenous IRF-3 level was down-regulated 
when compared to mock infected cell lysates. Western blot image also suggested that the 
intensity of IRF-3 down-regulation increased with the increased expression of viral late gene, gC 
(Fig 3.9 C). Densitometric analyses of the Western blot images suggested about 3.4 X and 105 X  
decreased level of total endogenous IRF-3 protein in the T953 infected EECs at 6 and 12 h.p.i. 




Figure 3.9: T953 causes down-regulation of IRF-3. EECs were infected with either T953 or 
mock infected. At indicated time points whole-cell lysates were prepared and equal amounts (40 
μg) of lysates were separated by 10% SDS-PAGE and blotted with (A) anti-IRF-3, (B) anti-β-
actin and (C) EHV-1 late protein gC antibodies. β-actin was used as endogenous loading control. 
(D) Densitometric analyses were done by NIH ImageJ software and the IRF-3 band intensity was 
normalized to β-actin band intensity. T953 infected cell lysates showed a decrease in relative fold 
intensity of IRF-3 compared to mock infected cells. The Western blot images were representative 
of 3 independent experiments. T953 induced down-regulation of IRF-3 at later time points (6 h 
and 12 h) in EECs when compared to mock infected EECs. Level of IRF-3 protein was reduced 







3.9 Role of T953 Virus in the Activation of IRF-3 
         It was evident from results of our previous experiments that, among possible mechanisms 
for interference with host type-I IFN production pathways, T953 directly or indirectly targeted 
transcription factor IRF-3 for its down-regulation. It was however, important to know if T953 
virus also interfered with other steps in the activation of IRF-3 signaling pathways including 
phosphorylation of IRF-3 or nuclear translocation of phosphorylated IRF-3 (pIRF-3) from 
cytoplasm. Therefore, EECs were either mock infected or infected with T953. At 3 and 12 h.p.i., 
cells were lysed and nuclear and cytoplasmic fractions of total proteins were separated by 
subcellular fractionation. SeV infection of EECs for 12 h was considered as positive control. 
Protein fractions were analyzed by Western blot using anti-pIRF-3, anti-IRF-3 and anti-lamin 
A/C Abs.  
         Western blot analyses (Fig 3.10) of the subcellular protein fractions of infected cell lysates 
showed that total (cytoplasmic plus nuclear) level of pIRF-3 in T953 infected EECs was down-
regulated from early (3 h) time points to later (12 h) time points. It was also evident that at 3 h 
T953 infection induced activation of IRF-3 molecules by phosphorylation and majority of the 
pIRF-3 was translocated into the nucleus from the cytoplasm (Fig 3.10 A). On the other hand, at 
12 h.p.i. the virus induced phosphorylation was greatly reduced and there was down-regulation in 
the nuclear accumulation of the activated pIRF-3 when compared with 3 h.p.i. (Fig 3.10 A).  
When membranes were blotted with anti-IRF-3 Abs  which detected total IRF-3 (both 
phosphorylated as well as unphosphorylated IRF-3) it was also observed that at early time points, 
the majority of the total IRF-3 molecules were translocated into the nucleus when compared with 
cytoplasmic IRF-3 (Fig 3.10 B, C). At later time points, however, the majority of the total IRF-3 
molecules were in the cytoplasm (Fig 3.10 B, C). Since, IRF-3 molecules in general translocate 
into the nucleus only after activation by phosphorylation, the down-regulation in the amount of 
total nuclear IRF-3 at later time points also indirectly suggests a down-regulation in the activation 
of IRF-3 molecules at those time points. It was noted that IRF-3 Ab (FL-425) from Santa Cruz 
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Biotechnology detected a nonspecific band in the mock infected nuclear lysates which was not 
detected when membranes were blotted with IRF-3 mAb (D6I4C) from Cell Signaling 
Technology (Fig 3.10 C). Densitometric analyses of the Western blot images showed that the 
fraction of total nuclear IRF-3 that was phosphorylated (pIRF-3/IRF-3) decreased over time when 
compared between nuclear lysates from 3 h.p.i. and 12 h.p.i. (Fig 3.10 J). Interestingly, the ratio 
of pIRF-3/IRF-3 in the cytoplasmic lysates increased over time when compared between 3 h.p.i. 
and 12 h.p.i. This increased cytoplasmic pIRF-3 fraction at later time points suggested that T953 
infection either prevented further translocation of pIRF-3 into the nucleus from cytoplasm at 12 
h.p.i. or the virus infection triggered nuclear pIRF-3 to translocate back into cytoplasm. In both 
cases, however, there was a down-regulation in the activation of IRF-3 at later time points. The 
data suggest that the transcription factor IRF-3 gets normally activated and translocated into the 
nucleus of the infected cells at early time points but at later time points IRF-3 signaling pathways 
are blocked either by inhibiting the translocation of pIRF-3 from cytoplasm to nucleus or 
stimulating pIRF-3 to translocate back into the cytoplasm from the nucleus or preventing IFR-3 










Figure 3.10: T953 prevents activation of IRF-3. EECs were infected with either T953 or mock 
infected. At indicated time points cells were lysed and nuclear and cytoplasmic protein lysates 
were separated. Equal amounts (20 μg) of lysates were separated by 10% SDS-PAGE and blotted 
with (A) anti-pIRF-3, (B, C) anti-IRF-3 and (D) anti-lamin A/C antibodies. Lamin A/C was used 
as nuclear loading control. Protein fractions of SeV infected cell lysates analyzed with (E) anti-
pIRF-3, (F) anti-IRF-3 (FL-425) and (G) anti-lamin A/C Abs were used as positive control. (H-K) 
Densitometric analyses were done by NIH ImageJ software and the fraction of IRF-3 that was 
phosphorylated was determined by the ratio of pIRF-3 to IRF-3 band intensity. The Western blot 
images were representative of 2 independent experiments. 
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 Figure 3.10: T953 prevents activation of IRF-3. EECs were infected with either T953 or mock 
infected. At indicated time points cells were lysed and nuclear and cytoplasmic protein lysates 
were separated. Equal amounts (20 μg) of lysates were separated by 10% SDS-PAGE and blotted 
with (A) anti-pIRF-3, (B, C) anti-IRF-3 and (D) anti-lamin A/C antibodies. Lamin A/C was used 
as nuclear loading control. Protein fractions of SeV infected cell lysates analyzed with (E) anti-
pIRF-3, (F) anti-IRF-3 (FL-425) and (G) anti-lamin A/C Abs were used as positive control. (H-K) 
Densitometric analyses were done by NIH ImageJ software and the fraction of IRF-3 that was 
phosphorylated was determined by the ratio of pIRF-3 to IRF-3 band intensity. The Western blot 
images were representative of 2 independent experiments. 
 
         As reviewed earlier activation of IRF-3 by phosphorylation followed by translocation from 
cytoplasm to nucleus is a key step in the IRF-3 signaling pathways. Studies were designed to 
confirm whether T953 virus was able to block the IRF-3 activation pathways by preventing 





 Indirect immunofluorescence images of EECs that were either mock infected or infected with 
T953 virus for 1, 3, 6 and 12 h. (Fig 3.11) clearly showed that in the mock infected EECs at all 
time points (1, 3, 6, and 12 h.p.i.) the transcription factor IRF-3 was mainly cytoplasmic (Fig 
3.11.II, 3.11.III, 3.11.IV, 3.11V); but when activated by a known stimulus, poly I:C, the majority 
of the IRF-3 molecules translocated into the nucleus (Fig 3.11.I).  
 
 
Figure 3.11.I: Poly I:C induces nuclear accumulation of IRF-3. EECs were stimulated with 
poly I:C and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. Panels 
show EECs that were poly I:C treated for 3 h were stained with anti-IRF-3 and anti-EHV-1 gC 
Abs. (A) Nuclear stain DAPI (blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and  (D) merged 
images. Long white arrows indicate magnified cells. Poly I:C stimulated EECs showed nuclear 







Figure 3.11.II: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953 
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. 
Panels show EECs that were  mock infected for 1 h (upper panel) and T953 infected for 1 h 
(lower panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI 
(blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and  (D) merged images. Long white arrows 
indicate magnified cells. T953 infected EECs showed both cytoplasmic and nuclear IRF-3 while 





Figure 3.11.III: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953 
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. 
Panels show EECs that were  mock infected for 3 h (upper panel) and T953 infected for 3 h 
(lower panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI 
(blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and  (D) merged images. Long white arrows 
indicate magnified cells. Majority of the T953 infected EECs showed nuclear IRF-3 while mock 





Figure 3.11.IV: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953 
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. 
Panels show EECs that were  mock infected (upper panel) and T953 infected for 6 h (lower 
panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI (blue), (B) 
IRF-3 (green), (C) EHV-1 gC (red) and  (D) merged images. Long white arrows indicate 
magnified cells. T953 infected EECs showed both cytoplasmic and nuclear IRF-3 while mock 





Figure 3.11.V: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953 
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. 
Panels show EECs that were  mock infected (upper panel) and T953 infected for 12 h (lower 
panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI (blue), (B) 
IRF-3 (green), (C) EHV-1 gC (red) and  (D) merged images. Long white arrows indicate 
magnified cells. The majority of the IRF-3 molecules were cytoplasmic both in T953 as well as 




In the T953 infected EECs, IRF-3 molecules started to become activated and translocated from 
cytoplasm into nucleus as early as 1 h.p.i. when the majority of IRF-3 molecules were still in the 
cytoplasm (Fig 3.11.II). At 3 h.p.i., however, the majority of the IRF-3 molecules were found to 
have translocated from the cytoplasm and accumulated in the nucleus (Fig 3.11.III). At 6 h.p.i. 
IRF-3 was found both in the cytoplasm as well as in the nucleus of virus infected EECs although 
the majority of the IRF-3 molecules were still in the nucleus (Fig 3.11.IV).  At 12 h.p.i. the 
majority of the IRF-3 molecules were in the cytoplasm of the T953 infected EECs (Fig 3.11.V). 
These data supported the findings of the Western blot images (3.10) that after an initial activation 
followed by nuclear accumulation of IRF-3 at early times post infection, T953 virus induced a 
gradual decrease in the nuclear accumulation of activated IRF-3 in EECs in vitro which could be 
responsible for suppressing type-I IFN production at later times. 
 
3.10 Effect of T953 Infection on NF-κB Signaling Pathways  
         In addition to the IRF-3 signaling pathways, NF-κB signaling pathways also play an 
important role in the production of type-I IFNs. To determine whether the virus was able to 
suppress the NF-κB mediated signaling pathways to inhibit type-I IFN induction, EECs were 
either infected with T953 or mock infected. At 3, 6, and 12 h.p.i., cells were lysed for total 
cellular lysates and were analyzed by Western blot with anti-IκBα, anti-β-actin and anti-IE1 Abs. 
Normally in the absence of stimuli, NF-κB transcription factors remains sequestered by 
associating with another inhibitory protein IκBα in the cytoplasm. When induced by a stimulus, 
IκBα is phosphorylated and degraded by cellular proteasome and subunits of NF-κB are released 
and activated [351]. These activated NF-κB subunits then enter into the nucleus and bind to the 
DNA of the cell regulating the transcription of a number of genes including IFN-β (Fig 1.8). The 
results showed that T953 infection caused a down-regulation of the endogenous level of NF-κB 
inhibitory protein, IκBα (Fig 3.12.I) suggesting an activation of the NF-κB signaling pathways at 




Figure 3.12.I: T953 infection induces degradation of IκBα. EECs were infected with either 
T953 or mock infected. At indicated time points whole-cell lysates were prepared and equal 
amounts (40 μg) of lysates were separated by 10% SDS-PAGE and blotted with (A) anti-IκBα, 
(B) anti-β-actin and (C) EHV-1 IE1 antibodies. T953 induced degradation of IκBα at later time 
points (12 h) in EECs when compared to mock infected EECs. (D) Densitometric analyses were 
done by NIH ImageJ software and IκBα band intensity was normalized to β-actin band intensity. 
T953 infected cell lysates showed a decrease in relative fold intensity of IκBα compared to mock 
infected cells. The Western blot images were representative of 3 independent experiments. 
 
 
         Additionally, NF-κB signaling pathways were also studied directly by IFA using NF-κB 
p50 specific Ab (Fig 3.12.II). EECs were either mock infected (negative control) or infected with 
T953 for indicated time points. Mock infected EECs stimulated with TNF-α at 45 ng/ml of media 
for 45 min were the positive control. Infected or TNF-α treated cells were then stained with NF-
κB p50 specific primary Ab. It was observed that in mock infected cells in the absence of TNF-α 






Figure 3.12.II.i: T953 infection does not activate NF-κB signaling pathways at early time 
points. EECs were mock infected (upper panel) or infected with T953 (lower panel) for 3h. Cells 
were then fixed in 4% PFA and analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC 
Abs. Figure shows (A) Nuclear stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red) 
and  (D) merged images. Long white arrows indicate magnified field. Majority of the NF-κB p50 





Figure 3.12.II.ii: T953 infection activates NF-κB signaling pathways at later time points. 
EECs were mock infected (upper panel) or infected with T953 (lower panel) for 12h. Cells were 
then fixed in 4% PFA and analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC Abs. 
Figure shows (A) Nuclear stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red) and  
(D) merged images. Long white arrows indicate magnified field.In T953 infected EECs, the 
majority of the NF-κB p50 molecules were located in the nucleus while in mock infected cells, 





Figure 3.12.II.iii: TNF-α causes activation of NF-κB p50 signaling pathways. EECs were 
stimulated with TNF-α at 45 ng/ml for 45 min. Then the treated cells were fixed in 4% PFA and 
analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC Abs. Figure shows (A) Nuclear 
stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red) and  (D) merged images. Long 
white arrows indicate magnified field. TNF-α stimulation caused nuclear translocation of NF-κB 
p50 suggesting an activation of NF-κB signaling pathways. 
  
But in the mock infected EECs treated with TNF-α, the majority of the p50 subunit was 
translocated into the nucleus (Fig 3.12.II.iii). At early time points (3 h) after T953 infection, the 
majority of the cells showed p50 subunit located in the cytoplasm indicating that NF-κB signaling 
pathways were not activated  (Fig 3.12.II i). On the other hand, at later time points after T953 
infection (12 h), the majority of the infected EECs were observed to possess p50 subunit in the 
nucleus (Fig 3.12.II.ii) indicating that NF-κB signaling pathways were activated. In summary, the 
results thus show that at the beginning of infection, NF-κB signaling pathways were not activated 
while at later time points of the virus infection the pathways were activated. These important 
findings also suggest that inhibition of type-I IFN by T953 infection in EECs at later time points 
was probably not due to the inhibition of NF-κB signaling pathways.  
         Altogether, the results shown in Figures 3.9, 3.10, 3.11 and 3.12 reveal that T953 virus 
inhibited type-I IFN production in EECs at later time points by a mechanism which includes 
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inhibiting IRF-3 signaling pathways through multiple strategies such as inducing degradation of 
IRF-3 and also preventing nuclear accumulation of IRF-3. 
 
3.11 Effect of Exogenous rEqIFN-α on the Replication of T953 
         The previous results support that EHV-1 has mechanisms to inhibit type-I IFN response at 
the production level by interfering with IRF-3 signaling pathways. But it was not clear whether 
the virus can also interfere with the effect of type-I IFN as there were contradictory reports 
regarding the antiviral effect of type-I IFN against EHV-1. Therefore, it was important to 
determine the effect of type-I IFN on the replication of T953 virus in vitro. For this, EECs were 
pre-treated for 24 h either with rEqIFN-α at a concentration of 1000 IU/ml of growth media or 
with equal volume of MEM in growth media and then the cells were challenged with T953 at a 
low MOI (MOI=0.5). At indicated time points (3, 6, 12, 24, 36 and 48 h.p.i.) cell supernatants 
were collected and titrated for the presence of T953 virus by plaque assay (Fig 3.13). The results 
of the plaque assay showed that exogenous treatment of the rEqIFN-α had very little inhibitory 
effect (less than 10 fold) on T953 virus replication at 12 and 24 h.p.i. At 36 and 48 h.p.i. this 
inhibitory effect was even less. In all the time points, however, no statistically significant 
differences in T953 titers were found between the rEqIFN-α treated and untreated EECs (Fig 
3.13). 
 




Figure 3.13: rEqIFN-α cannot block the replication of T953 in EECs. Cells were pre-treated 
for 24 h with rEqIFN-α at 1000 IU/ml of media and were challenged with T953 at an MOI of 0.5. 
At indicated time points cell supernatants were collected and T953 virus titers were determined 
by plaque assay. Bars show the means with standard errors from 3 independent experiments. 
rEqIFN-α treatment did not inhibit T953 replication. 
 
 
Figure 3.14: rEqIFN-α inhibits replication of VSV-GFP. (A) EECs were either pre-treated 
with rEqIFN-α  at 1000 IU/ml of media or left untreated for 24 h and then challenged with VSV-
GFP at an MOI of 0.5 for another 24 h. VSV-GFP replication was evaluated by determining the 
expression of GFP under inverted fluorescent microscope. (A) rEqIFN-α treatment completely 
inhibited expression of GFP (B) EECs untreated with rEqIFN-α could not suppress the expression 
of GFP. The images were representative of 3 independent experiments. rEqIFN-α treatment 





         As a positive control EECs were either pre-treated with rEqIFN-α for 24 h or left untreated 
and then challenged with an interferon sensitive virus, VSV-GFP at an MOI of 0.5. At 24 h.p.i. 
effect of rEqIFN-α on replication of the VSV-GFP virus was determined by evaluating the 
expression of GFP under an inverted fluorescent microscope. No GFP expression was observed in 
the VSV-GFP infected EECs pre-treated with rEqIFN-α at 1000 IU/ml of media (Fig 3.14 A). On 
the other hand, EECs which were not treated with rEqIFN-α showed expression of GFP (Fig 3.14 
B). VSV is known to be a type-I IFN-sensitive virus. The inhibition of VSV-GFP replication by 
rEqIFN-α in EECs confirmed that VSV is IFN-sensitive and also confirmed that EECs were IFN-
competent cells. 
 
3.12 Effect of rEqIFN-α on the Infection Process of T953 Virus in EECs 
         In the previous experiment (Fig 3.13), although rEqIFN-α had a little inhibitory effect (not 
statistically significant) at 12 and 24 h.p.i., even this minor inhibitory effect was further reduced 
by 36 and 48 h.p.i. It was possible that rEqIFN-α treatment would induce antiviral proteins or 
ISGs and would make the majority of cells resistant to T953 virus infection but few cells were 
still susceptible. When those few cells were infected, they produced progeny viruses which 
eventually amplified in numbers by more rounds of replication. By 24 h.p.i. these amplified 
progeny viruses could overpower the cellular antiviral immunity induced by ISGs and infect more 
nearby uninfected cells. These caused increase in the titer of the virus by 48 h which were not 
different when compared with the virus titer from the IFN-untreated cells. Alternatively, it could 
also be possible that rEqIFN-α treatment would cause all the cells equally resistant or susceptible 
to T953 infection. When challenged with T953 virus, equal number of cells were infected from 
IFN-treated and untreated cells. It is possible that antiviral immunity in the IFN-treated cell might 
prolong the multi-cycle infection process of the virus till 24 h.p.i. but did not completely block it. 
As a result, in spite of an initial little difference between virus titers (12 h and 24 h) between IFN-
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treated and untreated infected cells, there was no significant difference later (36 h and 48 h). To 
differentiate that, an infectious center assay was performed to elucidate whether IFN-treatment 
caused a difference in the number of infectious centers or a difference in the infected cell 
numbers or the IFN treatment prolonged the multi-cycle infection process.            
          
 
Figure 3.15: rEqIFN-α does not inhibit replication of T953 virus.  EECs were either pre-
treated with rEqIFN-α at 1000 IU/ml of media or left untreated. At 24 h cells were infected with 
T953 at an MOI of 0.5. After the adsorption of virus at 37 o C for 1 h, cells were trypsinized and 
single cell suspensions were made and equal number of cells were added to the confluent layer of 
another permissive cell, RK-13 in 6-well plates and were allowed to adhere for 30 min. Cells 
were overlaid with 0.75% CMC in growth medium and incubated at 37 o C for 96 h. 6-well plates 
were then washed and stained with 1% crystal violet in 10% buffered formalin. Numbers of 
plaques were counted and infected cell numbers in total cell suspension were determined. The 
data represent means with standard errors from 3 independent experiments. rEqIFN-α  treatment 





The infectious center assay showed no statistically significant differences in the infected cell 
numbers between rEqIFN-α treated and untreated EECs (Fig 3.15). Results from 3.13 and 3.15 
suggest that exogenous rEqIFN-α treatment of EECs neither blocked viral replication in those 
cells nor hindered the entry of the virus reducing the infection rate. Rather, the results support the 
hypothesis that rEqIFN-α pre-treatment prolonged the multi-cycle infection process of the virus 
resulting in reduced numbers of progeny viruses at the beginning which increased at later time 
points (48 h.p.i.). 
 
3.13 Effect of T953 Infection on the Type-I IFN Signaling Pathways 
         Because T953 virus was very resistant to the inhibitory effect of exogenous rEqIFN-α, this 
raises the question whether the virus was interfering with the type-I IFN mediated JAK-STAT 
signaling. It is common for different herpesviruses to target JAK-STAT signaling to subvert host 
interferon responses. To elucidate whether T953 interferes with JAK-STAT signaling, EECs were 
infected with T953 and, at 30 min before the indicated time points, cells were stimulated with 
exogenous rEqIFN-α at a concentration of 1000 IU/ml of media. Mock infected EECs treated 
with rEqIFN-α were used as positive control. At the indicated time points, cells were lysed to 
prepare whole cell lysate and equal amounts (30 μg) of protein lysates were analyzed by Western 
blot using anti-pSTAT-1, anti-STAT-1, anti-β-actin and anti-IE1 antibodies. The results showed 
that T953 virus did not prevent exogenous rEqIFN-α induced STAT-1 phosphorylation at early 
time points (3 h) but the virus down-regulated STAT-1 phosphorylation at late time points (12 h) 





Figure 3.16: T953 downregulates STAT-1 phosphorylation. EECs were infected with T953 at 
MOI of 5 and cells were either left untreated or treated with rEqIFN-α at 1000 IU/ml of media for 
30 min before lysis at indicated time points. Equal amounts (30 μg) of whole-cell lysates were 
separated on 10% bis-cross-linked polyacrylamide gels and subjected to Western blot analysis 
using (A) pSTAT-1, (B) STAT-1, (C) β-actin, and (E) EHV-1 IE1 antibodies. T953 
downregulated the phosphorylation of STAT-1 at later time points but did not alter the level of 
endogenous STAT-1 level. (D) Densitometric analyses were done to normalize the pSTAT-1 and 
STAT-1 levels against β-actin by NIH ImageJ software. The Western blot images were 
representative of 3 different blots from independent experiments. 
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But this down-regulation of pSTAT-1 at later time points were not due to the down-regulation of 
endogenous level of STAT-1 since the virus did not alter the endogenous level of STAT-1 (Fig 
3.16 B). T953 infection to EECs was confirmed by the expression of EHV-1 IE1 protein (Fig 
3.16 E). 
 
3.14 Role of T953 Infection in the Translocation of STAT-1 in EECs 
The Western blot findings of T953 mediated interference with JAK-STAT signaling pathways by 
down-regulating the phosphorylation of STAT-1 molecule was further studied by indirect 
immunofluorescence assays. EECs were infected with T953 for 12 h, and at 30 min prior to 
fixation in 4% PFA, infected cells were either treated with rEqIFN-α (1000 IU/ml of media) or 
with MEM. Mock infected EECs treated with rEqIFN-α were used as positive control. When cells 
were stained with anti-STAT-1 Ab, the majority of STAT-1 molecules were in the cytoplasm of 
the mock infected EECs (Fig 3.17.I). But when mock cells were stimulated with IFN the majority 
of the STAT-1 molecules were translocated into nucleus (Fig 3.17.I).  On the other hand, in the 
absence of rEqIFN-α  treatment the majority of the STAT-1 molecules were present in the 
cytoplasm of T953 infected EECs (Fig 3.17.II). Cytoplasmic STAT-1 in T953 infected EECs 






Figure 3.17.I: rEqIFN-α induces nuclear translocation of STAT-1. Mock infected EECs were 
either stimulated with rEqIFN-α at 1000 IU/ml or equal volume of MEM for 30 min prior to 
fixation in 4% PFA at 12 h.p.i. Cells were then stained with anti-STAT-1, and anti-gC (EHV-1) 
Abs. A, B, C, and D shows nuclear stain DAPI (blue), STAT-1 (green), EHV-1 gC (red) and 
merged images respectively. Mock infected EECs in the absence of rEqIFN-α (upper panel) 







Figure 3.17.II: T953 infection inhibits nuclear translocation of STAT-1. T953 infected EECs 
were either stimulated with rEqIFN-α at 1000 IU/ml or equal volume of MEM for 30 min prior to 
fixation in 4% PFA at 12 h.p.i. Cells were then stained with anti-STAT-1, and anti-gC (EHV-1) 
Abs. A, B, C, and D shows DAPI nuclear stain (blue), STAT-1 (green), EHV-1 gC (red) and 
merged images respectively. Both in the absence (upper panel) or presence (lower panel) of 





Moreover, T953 infection also prevented rEqIFN-α induced nuclear translocation of STAT-1 (Fig 
3.17.II). These findings from the IFA study corroborated the results of the western blot data in the 
previous section that T953 interfered with JAK-STAT signaling pathways. 
 
3.15 Role of Viral Gene Expression on Type-I IFN Signaling Pathways 
         It was clear that T953 infection could suppress the activation of STAT-1 molecules and also 
prevented the nuclear translocation of STAT-1, but it was not evident whether viral gene 
expression was necessary to exert that effect. Studies were designed to evaluate the role of viral 
gene expression in JAK-STAT signaling pathways. EECs were infected with WT T953 or UV 
inactivated T953 (UV T953) and stimulated with rEqIFN-α for 30 min before harvesting cells for 
total cellular lysates at 18 h.p.i. In the previous results (Fig 3.16) T953 infection for 12 h caused a 
down-regulation in the STAT-1 phosphorylation but the study was not continued beyond that 
time points. Protein lysates were analyzed by Western blotting using anti-pSTAT-1, anti-STAT-1 
and anti-β-actin Abs. Mock infected cells treated with rEqIFN-α was included as positive 
controls. Besides showing the role of viral gene expression in suppressing STAT-1 activation, 
this study also showed whether the suppression effect was continued beyond 12 h.p.i. 
         The results showed that WT T953 infection suppressed STAT-1 phosphorylation at 18 h.p.i. 
just as shown above at 12 h.p.i. UV T953, however, did not inhibit rEqIFN-α induced STAT-1 
phosphorylation (Fig 3.18). Neither WT T953 nor UV T953 degraded STAT-1 from its 
endogenous level. These findings suggest that viral gene expression which is absent in UV-T953 




Figure 3.18: UV inactivated T953 cannot prevent rEqIFN-α induced STAT-1 
phosphorylation. EECs were mock infected or infected with wild type (WT) T953 or UV 
inactivated T953 or left untreated. Cells were then either induced with exogenous rEqIFN-α at 
1000 IU/ml of media or left untreated 30 min before lysis at 18 h.p.i. Equal amounts (30 μg) of 
whole-cell lysates were loaded into each well of 10% bis-cross-linked polyacrylamide gel and 
electrophoresed and blotted using (A) anti-pSTAT-1, (B) cocktail of anti-STAT-1 and anti-β-









3.16 Effect of ORF1/2 Deletion on STAT-1 Phosphorylation 
         ORF1/2 of EHV-1 are the early genes of EHV-1 and have been shown to be involved in 
host immune responses by modulating cytokine responses such as IFN-γ [342]. ORF1 of the 
neuropathogenic EHV-1 Ab4 strain has been shown to down-regulate the expression of MHC-I 
molecules which might interfere with the antigen presentation resulting into the interference of T-
cell mediated immune responses [106]. Hence, considering the importance of ORF1 and ORF2, 
its effect on the activation of JAK-STAT signaling pathways was evaluated using ORF1and 
ORF2 deletion mutants of neuropathogenic strain Ab4 (Δ1/2 Ab4). EECs were infected with WT 
Ab4 virus, or Δ1/2 Ab4 mutant virus at low MOI (MOI=1) for 18 h. Before lysis cells were 
induced with rEqIFN-α for 30 min. Western blot analyses showed that Δ1/2 Ab4 virus infected 
EECs could not prevent rEqIFN-α induced phosphorylation of STAT-1 when compared with 
rEqIFN-α stimulated mock infected EECs (Fig 3.19 A). On the other hand, WT Ab4 infected 
EECs suppressed STAT-1 phosphorylation when stimulated with exogenous rEqIFN-α (Fig 3.19 
A). Neither WT Ab4 nor Δ1/2 Ab4 infection down-regulated the endogenous level of STAT-1 
(Fig 3.19 B). The membranes were also blotted with EHV-1 IE1 Ab to check that WT as well as 
mutants of Ab4 viruses successfully infected EECs (Fig 3.19 E). The results indicate that EHV-1 



















Figure 3.19: Δ1/2 Ab4 mutant virus cannot prevent STAT-1 phosphorylation. EECs were 
infected with another EHV-1 neuropathogenic strain Ab4 WT, or with an ORF1/2 deletion 
mutants of Ab4 (Δ1/2 Ab4) at MOI of 1 and cells were either left untreated or treated with 
rEqIFN-α at 1000 IU/ml of media for 30 min before lysis at 18 h.p.i. Equal amounts (30 μg) of 
protein lysates were separated on 10% bis-cross-linked polyacrylamide gels and subjected to 
Western blot analysis using (A) anti-pSTAT-1, (B) anti-STAT-1, (C, F) anti-β-actin and (E) anti-
EHV-1 IE1 antibodies. (D) Densitometric analyses were done to normalize the pSTAT-1 and 
STAT-1 levels against β-actin by NIH ImageJ software. The Western blot images were 







3.17 Deletion of ORFs 1 and 2 Does Not Interfere with the Entry and Gene 
Expression of Mutant Δ1/2 Ab4 virus 
The mutant virus Δ1/2 Ab4 was characterized by Soboll Hussey et al. [342] earlier in detail and a 
growth curve was made on NBL-6 cells. It was shown that deletion of ORF 1 and 2 does not 
lower the infectivity of the mutant virus when compared to its WT Ab4 virus. However, in this 
study also it was evaluated whether the Δ1/2 Ab4 mutants were able to infect and express its 
genes in the EECs by IFA study using antibodies against EHV-1 IE1 protein and also EHV-1 late 
protein gC. The IFA data showing the expression of IE1 protein indicated that Δ1/2 Ab4 mutant 
was able to enter into EECs successfully like its parental virus Ab4 (Fig 3.20). The expression of 
late protein gC also confirmed that the mutant virus was able to infect and express its genes in 







Figure 3.20: ORF1/2 deletion does not affect the capacity of Δ1/2 Ab4 mutant virus to infect EECs. 
Panels show images of i) mock infected EECs, ii) Ab4 WT infected EECs and iii) Δ1/2 Ab4 infected EECs. 
A, B, C and D represents DAPI (nuclear stain) stained images, anti-IE1 Ab (green) stained images, anti-gC 
Ab (Red) stained images and (D) Merged images of A, B, and C respectively.  
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3.18 Effect of T953 Infection on the Expression of Viperin in EECs 
         Type-I IFNs exerts their antiviral effects through the induction of ISGs. As EHV-1 T953 
interfered with the activation of STAT-1 molecules, which is important for downstream ISG 
induction, it was imperative to know if the virus was able to inhibit ISG induction partially or 
completely. Studies were designed to find out if T953 infection of EECs induced expression of a 
recently discovered IFN induced antiviral protein, viperin. As reviewed earlier that viperin has 
been found to inhibit many DNA as well as RNA viruses such as HCMV, HCV, dengue virus, 
influenza virus and many others. EECs were infected with T953, or treated as indicated (Fig 
3.21).  At 3 and 12 h.p.i whole cell lysates were prepared and equal amounts of protein lysates 
were subjected to Western blot analysis using anti-viperin and anti-β-actin Abs. Results indicate 
that T953 infection did not induce viperin protein at either early (3 h) or later (12 h) time points 
(Fig 3.21. Interestingly, T953 infection at later time points also suppressed poly I:C induced 
viperin expression. The results also indicated that T953 infection for 3 h did not prevent poly I:C 
induced viperin expression. The Western blot image also showed that late gene blocking of T953 
by PAA treatment permitted viperin protein expression compared to T953 infected EECs without 
PAA. In summary, T953 virus infection of EECs suppressed viperin expression and the virus also 







Figure 3.21: T953 infection suppresses viperin expression. EECs were infected with T953, or 
treated with poly I:C, or coinfected as indicated. At indicated time points whole cell lysates were 
prepared and equal amounts (30 μg) of proteins were separated on 10% SDS-PAGE and analyzed 
by Western blotting using anti-viperin and anti-β-actin Abs.(A) At 3 h.p.i. T953 neither induced 
viperin expression nor completely prevented poly I:C induced viperin expression. (B) At 12 h.p.i. 













3.19 T953 Infection Interferes with Exogenous IFN-α induced ISGs Viperin and 
ISG56 Expression 
         Because T953 infection did not induce any viperin protein either at early and later time 
points and viperin could be induced by both IFN-dependent as well as IFN-independent 
pathways, further studies were designed to determine whether the virus was able to inhibit 
exogenous rEqIFN-α -induced viperin expression both at mRNA and protein level. In addition to 
viperin, ISG56 was also evaluated in this study. 
         EECs were infected with T953 and at 6 h.p.i. stimulated with rEqIFN-α for another 1 or 6 h. 
Mock infected EECs were also stimulated with rEqIFN-α for 1 and 6 h. At the indicated time 
points transcription of viperin and ISG56 mRNA were evaluated by real-time RT-PCR assay. 
Results indicate that T953 infection of EECs for 6 h reduced transcription of rEqIFN-α-induced 
viperin mRNA significantly (Fig 3.22 A). The virus infection of EECs for 6 h also down-











Figure 3.22: T953 inhibits interferon induction of ISGs at the transcriptional level. EECs 
were either mock infected or infected with T953 at an MOI of 5. At 6 h.p.i., infected EECs were 
stimulated with exogenous rEqIFN-α  (1000 IU/ml of media) for either 1 h or 6 h. One group of 
mock as well as virus infected cells was left untreated. At indicated time points, cells were lysed 
for total cellular RNA and mRNA transcripts of ISGs were quantitated by real-time RT-PCR 
assays. T953 inhibited exogenous rEqIFN-α induced viperin (A) as well as ISG56 (B) mRNA 
transcription significantly (***= p<0.001 and *= p<0.05). Data represent means with standard 
errors from 3 independent experiments. 
 
The suppression of viperin and ISG56 transcription was confirmed by Western blot analyses of 




Figure 3.23: T953 inhibits interferon induced ISGs induction at translational level. EECs 
were either mock infected or infected with T953 for 6 h. Cells were then either stimulated with 
exogenous EqIFN-α  (1000 IU/ml of media) or left unstimulated for another 6 h. Whole-cell 
lysates were prepared and equal amounts of lysates were subjected to Western blot analysis by 
using (A) anti-viperin, (B) anti-ISG56 and (C) anti-β-actin Abs. T953 downregulated protein 
level of viperin and also reduced ISG56 protein translation induced by EqIFN-α. Images are 
representative of 3 independent experiments. 
         EECs were infected with T953 for 6 h and stimulated with rEqIFN-α for another 6 h. Whole 
cell lysates were prepared and equal amounts (30 μg protein) of lysates were subjected to Western 
blot analyses using anti-viperin, anti-ISG56 and anti-βactin Abs. The results showed that T953 
infection down-regulated rEqIFN-α induced viperin protein expression by more than half (3.23 
A). On the other hand, T953 infection to EECs suppressed rEqIFN-α induced ISG56 completely 
(3.23 B). Altogether, these data indicate that T953 infection suppressed rEqIFN-α induced ISGs 
such as viperin and ISG56 both at the transcriptional as well as translational levels. 
 
Copyright © Sanjay Sarkar 2014 
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CHAPTER IV: DISCUSSION 
 
         The first line of defense against infectious agents is mounted by the host’s innate immune 
system which was thought to be very simple [352] as until recently it was presumed that the 
adaptive immune system played the central role in the clearance of viral infections. It is now 
believed that innate immune system plays the crucial roles in acute infections especially in viral 
infections [353]. Generally, in microbial infections, innate immune system exerts its action by 
recognizing pathogens through different innate immune receptors (TLRs, RLRs and NLRs) and 
then secreting different types of cytokines to eliminate that infection from the host. Failing to do 
so, innate immune system recruits the adaptive immune system to eventually clear the infection 
[352]. It is now well documented that the type-I IFNs, namely IFN-α and IFN-β act as 
nonspecific antiviral agents against many viruses, including herpesviruses [314]. Besides 
inhibiting virus replication directly, type-I IFNs have also been reported to modulate adaptive 
immune responses by enhancing CD8+ T cell activation, regulating migration of immune cells, 
helping in the maturation of DC and also inducing apoptosis [300, 354, 355]. 
         
4.1 Suppression of Type-I IFN by EHV-1 T953 Strain After an Initial Transient 
Induction 
         Because effective replication of EHV-1 in endothelial cells is thought to be necessary for 
the development of EHM as well as also for abortions, control of virus replication in endothelial 
cells could be an effective way to control EHV-1 abortions and EHM. The central hypothesis of 
this research was that EHV-1 has mechanisms to evade the antiviral effects of type-I IFN 
response of the horse. The suppression of type-I IFN responses at either IFN induction or IFN 
signaling or both could make the microenvironment conducive for efficient lytic replication of 
EHV-1 leading to the inflammatory damage to the blood vessel and surrounding tissues. To date, 
there have been no detailed reports of type-I IFN responses to EHV-1 infection in endothelial 
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there have been no detailed reports of type-I IFN responses to EHV-1 infection in endothelial 
cells. Herpes viruses like HSV-1, BHV-1, VZV have been shown to inhibit type-I IFN production 
in fibroblast cells [303, 305, 356]. In contrast to this, HSV-1 has also been shown to induce the 
production of type-I IFN mainly by pDC indicating that induction of interferon responses is cell 
type specific [357]. In this study the type-I IFN responses to EHV-1 infection were investigated 
in EECs, as a model for simulating the infection in horses. 
         EHV-1 infection of EECs caused a transient induction of IFN-β mRNA at an early stage of 
infection (3 h.p.i.) but soon after that the virus started suppressing further induction of IFN-β 
mRNA and by 12 h.p.i., the virus shut off the transcription of IFN-β gene to a basal level when 
compared to mock infected cells. However, when measured at protein level by type-I IFN 
bioassay, it was observed that the virus infection showed type-I IFN activity in infected cell 
supernatants both at 3 h and at 12 h although reduced activity at later time points (12 h). The 
type-I IFN activity at protein level found in the later time points could be due to the accumulating 
effect of type-I IFNs that were secreted in 3 and 6 h.p.i. In contrast to this study, Edington et al. 
[332] observed that in vivo EHV-1 infection of horses induced high level of EqIFN in serum. 
Also, low levels of EqIFN were secreted by explanted mononuclear cells infected with EHV-1. In 
another in vitro study, Wagner et al. [349] found that EHV-1 infected PBMCs induced type-I IFN 
(IFN-α) and chemokines like CCL5, CXCL9 and CXCL10 but suppressed CCL2 and CCL3 
production. Although, the data from this study appears contradictory to the previous studies, upon 
careful evaluation it should be clear that the current results showed that EHV-1 was capable of 
inducing type-I IFN (IFN-β) gene expression (both at mRNA and protein level) in the endothelial 
cells. Furthermore, the kinetic analyses of type-I IFN production by EHV-1 infected EECs 
indicated that the virus also had the ability to interfere with later type-I IFN production, i.e., after 
an initial phase of induction. On the other hand, the previous studies, either in vivo (horse) or in 
vitro (equine PBMCs) did not address whether EHV-1 could also inhibit IFN-α/β production. The 
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apparent differences in EHV-1 induced type-I IFNs could be attributed to a number of factors. In 
the case of in vivo infection, a number of different cell types both immune cells (pDC, mDC and 
PBMCs) as well as non-immune cells (epithelial, endothelial and fibroblast cells) are present in 
the body and which specific cell type(s) produced the IFN response in the serum of EHV-1 
infected horses was not specified. Research has shown that type-I IFN induction is cell type 
specific and immune cells like DCs could respond differently than non-immune cells to a virus 
infection [358, 359]. Indeed, Le et al. [360] and others [359] reported that mouse 
cytomegalovirus (MCMV) infected pDC produced a significant amount of type-I IFNs, but non-
immune cells like fibroblasts did not. By inhibiting type-I IFN production in fibroblasts, MCMV 
made an ‘intracellular milieu’ or ‘virus factory’ which was optimized for viral genome replication 
[360]. pDCs have been reported to be the cells that primarily produce type-I IFNs in response to 
infectious agents [361]. It is entirely possible that during in vivo EHV-1 infection, pDCs along 
with other cells like mDCs and other mononuclear cells are activated to produce IFN-α/β which 
was detected by Edington’s group. Wagner’s group also found IFN-α in EHV-1 infected PBMCs 
(immune cells). Difference due to virus strains could not be ruled out since Wagner’s group used 
different strains of EHV-1 (Ab4, NY03 and RacL11) than the strain used in this study (T953). 
The relation of type-I IFN production to the strain differences needs to be further investigated.  
  
4.2 T953 Virus Mediated Shut-down of Type-I IFN Induction by SeV or Poly I:C 
         Next, it was important to determine if the virus actively shut down type-I IFN production in 
the host cells or the suppression of IFN-α/β at later time points was due to normal IFN production 
kinetics. To address that issue, a co-infection study was designed where EECs were infected 
either with T953 and SeV together or T953 and poly I:C together for different periods of time. In 
both cases results showed that T953 suppressed the SeV or poly I:C induced type-I IFN by EECs 
(Fig 3.3 and 3.4).  
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         Interestingly, when poly I:C treated EECs were taken as positive control, a biphasic 
induction of IFN-β gene transcription was found. After a peak of IFN-β mRNA at 3 h there was a 
downregulation of IFN-β mRNA at 6 h and again at 12 h there was increase in the IFN-β gene 
transcription (Fig 3.3). This phenomenon was also seen at the translation level (Fig 3.4). This 
biphasic induction of IFN-β was probably due to a positive feedback loop. Using an IFN-β-GFP 
reporter system, Hwang et al. [362] showed that synthetic dsRNA analogue, poly I:C causes a 
biphasic expression of IFN-β in the HepG2 cell line in a positive feedback loop. Poly I:C also has 
been found to induce STAT-1 phosphorylation in a biphasic manner [363]. Type-I IFNs have 
been shown to induce the expression of a number of ISGs, some of which like RIG-I and MDA-5 
are also involved in sensing foreign dsRNA [362, 364-366]. For example, secreted IFN-β 
stimulates the RLRs like RIG-I and MDA5 which stimulates autocrine feedback loop producing 
more IFN-β. IFN-β induction through RLRs involves a number of positive feedback loops which 
also involve multiple ISGs. IFN-β also stimulates LGP2 which competes with RLRs for binding 
of foreign cytosolic RNA to activate MAVS/IPS-1 in mitochondria to produce more type-I IFNs 
in a positive feedback manner [365]. The transcription factor IRF-7 which is an ISG plays an 
important role in the production of type-I IFNs [367]. It has been reported earlier that IFN-β 
induces the production of IRF-7 which in turn transactivates the transcription of more type-I IFNs 
resulting in a positive feedback loop [367]. Another reason for the biphasic expression of IFN-β 
could be the stochastic chromatin states before initiation of transcription, resulting in differential 
gene expression as has been found in the bimodal expression of IL-4 [362]. It has been shown 
that the biphasic expression of IL-4 due to the heterogeneous state of the chromatin in Th cells 
was not controlled by a positive feedback loop [362, 368]. However, chromatin state has not been 
found to be the principal reason for biphasic IFN-β gene expression since, blocking of IFN-β 
secretion disrupted this pattern indicating a positive feedback loop by secreted IFN-β [362]. If 
this bimodality was due to the heterogeneous status of the chromatin at IFN-β gene locus, 
blocking of IFN-β-loop would not have any effect. In the present study biphasic IFN-β gene 
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expression induced by poly I:C probably involved a positive feedback loop which caused a 
second peak at 12 h. 
         To verify that EHV-1 gene expression actively shut down the type-IFN production, another 
co-infection study was designed. In the earlier co-infection studies (Fig 3.3, 3.4) combinations of 
viruses (T953 and SeV) or combinations of virus and chemical (T953 and poly I:C) were added to 
cells at the same time and incubated for same duration. But in this co-infection experiment cells 
were pre-infected with T953 and the virus was allowed to express its genes for some time (6h) 
before the cells were coinfected with SeV to induce IFN-β induction and the results indicated that 
EHV-1 gene expression actively suppressed the ability of SeV for IFN-β mRNA induction (Fig 
3.5) . Sometimes, when a virus infected cells are co-infected with another different virus, entry of 
the second virus may be interfered. It could be argued that inhibition of SeV induced IFN-β gene 
transcription was due to the interference of SeV entry by T953. To test this another co-infection 
was done where cells were infected with T953 for different time periods (0 h, 3 h, 6 h and 12 h) 
and then induced with poly I:C for IFN-β gene expression (Fig 3.6). The inhibition of both SeV 
and poly I:C (Fig 3.5, 3.6) induced IFN-β gene transcription by T953 virus confirmed that the 
T953 virus not only suppressed IFN induction from its own stimulus but actively shut down type-
I IFN induction induced by other exogenous stimuli. 
        It is noteworthy that UV inactivated T953 virus did not induce any significant type-I IFNs 
(Fig 3.3, 3.4) at all-time points suggesting that active viral gene expression is necessary for the 
initial IFN-α/β production. It was expected that PRRs would recognize the UV inactivated T953 
and produce type-I IFNs which did not happen in this study. It is possible that UV inactivated 




4.3 Relationship of EHV-1 Late Gene(s) to Suppression of Type-I IFN Induction 
There was an indication that EHV-1 late genes might be responsible for the inhibition of type-I 
IFN induction as at later time points post infection there was no significant IFN production. Since 
the expression of EHV-1 late genes is dependent on the replication of viral DNA by DNA 
polymerase, the expression of EHV-1 late genes were blocked by inhibiting EHV-1 DNA 
polymerase using PAA. Although there are several reports that PAA preferentially inhibits 
herpesviral DNA polymerase and thereby inhibits the late gene expression of herpesvirus [369] 
we verified that PAA also blocked EHV-1 DNA polymerase without host cell toxicity. The 
immunofluorescence data (Fig 3.7) showed that in the presence of PAA, the T953 virus failed to 
express a marker late gene (gC) while expression of a marker IE gene (IR1) was unaffected.  
          Interestingly, when EHV-1 late gene expression was blocked, a robust type-I IFN response 
both at mRNA as well as protein level (Fig 3.8 A and 3.8 B) was observed at later time points (12 
h and 18 h). At these time points IFN was undetectable in the T953 infected EECs if late gene 
expression was not blocked. This result indicates that viral late gene(s) are partly or completely 
responsible for the anti-IFN activity. However, the specific gene(s) responsible for this inhibitory 
effect have not been determined and further investigations are required. 
 
4.4 Mechanism(s) of Suppression of Type-I IFN Induction by T953 Virus 
        To explore the mechanism(s) EHV-1 uses to suppress IFN production at later time points, 
additional studies were carried out to determine whether EHV-1 interferes with any of the steps in 
the activation of the principal pathways for type-I IFN production, such as IRF-3 signaling 
pathways. A number of different viruses from diverse families have been reported to interfere 
with IRF-3 signaling pathways [303, 307, 331, 360, 370-372]. From the recognition of PAMPs by 
PRRs to the production of IFN-β through IRF-3 signaling pathways, multiple signaling molecules 
and multiple steps are involved and viruses, therefore, have multiple opportunities to evade this 
important host response. While some viruses degrade the endogenous level of IRF-3, others 
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inhibit its activation by preventing phosphorylation, or dimerization, or even nuclear 
accumulation of activated IRF-3 [303, 306, 371, 373]. While other viruses that cannot interfere in 
the activation of IRF-3, they may interfere with the interaction between CBP/p300 and IRF-3 
[306]. Alphaherpesvirus HSV-1 was shown to suppress IRF-3 hyperphosphorylation as well as 
IRF-3 mediated ISG promoter activity by HSV-1 IE protein ICP0 [307]. HSV-1 however has not 
been reported to degrade endogenous IRF-3 protein [307]. On the other hand, BHV-1, another 
alphaherpesvirus, but a different genus, Varicellovirus through its IE protein ICP0 degrades 
endogenous level of IRF-3 protein to inhibit type-I IFN production [303]. Therefore, it was 
thought that EHV-1 being a Varicellovirus could adapt the same technique in order to evade host 
type-I IFN response. The Western blot (WB) data (Fig 3.9) indeed indicated that T953 virus 
down-regulates endogenous level of IRF-3 protein at later time points (6 h.p.i. and 12 h.p.i.) when 
compared to mock infected cell lysates. It is also to be noted that the down-regulation of IRF-3 
protein increased with the increase of the amount of late protein gC expression. This suggested 
that expression of T953 late gene(s) could be responsible for the degradation of IRF-3 at later 
time points resulting into the suppression of IFN production. Another possibility is that the down-
regulation of the total amount of endogenous IRF-3 protein at later time points could be 
nonspecific and it is due to the global shut down of gene expression after EHV-1 infection. This 
seems less likely to happen, since unlike HSV-1, EHV-1 infection does not show much inhibition 
of global gene expression [108]. 
         Many viruses evolve multiple targets to interfere with IRF-3 mediated signaling pathways. 
HSV-1 inhibits nuclear accumulation of IRF-3, induces degradation of activated IRF-3, and 
interferes with the binding of IRF-3 to CBP/p300 required transcriptional activation of different 
genes [306]. Therefore, it was also interesting to explore whether T953 evolved similar multiple 
strategies to subvert IRF-3 signaling pathways. Data from this study (Fig 3.10) show that at an 
early time points (3 h) T953 infection of EECs caused IRF-3 phosphorylation which was reduced 
at a later time points (12 h). The WB data from the subcellular fractionized cell lysates also 
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showed that initially the majority of the pIRF-3 molecules were located in the nucleus while 
cytoplasmic pIRF-3 increased at later time points. This phenomenon suggests that at the 
beginning of the infection IRF-3 is activated and translocated into the nucleus from the cytoplasm 
and this activated pIRF-3 might stimulate downstream signaling resulting in the IFN-β 
transcription that was observed at earlier time points in this study. At later time points the 
observed downregulation of pIRF-3 molecules in the nucleus explained why IFN-β was not found 
during that time. But a specific reason for this downregulation of pIRF-3 molecules in the nucleus 
was not identified in this study. However, T953 virus-induced down-regulation of endogenous 
IRF-3 molecules would likely be the major reason. In addition to this, it is possible that some 
unidentified viral proteins (late gene products) might interact with pIRF-3 and trigger the 
translocation of pIRF-3 back to the cytoplasm from the nucleus, downregulating the level of 
pIRF-3 in the nucleus. A similar mechanism has been proposed by Melroe et al [306] for HSV-1: 
viral ICP0 targets activated IRF-3 molecules for posttranslational modification to translocate back 
to the cytoplasm. An alternative possibility is that an unidentified T953 viral protein(s) could 
interact with activated IRF-3 (pIRF-3) and trigger its degradation at later time points. It has been 
shown that rotavirus NSP1 protein interacts with activated IRF-3 and enhances its degradation 
through cellular proteasomes [374]. It has been suggested that ICP0 of HSV-1 also associates 
with IRF-3 and targets activated IRF-3 molecules through the E3-ubiquitin ligase for enhanced 
ubiquitination and degradation [306]. 
When cell lysates were analyzed with IRF-3 Ab rather than pIRF-3 Ab, it was observed that IRF-
3 was translocated into the nucleus suggesting activation of IRF-3 at the early time points when 
IFN-β was also expressed. But at later time points the level of nuclear IRF-3 was drastically 
downregulated. Densitometric analyses of the band intensity also indicated that the total 
cytoplasmic IRF-3 level was increased at 12 h.p.i. compared to 3 h.p.i. This indicated that either 
IRF-3 phosphorylation was downregulated reducing the total nuclear level of IRF-3, or 
translocation of pIRF-3 to the nucleus from the cytoplasm was inhibited at later time points. In 
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either case there would be reduced nuclear IRF-3 but comparatively increased cytoplasmic IRF-3. 
But when the ratio of pIRF-3/IRF-3 was calculated to find out the fraction of IRF-3 molecules 
that was activated, it was observed that although the ratio was decreased in the nucleus from 3 h 
to 12 h, there was also an increase in the ratio in the cytoplasm, and the total pIRF-3/IRF-3 ratio 
(cytoplasmic + nuclear) was not altered much. This indicated that perhaps T953 infection 
prevented pIRF-3 nuclear translocation from the cytoplasm at later time points rather than 
preventing phosphorylation of IRF-3. 
         The IFA data (3.11) also suggested that T953 infection induces IRF-3 activation followed 
by nuclear translocation as early as 1 h.p.i. and peaks at 3 h.p.i. At 6 h.p.i., although the majority 
of T953 infected cells showed nuclear IRF-3, a number of cells also showed cytoplasmic IRF-3 
indicating T953 infection either reduced IRF-3 activation or reduced translocation into the 
nucleus. At 12 h.p.i. however, the majority of cells showed cytoplasmic IRF-3 suggesting the 
virus infection prevents nuclear accumulation of IRF-3. Therefore, whether T953 infection 
degrades activated IRF-3 or prevents activation of IRF-3 or inhibits translocation of activated 
IRF-3 is not clear in this study and further studies are required to specifically identify the step(s) 
in the IRF-3 signaling pathways at which virus interfered. But it is certainly clear that in all cases 
T953 infection induced down-regulation of endogenous IRF-3 and also prevented nuclear 
accumulation of IRF-3 at later time points thus down-regulating IRF-3 signaling pathways. These 
interferences in the IRF-3 signaling pathways probably were responsible for the absence of IFN-β 
in the later time points. 
         This study was also intended to see whether T953 virus infection also inhibited NF-κB 
signaling pathways as the activation of the transcription factor NF-κB also plays a role in IFN-β 
induction [375]. In the inactive state, the NF-κB subunits, p50 and p65 are associated with an 
inhibitory protein IκBα and thus sequestered in the cytoplasm [351, 376]. When activated by 
different stimuli like LPS or infectious agents like virus or bacteria, the inhibitory protein IκBα is 
phosphorylated by cellular kinases and then degraded by cellular proteasomes resulting in the 
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activation of p50 and p65 subunits which then translocate into the nucleus to transactivate 
transcription of a diverse set of genes [376].  In this study it was observed that T953 virus 
infection induced degradation of the inhibitory protein IκBα (Fig 3.11.i) at later time points (12 
h.p.i.) indirectly suggesting an activation of the NF-κB signaling pathways. During the early 
phase of the infection IκBα was not degraded indicating that at early time points (3 h.p.i.) NF-κB 
signaling pathways were not activated. The IFA data (Fig 3.12.ii) using anti-p50 Ab showed that 
at early time points the p50 protein was located in the cytoplasm of T953 infected cells. But at the 
later time points p50 protein was found to be translocated from the cytoplasm into the nucleus in 
T953 infected cells. This indicates that T953 infection of EECs does not activate NF-κB signaling 
pathways at early times post infection but at later times post infection the virus activates the 
transcription factor NF-κB. This also indicates that probably the type-I response induced by T953 
infection at early time points is not due to the involvement of NF-κB signaling pathways, rather, 
it is a result of the activation of IRF-3 signaling pathways. Also at later time points, the 
suppression of type-I IFN is probably not due to the inhibition NF-κB signaling pathways but due 
to interference with IRF-3 signaling pathways at multiple levels. By activating NF-κB signaling 
pathways at later time points, the virus may trigger the expression of NF-κB dependent gene 
expressions especially expression of pro-inflammatory cytokines like IL-1β, IL-6 and TNF-α. 
These proinflammatory cytokines in turn could play vital role in the inflammation of the blood 
vessels of uterus and CNS causing EHV-1-induced pathology [377]. Again by activating the 
expression of NF-κB dependent genes, the virus also could trigger cell survival [377] which in 
turn would be advantageous to the virus for its replication. Some viral proteins like African Swine 
Fever virus protein A238L interact with p300 protein and inhibit the association between NF-κB-
p65 and p300 which is required for transactivation of genes and thus prevents NF-κB signaling 
mediated  gene transcription [378]. Adenovirus protein E1, Simian Virus 40 (SV40) T large Ag 
and E6 or E7 protein of human papillomavirus (HPV) have also been reported to interact with 
p300 and inhibit the association of NF-κB sububit and CBP/p300 [379-382]. As a result of this, in 
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spite of activation of NF-κB signaling pathways sometimes there is no transcription of NF-κB 
dependent genes.  Therefore, an alternative explanation could be that in addition to IRF-3 
activation pathways, NF-κB signaling pathways are also inhibited but downstream to the 
activation and nuclear accumulation of the transcription factor NF-κB. It is entirely possible that 
T953 virus proteins may interact with CBP/p300 and interfere with the association between 
activated NF-κB subunits and CBP/p300 which also could suppress type-I IFN production at later 
time points.  
         Taken together, these data indicate that during the early stage of the T953 infection in vitro 
in EECs, the host cells respond by inducing a type-I IFN response. At the late stage of the 
infection, however, viral late proteins interfere with the IRF-3 signaling pathways by inducing 
down-regulation of IRF-3 as well as by interfering with the translocation of activated IRF-3 into 
the nucleus from the cytoplasm. Further studies are required to confirm whether the NF-κB 
signaling pathways are also inhibited at single or multiple steps by T953 virus infection. This 
study was not focused on the identification of the specific proteins of T953 virus that may have a 
role in suppressing type-I IFN production by interfering with IRF-3 signaling pathways. Future 
studies in this area are very important in order to identify the specific viral proteins that could 
help understand the virus-host interaction better and may provide insights in designing of future 
therapies against this viral disease. 
4.5 Resistance of T953 Virus to the Effect of rEqIFN-α 
         The next part of this study was focused on characterization of the efficacy of type-I IFNs 
against T953 infection. As reviewed earlier, type-I IFNs bind to its cognate receptors IFNAR1 
and IFNAR2 which trigger a cascade of signaling events (JAK-STAT signaling) resulting inthe 
activation of STAT-1and STAT-2 proteins by phosphorylation [278]. Phosphorylated STATs 
then dimerize and enter into the nucleus and bind to the interferon stimulated response elements 
(ISRE) of a number of ISGs enhancing their transcription [288]. These ISGs actually inhibit 
replication of viruses from diverse families through various mechanisms [288]. It was very 
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important to know whether T953 was sensitive or resistant to the inhibitory effects of type-I IFNs. 
Viruses like SeV and VSV have been shown to be very sensitive to the inhibitory effect of type-I 
IFNs [383-385]. On the other hand herpesviruses like HSV-1 have been known to be resistant to 
the effect of IFN-α/β because of the ICP0 protein [386]. In this study also the effect of exogenous 
rEqIFN-α on the replication of EHV-1 T953 strain in vitro in EECs was evaluated. It was 
observed that pre-treatment of EECs with rEqIFN-α at a concentration of 1000 IU/ml for 24 h had 
very little inhibitory effect on T953 replication indicating that T953 virus is very resistant to the 
inhibitory effect of IFN-α (Fig 3.13). The IFN-α treatment could not even decrease the number of 
plaques by 10 fold (1 log scale). On the other hand, replication of IFN-sensitive virus VSV was 
shown to be completely blocked. Interestingly, the minimal inhibitory effect that was shown by 
rEqIFN-α against T953 virus at 12 and 24 h.p.i. were reduced at 36 and 48 h.p.i. This could occur 
if rEqIFN-α treatment prolonged the replication cycle of T953 virus but not completely blocking 
it. It is also possible that pre-treatment of rEqIFN-α caused interference with the entry of the 
T953 virus and less number of the virus got entry to the cells. This could explain the lower 
number of plaques in the beginning of infection (12 and 24 h.p.i.) in IFN-treated cells. But while 
few viruses entered into EECs and replicated, those progeny viruses then would have infected 
nearby cells producing more progeny viruses and this increased the titer of the virus at 36 and 48 
h.p.i. To investigate that possibility, an infectious center assay was performed and the result 
showed no differences in the number of infectious centers in IFN-treated and non-treated EECs. 
This suggests that rEqIFN-α pre-treatment could not restrict T953 replication in EECs but it 
delayed the replication cycle. By resisting the effect of type-I IFN, the virus may interfere with 
the MHC-I expression or DC maturation both of which interferes with the Ag presentation to the 
CTLs. This would be advantageous to the virus for its replication. Although rEqIFN-α pre-
treatment did not block EHV-1 replication, other IFNs such as IFN-β have not been tried in this 
study. However, it is very unlikely that IFN-β could make a significant difference since both IFN-
α and IFN-β signal through the same receptors and exert their biological effects through very 
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similar mechanisms mediated by ISGs. On the other hand, it would be interesting to see if IFN-α, 
IFN-λ and IFN-γ together had any synergistic effect and whether these combination therapies 
could restrict EHV-1 replication. There has been multiple reports that replication of HSV is 
restricted significantly by the synergistic effects of either IFN-α and IFN-γ [387] or IFN-β and 
IFN-γ [388] combination therapies in fibroblasts as well as in epidermal cells or even in vivo in 
mice [389]. Therefore, it is possible that same combination therapy may work for EHV-1 also. 
 
4.6 T953 Mediated Suppression of JAK-STAT Signaling Pathways 
         Because rEqIFN-α had no significant inhibitory effect on T953 replication, it was thought 
that the virus must be interfering with the effector arm of type-I IFNs, i.e., signaling of type-I 
IFNs. An alternative explanation could be that the virus does not interfere with JAK-STAT 
signaling but interferes with the transcription of ISGs which actually provide antiviral immunity 
to the host cells. It is, however, also possible that T953 virus may not even inhibit ISG induction 
but could inhibit ISGs by posttranslational modifications such as ubiquitination for enhanced 
degradation by cellular proteasomes. 
         To understand the mechanism of resistance against rEqIFN-α inhibitory effect, studies were 
designed to evaluate whether the virus interfered with JAK-STAT signaling pathways. In the WB 
results (Fig 3.16) it was observed that in early phase of the infection T953 virus not only activated 
STAT-1 molecules by phosphorylation but also the virus did not prevent exogenous rEqIFN-α 
induced STAT-1 phosphorylation. This suggested that T953 virus infection activated JAK-STAT 
signaling at early time points of infection. However, by late phase of the infection T953 virus 
inhibited STAT-1 phosphorylation without exogenous rEqIFN-α treatment and the virus also 
down-regulated exogenous rEqIFN-α induced STAT-1 phosphorylation, indicating an 
interference with the JAK-STAT signaling.  
These findings from WB were confirmed by the IFA (Fig 3.17) showing that T953 down-
regulated nuclear accumulation of STAT-1 molecules both in the presence or absence of rEqIFN-
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α at later time points of the infection, as the majority of the STAT-1 molecules were in the 
cytoplasm of the infected cells. The virus infection did not change the endogenous level of 
STAT-1 molecules based on the WB data (Fig 3.16 B). Therefore, the down-regulation of the 
pSTAT-1 in T953 infected cells were not due to the down-regulation of the endogenous level of 
STAT-1. Moreover, the densitometric analyses of the WB image showed that there was a down-
regulation in the pSTAT-1/STAT-1 ratio indicating a suppression of STAT-1 phosphorylation in 
the later time points of the infection. The presence of a majority of STAT-1 molecules in the 
cytoplasm of T953 infected cells at 12 h.p.i. (Fig 3.17.iii and 3.17.iv) also suggests that in the late 
phase of infection the virus prevents STAT-1 phosphorylation. It is also possible that T953 
infection triggers STAT-1 molecules to translocate back into the cytoplasm from the nucleus at 
12 h.p.i. In both cases, however, there is down-regulation of STAT-1 phosphorylation and 
therefore, the interference with JAK-STAT signaling provids T953 virus with resistance to the 
inhibitory effect of rEqIFN-α. Similar cases of JAK-STAT signaling inhibition by herpesviruses 
such as HSV-1, VZV and cytomegalovirus have been reported [313, 390, 391]. HSV-1 ICP27 
was shown to be the major protein that inhibits STAT-1 phosphorylation induced by exogenous 
IFN-α/β [313]. Being an alphaherpesvirus, EHV-1 also might evolve the same strategies to 
subvert type-I IFN signaling and gain resistance to the inhibitory effects of rEqIFN-α. 
         The next goal was to determine the importance of viral gene expression for inhibition of 
JAK-STAT signaling induced by rEqIFN-α. When T953 was UV inactivated to restrict its gene 
expression, it was observed that inactivated T953 infection could not prevent STAT-1 
phosphorylation anymore induced by exogenous rEqIFN-α (Fig 3.18). This indicates that viral 





4.7 Involvement of ORF1/2 in the Inhibition of JAK-STAT Signaling Pathways 
         In the next step, studies were designed to identify the viral proteins that were involved in the 
suppression of type-I IFN signaling. Reports have earlier been published about the importance of 
EHV-1 ORF1 and ORF2 as virulence factors in the in vivo challenge of horses as well as also in 
vitro infection [106, 342]. A deletion mutant of Ab4 virus devoid of ORF1 and ORF2 (Δ1/2 Ab4) 
has been shown to cause decreased interleukin-8 (IL-8) and increased T-bet mRNA expression. 
Again IFN-β has been reported to decrease IL-8 expression in several reports [392, 393] and T-
bet is a transcription factor known to induce the hallmark Th1 cytokine, IFN-γ expression [394]. 
Therefore, the in vivo study with Δ1/2 Ab4 recombinant virus suggests that the mutant virus 
likely modulate the IFN-β as well as IFN-γ mediated immune response when compared to WT 
Ab4 although that study did not involve IFN-β responses. Another study with ORF1 deletion Ab4 
(d1 Ab4) mutant virus showed that ORF1 is involved in the EHV-1 induced down-regulation of 
MHC-I molecules. MHC-I is involved in the Ag presentation by APCs such as DCs and 
macrophages but MHC-I is also an ISG inducible with type-I IFNs through JAK-STAT signaling 
[395]. Therefore, these studies raise the possibility that ORF1/2 of EHV-1 could be candidate 
genes involved in suppressing the STAT-1 phosphorylation at the later phase of the infection. The 
WB results (Fig 3.19) indeed showed that Δ1/2 Ab4 mutant virus did not prevent STAT-1 
phosphorylation induced by exogenous treatment of EECs with rEqIFN-α when compared to its 
WT parent virus (WT Ab4). There was no difference in the endogenous levels of STAT-1 
proteins among mock, Δ1/2 Ab4 and WT Ab4 infected EECs. It could be argued that deletion of 
ORF1 and ORF2 cause the mutant virus to be inefficient in the entry or replication processes in 
infected cells. But Dr. Klaus Osterrieder who provided the virus already characterized the virus in 
RK-13 cells and found that the mutant virus is capable of replicating with titers comparable to 
WT Ab4 [342]. In this study, however, the entry and gene expression capacity of the Δ1/2 Ab4 
mutant virus were analyzed by IFA using anti-IE1 (IE gene product) and anti-gC (L gene 
product) Abs. The IFA (Fig 3.20) results showed that the mutant virus is capable of entry and 
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expression of viral genes, indirectly supporting the replication capacity of mutant Ab4 virus. 
Thus, these findings suggest that EHV-1 ORF1 or ORF2, or ORF1 and ORF2 together, are 
capable of interfering with JAK-STAT signaling by preventing STAT-1 phosphorylation. 
However, there could be other proteins of EHV-1 which also inhibit type-I IFN signaling and 
further studies are required to identify those proteins. 
4.8 T953 Virus Mediated Inhibition of ISG Induction  
         Because the virus down-regulated type-I IFN production as well as signaling at later time 
points (12 h.p.i.), further studies were conducted to evaluate whether the virus was interfering 
downstream to the JAK-STAT signaling. Two important ISGs, viperin and ISG56 which have 
been shown to have antiviral properties against diverse group of viruses such as HCV, Dengue 
virus, influenza virus, HPV including herpesviruses were evaluated in the study [296, 298, 396-
398]. It was tested whether T953 virus was influencing the expression of these two ISGs at either 
the transcriptional level or the translational level, by real-time RT-PCR assay and WB 
respectively. 
         In the absence of rEqIFN-α treatment T953 infection did not induce any viperin protein 
expression (Fig 3.21, 3.23) at either early or later time points although at early time points IFN-β 
was found. At late time points T953 also prevented poly I:C induced viperin expression. 
However, when viral late gene expression was blocked then T953 infection of EECs induced 
viperin protein expression even in the absence of any external stimuli such as poly I:C (Fig 3.21 
B). These suggested that inhibition of viperin expression by T953 is viral late gene dependent.  
         When EECs were treated with rEqIFN-α to induce expression of viperin as well as ISG56 
mRNA, T953 infection in the presence of rEqIFN-α showed a significant decrease of viperin and 
ISG56 mRNA when compared with mock infected cells treated with rEqIFN-α (Fig 3.22). This 
inhibitory effect of T953 virus on viperin and ISG56 expression was also seen at the protein level 
(Fig 3.23). Similar to this, HSV-1 inhibits ISG56 induction at both mRNA and protein level 
[399]. HSV-1 ICP0 protein is sufficient to inhibit ISG56 induction [400] although other proteins 
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are also possibly involved in the inhibition of ISG56 and other ISGs [399, 401]. In summary, the 
data suggests that T953 infection not only inhibits type-I IFN induction but also suppresses type-I 
IFN signaling and its downstream effects in vitro in EECs. By these mechanisms EHV-1 subverts 
the host’s principal type-I IFN mediated immune responses which is undoubtedly related to its 
success as a pathogen. 
4.9 Future Scope  
         To the best of our knowledge, for the first time, results from this dissertation have identified 
new and novel strategies that EHV-1 T953 strain adopts to subvert the host’s most important 
innate antiviral immunity. This study has also identified for the first time that EHV-1 genes ORF1 
and/or ORF2 have anti-IFN activity. Maa et al [106] and Soboll Hussey et al [342] also have 
identified ORF1 and ORF2 as viral virulence factors. The ORF1 and ORF2 encode membrane 
protein UL56 (pUL56) and membrane protein VI respectively (Table 1.1). Identification of these 
virulence factors will give new insights for the design of more effective modified live virus 
vaccines (MLV), by creating recombinant viruses devoid of those pathogenicity factors to control 
EHV-1 infection. Future studies to identify more viral proteins which are responsible for 
suppressing type-I IFN induction will also improve the quality of MLV and the control of the 
infection. 
         This study provides the groundwork for a new prospective area in the field of EHV-1 
research. Findings from this dissertation show that EHV-1 suppresses type-I IFN induction in 
EECs which is a relevant cell type for the pathogenesis of EHV-1. Previous reports showed that 
serum IFN levels in EHV-1 infected horses are at their peak when clinical signs are highest 
suggesting that a high level of serum IFN correlates with the severity of clinical disease. We think 
that EHV-1 infection causes induction of type-I IFN by other cells in the body such as PBMCs, 
dentritic cells but for the benefit of virus replication, EHV-1 shuts down the production of type-I 
IFN in the endothelial cells of the blood vessels after an initial transient induction. Furthermore, 
EHV-1 infection also down-regulates type-I IFN signaling by suppressing STAT-1 translocation 
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into the nucleus from the cytoplasm and preventing subsequent ISG induction. This inhibition of 
ISG production makes the virus highly resistant to the effect of type-I IFN.  
         While this study was done using a neuropathogenic virus T953 as a model virus, to show 
the relationship of type-I IFNs to EHM, for comparison a non-neuropathogenic EHV-1 virus 
should be studied to evaluate the type-I IFN response. Although this study shows that the T953 
late genes are probably responsible to suppress the type-I IFN induction, the specific viral genes 
or proteins were, however, not identified. Viral proteins encoded by ORF1/2 appear to be 
involved in the evasion of type-I IFN mediated JAK-STAT signaling. There could be other 
proteins also involving in this type-I IFNs evasion strategies. Further studies are required to 
identify those novel anti-IFN proteins. Taken together all the data, we propose the following 
model: 
 
     All the blocks in the type-I IFN signaling in our model may be non-specific to the downstream 
effect to the downregulation of IFNAR1 and IFNAR2 which was not studied. 
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         During natural infection in horses, endothelial cells of the blood vessels of particular 
targeted organs including the nasal mucosa, lungs, pregnant uterus and nervous system become 
infected with EHV-1. The local IFN milieu in those targeted organs might strongly influence the 
pathogenesis of EHV-1 disease [338]. So, another important area of study will be why endothelial 
cells of some targeted organs or systems of horse are particularly affected by T953 infection. 
Does IFN-β have any role in the EHV-1 infection process particularly in endothelial cells of some 
targeted organs? The answers to these questions may give us clues to identify host factors that 
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